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Résumé 
Au cours de la dernière décennie, le domaine de la fonctionnalisation directe des liens 
C–H a connu un intérêt croissant, en raison de la demande de processus chimiques moins 
dispendieux, plus efficaces et plus écologiques. . Les cyclopropanes représentent un motif 
structural souvent retrouvé dans des agents biologiquement actifs importants et dans des 
intermédiaires de synthèse permettant l'accès à des architectures complexes. Malgré leur 
valeur intrinsèque, la fonctionnalisation directe des cyclopropanes n’a pas été largement 
explorée. Ce mémoire traitera de deux méthodologies  liées, mais  tout aussi différentes, 
impliquant la fonctionnalisation directe des liens C–H cyclopropaniques impliquant des 
réactions intramoléculaires catalysées par un complex de palladium et assistées par l’argent. 
Le premier chapitre présentera d’abord un bref survol de la littérature sur les fondements de la 
fonctionnalisation directe ainsi que les contributions majeures réalisées dans ce domaine. 
L’accent sera notamment mis sur la fonctionnalisation des centres sp3 et sera souligné par des 
exemples pertinents.   Les découvertes clés concernant le mécanisme et les cycles catalytiques 
de ces processus seront discutées. 
Le second chapitre décrira comment les 2-bromoanilides peuvent être utilisés pour 
accéder à des motifs particuliers de type spiro 3,3’ oxindoles cyclopropyliques. L'optimisation 
et l’étendue de la réaction seront abordés, suivis par des études mécanistiques réfutant 
l’hypothèse de la formation d’un intermédiaire palladium-énolate. Ces études mécanistiques 
comprennent une étude cinétique de l'effet isotopique ainsi que des études sur épimérisation; 
celles-ci ont confirmé que la réaction se produit par arylation directe. 
Sur la base des résultats obtenus dans le deuxième chapitre, nous aborderons ensuite la 
fonctionnalisation directe des benzamides cyclopropyliques lesquels, après une ouverture de 
cycle, donneront de nouveaux produits benzo [c] azépine-1-ones (chapitre trois). Après avoir 
présenté une brève optimisation et l’étendue de la réaction, nous discuterons des études 
mécanistiques impliquées à déduire l'ordre des événements dans le cycle catalytique et à 
déterminer le rôle des réactifs. Celles-ci permetteront de conclure que la fonctionnalisation de 
l’unité cyclopropyle se produit avant l’ouverture de cycle et que l'acétate est responsable de la 
déprotonation-métalation concertée. 
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Le dernier chapitre (chapitre quatre) traitera en rétrospective de ce qui a été appris à 
partir de deux méthodologies divergentes et connexes et de comment ces résultats peuvent être 
exploités pour explorer d’autres types de fonctionnalisations directes sur des cyclopropanes. 
 
Mots-clés : palladium, argent, arylation directe, fonctionnalisation directe, cyclopropanes, 
catalyse, benzoazepinones, spirooxindoles 
v 
 
Abstract 
Over the last decade, the field of direct C–H functionalization has expanded as a 
consequence of the demand for cheaper, more efficient and greener chemical processes. 
Cyclopropanes represent a privileged moiety possessing numerous functions including the use 
as important biologically active agents and as useful synthetic intermediates towards accessing 
complex architectures. Despite their inherent value, cyclopropanes have not been widely 
explored as targets for direct C–H functionalization processes.   
This thesis will discuss two related but equally different methodologies involving the 
direct C–H functionalization of cyclopropanes via intramolecular palladium-catalyzed, silver-
mediated reactions. Chapter One will provide a brief glimpse into the foundations of direct 
functionalization and the contribution of these original findings towards key themes and 
concepts currently utilized in this field.  Challenges and strategies associated with the direct 
functionalization of sp3 centers will be highlighted with pertinent examples. Recent 
contributions from the literature towards directly functionalizing cyclopropanes will also be 
addressed. Key investigations regarding the mechanism and catalytic cycles for these 
processes will also be discussed.  
 Chapter Two will describe how 2-bromoanilides can be used to access valuable spiro 
3,3’-cyclopropyl oxindoles. The optimization and scope for this project will be discussed, 
followed by mechanistic studies to disprove the formation of a putative palladium-enolate. 
These mechanistic studies include a kinetic isotope effect and epimerization experiments, both 
of which confirmed that the reaction proceeds via a direct arylation manifold. 
Based on the findings from Chapter Two, the direct functionalization of cyclopropyl 
benzamides will be presented, whereby subsequent ring-opening gives rise to novel 
benzo[c]azepin-1-ones (Chapter Three). After presenting a brief optimization and scope, 
mechanistic studies will be presented to support the proposed catalytic cycle. Isomerization 
studies will also be discussed for both benzazepinone products. This section will conclude that 
cyclopropyl C–H functionalization occurs prior to ring-opening and that acetate is responsible 
for mediating the concerted-metallation deprotonation event.  
vi 
 
 The final chapter (Chapter Four) will conclude with insights into what has been learned 
from both divergent, yet related methodologies and how these findings can be exploited to 
further explore other direct functionalizations targeting cyclopropanes.  
 
Keywords : palladium, silver, direct arylation, direct functionalization, cyclopropanes, 
catalysis, benzoazepinones, spirooxindoles 
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Some men see things as they are and ask why.  
Others dream things that never were and ask why not.   
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Chapter 1 Introduction 
1.1 Utility and Applications of Cyclopropanes 
Cyclopropanes are a privileged class of molecules valued for their illustrious synthetic 
utility and for their continual presence in numerous pharmacological active compounds and 
natural products. When activated, cyclopropanes can undergo further functionalization via 
formal cycloadditions, ring-opening, and ring-opening-cyclization reactions, serving as useful 
synthetic building blocks (Figure 1).1  
 
 
Figure 1. Recent examples of total syntheses employing cyclopropane-based strategies.2,3,4 
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Nature has utilized the cylopropane motif to construct a range of natural products with 
varied complexities (Figure 2). For example, one of the simplest cyclopropane derivatives, 1-
aminocyclopropanecarboxylic acid (1) is a biosynthetic precursor to ethylene and plays an 
important role in plant growth regulation.5 
 
Figure 2. The cyclopropane motif can be observed in numerous natural products.6, 7, 8 
 
Following Nature’s cue, chemists have synthesized a collection of cyclopropane-
containing compounds and have exploited the diverse pharmacological profile of these 
cyclopropyl substrates to create several current market drugs (Figure 3).  
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Figure 3. Examples of 2011-2013 FDA-approved cyclopropane-containing drugs.9,10,11 
Medicinal chemists have commonly utilized cyclopropyl units to create 
conformationally-restricted compounds, often leading to improved target binding and 
increased potency.12 For example, Japan Tobacco employed this technique in developing a 
more potent ADAMTS-5 inhibitor (2) to treat osteoarthritis and observed a 8-fold 
improvement in activity (Figure 4).7  
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Figure 4.  Incorporating a cyclopropyl unit can improve potency.7  
Aside from widespread utility in organic and medicinal chemistry, cyclopropanes have 
been useful in mechanistic studies as radical clocks particularly in the study of cytochrome 
P450 enzymes.13 Following hydrogen abstraction, some cyclopropane derivatives can undergo 
a rapid ring-opening rearrangement to relieve ring strain, producing alkenes.  This reactivity 
can be exploited to both differentiate between hydrogen abstraction and electron transfer 
mechanisms, and to deduce the rate of reaction.13-15   
1.2 Properties of Cyclopropanes 
The cyclopropane unit has also attracted the attention of chemists due to its unique 
properties and bonding modes. Certain anomalous properties such as reactivity, bond 
dissociation energies, 13C coupling constants, and bond angles illustrate how cyclopropanes 
share more similarities with alkenes than with cycloalkanes (Table 1).   
Table 1. Comparison of properties between ethylene, cyclopropane and cyclobutane.16 
Entry Parameter Ethylene Cyclopropane Cyclobutane 
1 Bond Angle (∠HCH) (º) 117 114 109 
2 Bond Dissociation Energy (C–H)  (kcal/mol) 112 109 99 
3 Coupling Constant J (13C–H) (Hz) 156 161 134 
Cl S
O
O
N
N
O
HO2CIC50=1.6 µm
Cl S
O
O
N
N
O
HO2CIC50=0.2 µm
(2)
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Cyclopropanes also exhibit two types of strain: a.) angular (Bayer) strain and b.) 
torsional (Pitzer) strain. The ideal internuclear bond angle for sp3-hybridized orbitals is 109.5º; 
however, cyclopropanes have internuclear bond angles of 60º. Consequently, this drastic 
deviation from the ideal bond angle results in angular strain. As the cyclopropyl carbon atoms 
are arranged in a coplanar fashion, the C–H bonds are eclipsed, producing torsional strain 
(Pitzer).17 Cyclopropyl strain can serve as a thermodynamic driving force to produce a less-
strained product. Strain also enhances reactivity due to the resulting orbital re-hybridization, 
forcing electrons to occupy higher energy orbitals.18 
In order to account for the unusual properties of cyclopropanes, two main bonding 
models emerged: a.) The Walsh Model, and b.) The Coulson-Moffitt Model (Figure 5). 
 
Figure 5. The two main bonding models for cyclopropane.  
Based on Hartree-Fock (HF) calculations, Walsh proposed that cyclopropyl bonding 
resulted from the overlap of three-sp2 hybridized orbitals pointing towards the centre from 
each carbon, forming a delocalized MO-orbital. This stabilization gained from delocalization 
can account for the similarity in strain energies between cyclopropanes and cyclobutanes (27.5 
kcalmol-1 vs. 26.5 kcalmol-1), despite major geometrical differences.19 
To construct their model, Coulson and Moffitt invoked Valence Bond (VB) theory. As 
the smallest angle formed from s and p orbitals would be 90º, it was reasoned that higher “p” 
character in the C–C bond could allow for “bent bonding,” improving orbital overlap. Using 
this reasoning, their model involved three orbitals pointing outward by 22º.  This would 
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construct pseudo-sp2 hybridization for the cyclopropyl orbitals, which could account for the 
similarities between cyclopropanes and alkenes.16 
Due to the increased “p” character in cyclopropyl C–C bonds, the C–H bonds have 
enhanced “s” character, resulting in shorter C–H bonds and enhanced acidity compared to 
alkanes. This enhanced C–H bond acidity would make cyclopropanes enticing targets for 
direct C–H functionalization processes. 
1.3 Motivations for Direct Functionalization 
1.3.1 Sustainability and Efficiency as Motivational Forces 
Advances in chemistry have contributed to an increased standard of living via life-
saving drugs, essential commodities, and innovative materials. However, the side-effects of 
these beneficial discoveries are the detrimental effects of waste production, ecological damage 
and health hazards.20  
In the early 1990’s Anastas and Warner developed the 12 Principles of Green 
Chemistry as guidelines for chemists to consider when developing a new process. These 
principles emphasize waste prevention, energy conservation, and the elimination of 
unnecessary and hazardous reagents.21 This philosophy encourages chemists to innovate and 
to strive towards developing the most efficient process possible as a measure of excellence. 22   
Focusing on designing greener, more efficient processes also benefits industry as 
reducing operational costs and creating a better public image can provide corporations with a 
significant competitive advantage.23 
Therefore, despite different motivational factors, all players in the chemical community 
can mutually profit from adopting Green Chemistry principles in terms of scientific progress, 
improved profitability, and the satisfaction of creating a more sustainable future.  
1.3.2 The Role of Catalysis  
 Paul Anastas stated, “Catalysis is one of the fundamental pillars of Green 
Chemistry.”24 This is because adopting catalytic methods can reduce reagent amounts, can 
minimize energy input, and can eliminate required hazardous and toxic reagents. Catalysis can 
also increase the selectivity of reactions, nullifying the need for derivatization. In addition, the 
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use of catalysts opens up the potential for new synthetic disconnections, which can provide 
shorter, more flexible routes towards targets.  
 Industry has already realized the advantages; catalytic processes were responsible for 
90% of chemical products and profits of 900 billion dollars per year as of 2007.25 
Additionally, the scientific community continues to recognize the merits of catalysis research. 
The most recent example of this recognition was awarding the 2010 Nobel Prize to Heck, 
Negishi and Suzuki for their contributions to transition metal-catalyzed cross-coupling 
chemistry.  
1.4 A Brief Overview of Direct Functionalization 
1.4.1 Beyond Traditional Cross-Coupling 
Traditional cross-coupling chemistry has offered chemists greater flexibility in the 
design and synthesis of a myriad of novel compounds. However, with the desire to greater 
improve efficiency, researchers sought out new methods to further refine cross-coupling. 
 
 
Figure 6. Comparison between traditional cross-coupling and direct C-H functionalization.  
 
As Figure 6 illustrates, traditional cross-coupling involves pre-functionalization of the 
starting material to form an organometallic or pseudo-organometallic species. This species can 
 Traditional Cross-Coupling
Direct C-H Functionalization
H [M]
X
H H
R
pre-functionalization cat. [TM] R
H H
X
H H
R
[TM]= transition metal, eg. Pd, Fe, Cu, Ni
[M]= B, Si, Sn, Mg, Zn
X= I, Br, OTf, Cl, F
-HX
-MX
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then be coupled with a halide or pseudo-halide partner using transition metals such as 
palladium, iron, or copper.26 
Direct C–H functionalization endeavors to improve these traditional cross-couplings by 
eliminating the need for pre-activated stoichiometric and toxic organometallic reagents and by 
alternatively treating the C–H bond as a functional group that can be converted like any other 
activated C–X bond.27 Therefore, devising new methods to directly activate and functionalize 
C–H bonds can minimize waste production, and improve process efficiency.28 Consequently, 
it becomes evident how developing direct functionalization processes can lead to the 
modernization of these traditional reactions. 
The following sections will provide an overview of key themes and concepts used in 
direct functionalization processes. The first section will provide early examples of C–H 
activation involving both organometallic and coordination chemistry. The second section will 
describe the evolution of intramolecular direct arylation and mechanistic considerations. 
Finally, the third section will address the challenges and strategies involved in the C–H 
functionalization of sp3 centers and provide literature precedence for C–H functionalization of 
cyclopropanes.  
1.4.2 Outer-Sphere vs. Inner-Sphere Mechanisms 
Direct C-H bond functionalization can be described by two distinct mechanisms. The 
outer-sphere mechanism depends on ligand interactions with the substrate instead of direct 
interactions between the substrate and the metal species.  The metal complex is oxidized, and 
then the ligand can mediate C–H cleavage via either a concerted C–H insertion process or via 
H-atom abstraction/ radical rebound. In contrast, the inner-sphere mechanism involves C–H 
bond cleavage to form an organometallic species. An external reagent can then be added or an 
intramolecular reaction can occur at the metal center to produce a newly functionalized 
product (Figure 7). 29,30 
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Figure 7. Outer-sphere mechanism vs. inner-sphere mechanism. [M]=metal, Y=ligand, 
FG=functional group. 
 
Most commonly referred to as “C–H activation” or “C–H functionalization” processes, 
inner-sphere mechanisms study the intimate interactions between the transition metal, ligand 
and substrate; this topic will be the focus of this work.   
 
1.4.3 Early Examples of C–H Activation 
Chemists have been investigating and developing new ways to activate small “inert” 
molecules since the late 1950’s via transition-metal chemistry. These early examples often 
required π-group participation of aromatic C–H bonds (eq 1) or for the C–H bond of interest to 
be already attached to the metal system, leading to intramolecular C–H activation via 
cyclometalation (eq 2) (Scheme 1). 28  
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Scheme 1. Early examples of arene C–H activation via transition-metal systems. 
 
 
 
In 1982, Janowicz and Bergman discovered an example of intermolecular alkane activation 
involving IrICp* catalyst 3 (Scheme 2). 
 
Scheme 2. Intermolecular C–H activation of alkanes using an IrICp* catalyst. 
 
 
 
Despite being stoichiometric in nature, these early examples demonstrated that 
transition metals were capable of activating aryl and alkyl C–H bonds. The next step towards 
harnessing the synthetic potential and applications of these reactions was to design catalytic, 
air-stable processes.  
1.5 Intramolecular Direct Arylation 
When developing direct arylation methodologies, intermolecular reactions are often 
more challenging in terms of regioselectivity, as there is a greater degree of freedom. In 
comparison, intramolecular reactions utilize tethers to restrict the freedom of motion, 
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imparting regiocontrol (Scheme 3).27 By modifying the tether systems, these reactions can 
provide access to an assortment of heterocyclic and polycyclic systems. 
 
Scheme 3. General reaction for intramolecular direct arylation. [TM]=transition metal, 
X=halide or pseudo-halide, Y=C, O, NH, etc. 
 
 
 
 
 
 
 
 
 
1.5.1 Early Intramolecular C–H Arylation: Ames and Opalko 
 
In 1983 Ames and Opalko published one of the first examples of direct intramolecular 
arylation involving the synthesis of dibenzofurans from 2-bromophenyl phenyl ethers.31 
Despite requiring high temperatures (170 ºC), these initial conditions were tolerant of both 
electron-withdrawing and electron-donating substitutions, producing various substituted 
dibenzofurans in moderate to good yields (Scheme 4). 
 
Scheme 4. Early example of intramolecular direct arylation to produce dibenzofurans.  
 
 
 
O
Br
R
O
Pd(OAc)2 (10 mol %)
Na2CO3
R
H
DMA, 170 ºC
R Yield (%)
4-NO2 78
2-NO2 76
2-CN 80
H 74
2-CO2H 56
2-HOCH2 66
Y
H
R2R1
X [TM]
YR
1 R2
Intramolecular
Direct Arylation
12 
 
 In a subsequent paper, Ames and Opalko extended their methodology to include 
different types of tethers and to target six-membered rings in addition to five-membered ring 
systems.32 Both organic and inorganic bases were screened and different 2-haloarenes were 
tested (Scheme 5). During the synthesis of 5, a solvent effect was observed with the iodo 
analogue. Both DMA and MeCN gave the same yield (55%); however, MeCN gave a higher 
ratio of dehalogenation to homocoupling (50:5 vs. 30:25). Compounds 4 and 6 were both 
formed in good to excellent yields from their iodo precursors using organic bases.  
 
Scheme 5. Intramolecular direct arylation to produce 5-membered rings.  
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 Ames and Opalko also studied the effect of the halide on the synthesis of 7 (Scheme 
6).32 The chloro derivative required 36 hours and gave low yields (15%); however, the bromo 
substrate gave moderate conversion (53%) in only 2.5 hours. When N-methylimidazole (NMI) 
was utilized as a base instead of sodium carbonate, the iodo substrate produced 7 in moderate 
yields (44%). 
 
Scheme 6. Effect of halide on synthesis of 6-(5H)-phenanthridinone 7. 
 
 
Other interesting six-membered heterocycles (8-9) were also accessible in moderate 
yields  (Scheme 7). It is worth noting that only bis-sulfonamide 9 produced cyclized product; 
mono-sulfonamide 10 gave no conversion.32  
 
Scheme 7. Other accessible heterocycles. 
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To explain the difference in reactivity between using protected vs. unprotected tethers 
(11 vs. 12) Ames and Opalko proposed that if the bridged atom was too Lewis-basic, Pd 
would form non-productive complex 15 instead of generating desired products 13 and 14 
(Scheme 8). This also accounted for the poor reactivity of mono-sulfonamide 10. 
 
Scheme 8. Effect of using a Lewis-basic group on reactivity. 
 
 
 In summary, Ames and Opalko synthesized several interesting five- and six-membered 
ring systems in moderate to excellent yields using Pd(OAc)2, an organic or inorganic base and 
high temperatures (150 ºC to 170 ºC). It was also the first work to propose six- and seven-
membered palladacycle intermediates,33  and provided foundations for future chemists to 
expand upon, while leaving several mechanistic questions worthy of further investigation.  
 
1.5.2 Intramolecular Direct Arylation Accelerated by Phenolates 
 In 1997, Rawal et al. reported an anion-accelerated palladium-catalyzed intramolecular 
cyclization utilizing phenolate 16, which yielded predominantly ortho product 17 and trace 
amounts of para product 18 (Scheme 9).34 
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Scheme 9. Initial conditions by Rawal et al. yielding both ortho and para products. 
   
 Further optimization led to the use of Herrmann’s catalyst (25) in the presence of 
Cs2CO3 and DMA.  In addition to bromo and iodo substrates 19 and 20, other tethered systems 
were also viable (21-23), although heteroatom-containing atoms were thought to accelerate the 
reaction (Scheme 10). Blocking of the ortho position gave exclusively product 24.  
Scheme 10. Modified reaction conditions and scope. 
 
Rawal et al. also tested methoxy substrate 26 and obtained minimal conversion of para 
product 27, indicating that: a.) the free hydoxy group was essential for reactivity and b.) the 
O
O
Pd(PPh3)4 (20 mol%)
tBuOK (3.0 equiv)
DMA, 95 ºC
48 h
Br
(17)
87% yield
OH
OH
O
(18)
2-5% yield
HO
H
H
(16)
Y
Y
Catalyst (5 mol%)
Cs2CO3 (3.0 equiv)
DMA, 90-115 ºC
24-60 h
X
OH
OH
Pd
P
Ar Ar
O
O
Me
O
Me
O
Pd
P
Ar
Ar
Ar= o-tolyl
Catalyst
 X= Br (19), I (20)
 Y= C (21), O (22), NCO2Me (23)
75-96% yield
O
O
Catalyst (5 mol%)
Cs2CO3 (3.0 equiv)
DMA, 95 ºC
24 h
I
OH
Me
HO
80% yield
(24)Me
(25)
16 
 
reaction is sterically sensitive (Scheme 11).  The increased reactivity of the phenol was 
attributed to increased electron density of the aromatic ring.  
Scheme 11. Replacing the free hydroxy group with methyl ether 26 gave poor conversion. 
 
  As milder bases could be utilized (K2CO3, Cs2CO3) and palladium was also required, a 
potential benzyne intermediate could also be disproved. These observations led to the 
following proposed catalytic cycle (Figure 8). Oxidative addition by palladium into the aryl-
halide bond of 28 generates phenolate 29. Nucleophilic attack by phenolate 29 onto palladium, 
followed by tautomerization produces diaryl palladacycle 30. Finally, reductive elimination 
from palladacycle 30 generates cyclized product 17.  
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Figure 8. Proposed catalytic cycle for anionic-accelerated cyclization, M= Cs, K. 
 
1.5.3 Improvements to Early Intramolecular Direct Arylation 
The Fagnou group began its foray into intramolecular direct C–H functionalization by 
improving both Ames and Opalko’s, and Rawal’s methodologies (Scheme 12). Bromo 
substrates 31-33 gave their desired cyclized products utilizing a variety of tethers in excellent 
yields, allowing for easy access to a range of polycyclic systems (34-36).  Electron-
withdrawing, electron-donating, ortho, meta, and para substituents were all well-tolerated.  
Most importantly, Fagnou et al. could access substrates that were previously unreactive. 
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Scheme 12. Fagnou et al ’s improvement upon the work by Ames, Opalko and Rawal. 
 
 
  
The key component was electron-deficient biaryl phosphine ligand 37. Upon 
increasing the temperatures (125 ºC to 145 ºC), lower catalyst loadings could be employed 
(0.1 mol% to 0.5 mol%).  It is also worth noting that K2CO3 was an important base as this 
reduced dehalogenation  (24:1 using K2CO3 vs.165:1 using Cs2CO3). Mechanistic studies 
determined that the intramolecular KIE was 3.5, which was atypical for electrophilic additions 
to arenes and suggested that C–H cleavage could be the rate-determining step. 35 
 These types of intramolecular direct arylation reactions were fully explored by the 
Fagnou group in several subsequent papers. By using NHC-catalysts 38 and 39, aryl chlorides 
40 and 41 could be used as starting materials (Scheme 13). A large collection of five- and six-
membered ring systems (42 and 43) were formed including several targets that Ames and 
Opalko could not obtain, demonstrating the importance of ligand selection in producing a 
sufficiently reactive catalyst.36 
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Scheme 13. An NHC-catalyst system provides access to various 5- and 6-membered 
heterocycles from aryl chlorides. Ar= 2,5-diisopropylphenyl. 
 
 
 
 Aryl iodides 44 and 45 could also be adapted for this intramolecular direct arylation 
methodology targeting both five- and six membered rings 46 and 47. Using Pearlman’s 
catalyst (Pd(OH)2/C), a ligand-free methodology was developed which showed excellent 
functional group tolerance and was unaffected by steric hindrance (Scheme 14). 
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Scheme 14. Pearlman’s catalyst reacts with aryl iodides to produce 5- and 6-membered ring 
systems. 
 
 
 
Initially the goal was to develop a heterogeneous system as solid-supported catalysts 
can be easily filtered from the reaction mixture. Further studies, however, showed that 
Pearlman’s catalyst was leaching into solution and forming a homogenous catalyst system. 
This observation accounted for higher catalyst loadings (10 mol%) compared to previous 
methodologies employing aryl chlorides and aryl bromides (1-3 mol%).37 
Subsequently, Fagnou et al. published a unified, improved method for aryl chlorides 
and aryl bromides 48 and 49 (Scheme 15).38 A ligand screen indicated that trialkylphosphines 
and a few NHC-ligands gave better conversions compared to triarylphosphines and ortho-
biaryl phosphines. Although several organic and inorganic bases gave good yields, NaOAc 
and K2CO3 reported superior yields (81% and 100% respectively) while producing low 
amounts of dehalogenated by-products (99:1 for both bases). Electron-deficient and electron-
rich arenes were tolerated for both aryl bromides and aryl chlorides and sterics did not have a 
detrimental effect on reactivity. 
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X
I
Z
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X=C, Z= NCOPh
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KOAc (2 equiv) 
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KOAc (2 equiv) 
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R= 5-MeO
R= 3-CN
R= 3,5-dimethyl
R R
H
H
(44)
(45)
(46)
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Scheme 15. Improved conditions for aryl chlorides and aryl bromides. 
 
As aryl iodides gave poor conversion under these new conditions, it was postulated that 
perhaps excess iodide was poisoning the catalyst. The addition of KI to bromo substrates 
confirmed this suspicion (Entry 3, Table 2). Although Cs2CO3 gave better yields without the 
need for silver, it increased dehalogenation (Entry 4, Table 2).  One equivalent of silver was 
then added, causing improved yields, most likely due to sequestration of the excess iodide 
(Entries 5-6, Table 2). The reaction also proceeded much faster and could be conducted at 
lower temperatures due to silver’s accelerating effect. 
 
 
 
 
 
 
 
 
 
 
Y
X
Z
Y Z
K2CO3 (2 equiv) 
DMA, 130 ºC
8 to 16 h
Pd(OAc)2 (1-5 mol%)
PCy3 •HBF4 (2-10 mol%)
R R
             X= Cl, Br
Y =C, Z = O
   =C,     = NBz
   =C,     = NMs
   =CO,  = NMe
   =C,     =  NTs
   =C,     = C
R=Cl, OMe, CN, CF3, 
     3,5-dimethoxy, CO2Me
75-99% yield
H
Y
X
Y
R
R
              X=Cl, Br
              Y=O, NH
              R=F, CF3, 
              3,5-dimethyl,
              Me, OMe
78-94% yield
K2CO3 (2 equiv) 
DMA, 130 ºC
8 to 16 h
Pd(OAc)2 (1-5 mol%)
PCy3 •HBF4 (2-10 mol%)
H (50)
(51)
(48)
(49)
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Table 2. The halide effect. 
 
 
Using these new conditions, an assortment of 5- and 6-membered rings (52 and 53) 
could be accessed in excellent yields from aryl iodides 54 and 55 (Scheme 16). 
Scheme 16. Improved conditions for aryl iodides employing silver carbonate. 
 
 
 
 The KIE was also recalculated to be 4.25 using the new reaction conditions (Scheme 
17), which again disfavored an electrophilic aromatic substitution-type mechanism. 
 
 
X
O
O
Base, Additive
DMA, 130 ºC
12 h
Pd(OAc)2 (1 mol%)
PCy3 •HBF4 (2 mol%)
Entry X Base Additive Yield
1 Br K2CO3 none 99
2 I K2CO3 none 64
3 Br K2CO3 KI <5%
4 I Cs2CO3 none 89
5 I K2CO3 AgOTf 99
6 I K2CO3 Ag2CO3 99
Y
I
Z
Y Z
R R
81-94% yield
Pd(OAc)2 (3-5 mol%)
PCy3 •HBF4 (6-10 mol%)
K2CO3 (2 equiv) 
Ag2CO3 (0.5 equiv)
DMA, 130 ºC
8-16 h
Y
I
Y
81-99% yield
Pd(OAc)2 (3-5 mol%)
PCy3 •HBF4 (6-10 mol%)
K2CO3 (2 equiv) 
Ag2CO3 (0.5 equiv)
DMA, 130 ºC
8-16 h Y=O, NH, C
        Y=C,   Z=O
        Y=C,   Z=NPiv
        Y=CO, Z= NMe
        R=OMe, furyl, thiophenyl
H
H
(54)
(55)
(52)
(53)
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Scheme 17. Intramolecular KIE study expressed as a ratio of non-deuterated product (PH) to 
deuterated product (PD). 
 
The Fagnou group also explored utilizing other additives for this methodology and 
discovered that pivalic acid was the most effective additive, producing quantitative yields of 
product 57. A more electron-deficient triarylphosphine was also selected as these ligands have 
been shown to enhance reactivity by creating a more electrophilic palladium center. These 
discoveries led to a new set of low temperature conditions  (45 ºC compared to 130 ºC) which 
still maintained excellent conversions and functional group tolerance (Scheme 18).39 
 
Scheme 18. Changes to ligand and additive allow for lower reaction temperatures.  
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K2CO3 (3.0 equiv)
PivOH (30 mol %)
DMA, 50 ºC
12 h
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1.6 Mechanistic Considerations: Carboxylate–Assisted Metalation  
 The emergence of novel C–H bond functionalizations and early mechanistic 
investigations required a new mechanistic explanation to account for the C–H bond metalation 
step.  Previous explanations included oxidative addition, σ-bond metathesis and electrophilic 
substitution; however, it was discovered that invoking a carboxylate-assisted concerted 
metalation step could justify these anomalous experimental results (Figure 9). 
 
 
 
Figure 9. C–H bond metalation mechanisms. 40,41 
 
 Carboxylate-assisted C–H bond metalation has been previously proposed to occur in 
early stoichiometric reactions.41 The first example of concerted-metalation deprotonation 
emerged in 1955 when Winstein and Traylor attempted to explain the acetolysis of 
diphenylmercury in acetic acid.42 In 1980, Roberts et al. used this mode of action to explain 
arene mercuration after extensive kinetic studies including a KIE of 6, which suggested 
simultaneous intramolecular proton-transfer (Figure 10). Despite the parallels between the 
results of both Roberts, and Winstein and Traylors’s, there was insufficient evidence to 
disprove electrophilic aromatic substitution. 
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Figure 10. Proposed transition state for carboxylic-assisted C–H cleavage in arene 
mercuration. 
 
Other researchers observed similarities between the palladation and mercuration of 
benzene; however, Ryabov was the first to provide detailed mechanistic studies to support a 
concerted-metalation deprotonation mechanism. The ortho-palladation of N,N–
dimethylbenzylamine (DMBA–H) with Pd(OAc)2 was the reaction of study (Scheme 19).  
 
Scheme 19. Ortho-palladation of N,N–dimethylbenzylamine  using Pd(OAc)2. 
  
Kinetic studies indicated that C–H metalation in chloroform was rate-limiting and that 
the Pd(II) species was electrophilic based on the negative slope on the Hammett plot (ρ= -1.6) 
for the reaction. Ryabov also reported a KIE of 2.2 and a negative entropy of activation of 60 
calK-1mol-1 which was suggestive of a highly ordered transition state formed via acetate-
mediated intramolecular proton abstraction (Figure 11).  Crystallographic data of related 
palladium precursors also indicated possible agostic interactions.40,41 
 
Figure 11. Proposed transition state for ortho-palladation of N,N-dimethylbenzylamine. 
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 Davies, McGregor and Donald followed in the footsteps of Ryabov by conducting 
density field theory (DFT) calculations for the cyclometalation of Pd(OAc)2[DMBA–H]. 
These studies disproved the possibility for a Wheland intermediate and instead indicated that 
C–H metalation proceeds via an initial C–H agostic interaction observed in complex 58, which 
enhances the acidity of the ortho-proton to promote facile intramolecular deprotonation by 
acetate. This process was proposed to occur via six-membered cyclic transition state 59 which 
was calculated to have a low energy barrier for proton transfer (ΔEA= +0.1 kcalmol-1) and 
favored the formation of resulting palladacycle 60 (Scheme 20). 40,41 
 
Scheme 20. Calculated reaction profile for the cyclometalation of Pd(OAc)2[DMBA–H]. 
  
 
 In 2006, Echavarren and Maseras conducted experimental and theoretical studies to 
develop a modified mechanism for intramolecular direct palladium arylation.43 Two 
observations indicated that an electrophilic aromatic substitution pathway was not viable. 
Firstly, both literature precedent and their results reported significant KIE’s (3.5-6.0), 
indicating that C–H cleavage could be the rate-determining step. Secondly, the regiochemistry 
for these reactions contradicted reactivity patterns for an electrophilic aromatic substitution 
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pathway and electron-withdrawing substituted substrates 61 and 62 increased reactivity, 
instead of deactivating the arene (Scheme 21). 
 
Scheme 21. Regiochemical ratios disfavor electrophilic aromatic substitution.  
 
 
 
 DFT calculations were then performed to study the potential reaction mechanisms for 
carbonate-assisted direct arylation (Figure 12).  Both intramolecular (63) and intermolecular 
(64) concerted-deprotonation processes were feasible; however, the intermolecular process 
was more energetically favorable by 6.1 kcalmol-1. The least energetically favorable state did 
not involve carbonate (65).  In accordance with both these DFT calculations and their 
experimental results (Scheme 21), Echavarren and Maseras proposed that carbonate could 
assist as an external non-coordinated base via an intermolecular concerted-metalation 
deprotonation mechanism.40,41 This conclusion was further supported by additional ligand 
screens, which showed improved conversions when bidentate ligands were used over 
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monodentate ligands.44 As it is difficult for carbonate to displace these bidentate ligands, only 
an intermolecular mechanism would be possible.  
 
 
 
Figure 12. Calculations for potential mechanisms for carbonate-assisted direct arylation.  
 
Lafrance and Fagnou observed a beneficial effect when pivalic acid was used an 
additive in the palladium-catalyzed direct arylation of benzene (Scheme 22).45 
 
Scheme 22. Direct arylation of benzene using pivalic acid as a co-catalyst. 
 
 
 
Competitive studies reflected previous observations whereby electron-deficient arenes such as 
fluorobenzene were favored over electron-rich substrates such as anisole as indicated by the 
regiochemical ratios for the biaryl products (2:1 for (66:67) vs. 1:11 for (68:69)) (Scheme 23).   
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H
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Me2N
PCy2
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Scheme 23. Competitive experiments demonstrate a preference for electron-deficient arenes 
over electron-rich substrates. 
 
 
 
The intermolecular KIE was also determined to be 5.5 (Scheme 24), suggesting that C–H 
cleavage could be the rate-determining step. 
 
Scheme 24. Intermolecular kinetic isotope experiment using deuterated benzene. 
 
 
 It is worth noting that both intermolecular (A) and intramolecular primary KIE 
experiments (B) cannot be used to confirm C–H cleavage as the rate-determining step 
(Scheme 25). 46 However, if the KIE is equal to 1 for intramolecular and intermolecular 
experiments, it can be concluded that C–H cleavage is not the rate-determining step.  To 
conclusively determine that C–H cleavage is the rate-determining step, a parallel set-up should 
be employed (C), and the rate constants of the non-deuterated (kH) and deuterated constants 
Br
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DavePhos (2-3 mol%)
K2CO3 (2.5 equiv)
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OMe
2:1
95% conversion
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PivOH (30 mol%)
benzene (0.5)
/PhF (0.5)/DMA (1.2)
120ºC
F
F
1:11
100% conversion
(66) (67)
(68) (69)
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(KD) should be measured. If the ratio between kH and kD is greater than 1, C–H cleavage can 
then be identified as the rate-determining step.  
 
Scheme 25. Examples of commonly used KIE experiments. 
 
 
 Lafrance and Fagnou further examined the role of pivalate via conducting DFT 
calculations. The transition state energy employing the pivalate anion (70) was reduced by 1.3 
kcalmol-1 compared to a transition state utilizing bicarbonate anion (71) (24.9 kcalmol-1 vs. 
26.2 kcalmol-1), indicating the stabilizing effect of pivalate (Figure 13).  
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Figure 13. Comparisons between transition state energies containing pivalate (70) and 
bicarbonate (71). 
 
Lafrance and Fagnou also noticed a concentration dependence on pivalate. Lower 
yields and increased dehalogenation were observed using stoichiometric sources of pivalate 
(KOPiv), suggesting an inhibitory effect of excess pivalate on the catalyst.  
 The Fagnou group further studied the role of pivalate and carbonate when investigating 
the direct alkane arylation of N-methylamides.47 By monitoring the concentration of PCy3 with 
and without pivalate, it was discovered that pivalate also promotes the dissociation of 
phosphine from Pd(II). Pivalate also prevents the formation of nonproductive intermediate 72, 
which forms as a result of excess phosphine (Scheme 26). Additionally, a synergistic 
relationship between carbonate and pivalate was observed; poor reactivity was detected in the 
absence of a carbonate-containing base. Further calculations revealed that the concerted-
metallation step is reversible. Consequently, to prevent intermediate 73 from reverting back to 
72, it was proposed that carbonate drives the reaction to completion by sequestering the 
proton. In this sense, pivalate acts as a proton shuttle to transfer the proton from the substrate 
during C–H cleavage to the carbonate base.  
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Scheme 26. Carbonate as a driving force via proton sequestration. 
 
 
These experimental and theoretical results led to the following proposed catalytic cycle 
(Figure 14). Pd(0) undergoes oxidative addition into the Ar–Br bond of 75 to form 76, 
followed by ligand exchange to form κ2-intermediate 72. Pivalate mediates the concerted-
metalation deprotonation event to form palladacycle 77, which undergoes irreversible 
deprotonation, then reductive elimination to produce 74.  
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Figure 14. Proposed catalytic cycle for alkane arylation based on experimental evidence and 
DFT calculations. 
 
Over the last ten years, chemists have gained a greater understanding regarding C–H 
bond metalation mechanisms. Experimental and theoretical evidence including significant 
KIE’s, the superior reactivity of electron deficient species and DFT calculations disfavored 
electrophilic aromatic substitution as a viable pathway. Additionally, these mechanistic studies 
revealed the crucial role of carboxylate counter ions such as acetate, carbonate and pivalate in 
mediating C–H bond metalation. 
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1.7 Direct Functionalization of sp3 Centers 
   As previously highlighted, understanding how to directly functionalize C-H bonds, can 
contribute to greener and more efficient reactions that can enhance the current synthetic 
toolbox. The literature reports a vast array of reactions targeting the direct functionalization of 
sp2 centers and these methods have been successfully employed as impressive synthetic 
devices.27,48-51 In contrast, despite the prevalence of C-(sp3)–H bonds, methods targeting the 
formation of C–C bonds via directly functionalizing sp3 centers remains underexplored.  
1.7.1 Challenges and Strategies 
 In comparison to C-(sp2)–H bonds, the activation of C(sp3 )–H bonds poses a different 
set of challenges.30,52 For instance, C-(sp3)–H systems lack “active” HOMO or LUMO orbitals 
for transition-metal interactions. Additionally, these systems have higher bond dissociation 
energies and are, therefore, more “inert” compared to sp2 centers. Finally, developing a system 
with good regiocontrol poses its own set of difficulties. As a compound can contains several 
types of C–H bonds, an ideal system must be capable of preferentially activating one type of 
C–H bond over the other. 
 In relation to reactivity, more acidic C–H bonds are much easier to functionalize 
compared to non-acidic C–H bonds. Figure 15 compares C–H bond acidities for sp2 and sp3 
centers. For example, secondary C–H bonds are more difficult to functionalize compared to 
primary C–H bonds.  
 
 
Figure 15. Comparison of C–H bond acidities.  
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In terms of regiocontrol, certain systems pose fewer difficulties in obtaining 
preferential C–H functionalization (Figure 16).  For example, it is much easier for systems 
containing C-(sp3)–H bonds adjacent to quaternary centers, as this eliminates the possibility 
for β-hydride elimination. In other cases, other positions can be blocked so that only one type 
of C–H bond is available; however, this approach limits the types of accessible substrates. 53 
 
  
Figure 16. Regiocontrol challenges based on substrate of interest. 
 
Two main approaches have been utilized to combat these difficulties. The first strategy 
involves installing Lewis-basic directing groups containing lone pairs or a π-system, which 
provides coordination sites to guide the metal, leading to enhanced reactivity and improved 
regiocontrol. Another strategy exploits the conformationally restricted nature of intramolecular 
reactions. Oxidative addition into an aryl–halide bond can generate an electrophilic Pd species, 
which can then undergo C–H bond metalation with a C–H bond in close proximity.  
By designing systems to take advantage of these strategies, chemists have been able to 
successfully directly functionalize some sp3 centers. The next sections will discuss these 
strategies in more detail and provide pertinent examples.  
1.7.2 Examples of Heteroatom-Directed C-(sp3)–H Arylation 
Employing a directing group can often circumvent reactivity and regioselectivity issues 
through providing sites for coordination or chelation, leading to a more ordered and 
energetically favorable transition state. These groups often contain heteroatoms such as 
nitrogen, sulfur and phosphorous (i.e: pyridine, sulfide, phosphine moieties) as these can act as 
strong σ−donors or  π−acceptors to coordinate and orient the C–H bond for cleavage (Figure 
17). 53,54 
easier more difficult
Regiocontrol Challenges
>
H
H
H
H
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Figure 17. Heteroatom-containing directing groups provide regiocontrol and enhance 
reactivity via chelation. DG= directing group, [M]= transition metal, FG= functional group. 
 
 Although directing groups can help mediate C–H functionalization, there are also 
drawbacks. Firstly, a weakly coordinating group must be selected or the metallacycle formed 
may be too stable and prevent further functionalization. Secondly, it is ideal to select directing 
groups that are easily removable, can be post-functionalized, or that can be incorporated into 
the resulting product.  However, installing and removing a directing group is only useful when 
the substrate cannot be accessed via other means, as this decreases the synthetic efficiency, 
causes stoichiometric waste production and most importantly defeats the purpose of direct 
functionalizations. 55 
 Directing groups have previously exhibited great utility in classical ortho-metalation 
reactions. For example, Tremont and Ur Rahman made an important contribution when they 
published the first example using acetanilide 78 as a directing group in ortho-alkylation  
(Scheme 27).56 
Scheme 27. Use of acetanilides as directing groups for ortho-alkylation. 
 
 
As this original finding was stoichiometric in Pd, further investigations indicated that 
the addition of excess AgOAc could regenerate the Pd(II) species, producing a TON of 10  
To explain these observations, Tremont and Ur Rahman proposed a Pd(II)-Pd(IV) 
cycle where 78  undergoes cyclometalation to give palladacycle 79 , followed by oxidative 
addition to produce  highly reactive Pd(IV) species 80 . Reductive elimination produces ortho-
alkylated product 81. Anion exchange between AgOAc and the Pd(II) species then regenerates 
Pd(OAc)2 by producing AgI (Figure 18).  
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Figure 18. Proposed Pd(II)-Pd(IV) cycle for ortho-alkylation of 78. 
 
Inspired by Tremont and Rahman, the Daugulis group developed a catalytic method 
employing pivalamides (82) and acetanilides (83) as excellent directing groups for the ortho-
arylation of aryl iodides (Scheme 28).57  
 
Scheme 28. Daugulis’s improvement on Tremont and Rahman’s seminal work. 
 
 
 
This class of directing groups (84-86) could also be post-functionalized via hydrolysis 
or cyclization procedures, providing access to other valuable molecules such as 
phenanthridines (87), benzonitriles (88) and fluorenones (89) (Scheme 29).58, 59 
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Scheme 29. Post-functionalization of directing groups can lead to other valuable products. 
 
 
 
 The formation of cyclized products 87 and 89 depends on the substituent on the amide 
(Scheme 30). If an alkyl subsitutent is present as observed for substrate 90, a stabilized 
carbocation cannot be formed and electrophilic aromatic substitution occurs instead to 
generate intermediate 91. Hydrolysis then renders the cyclized product 92. However, in the 
case of cyclohexyl substituted 93, a stable carbocation can be formed; therefore, dealkylation 
can occur, followed by formation of benzonitrile product 94.59 
Literature precedence has indicated that the cyclohexyl carbocation is much more stable than 
the isopropyl cation.60 
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Scheme 30. Mechanism illustrating the subtleties in forming cyclized product 92 vs. 
benzonitrile 94 based on differing carbocation stabilities. 
 
 
 
The Daugulis group then applied the principles from earlier sp2 methodologies towards 
developing some of the first examples of C-(sp3)–H arylation. Depending on whether 8-
aminoquinoline amide or picolinamide was used as a directing group, primary or secondary 
C–H bonds could be arylated regioselectively.61  
8-aminoquinoline-derived auxiliaries 95 and 96 provided access to β-arylated products 
97 and 98, respectively (Scheme 31). It was also observed that secondary C–H bonds reacted 
faster than primary C–H bonds using this auxiliary, allowing for the tetraarylation of 
isobutyric amide 96.  
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Scheme 31. 8-aminoquinoline-directed β-arylation of secondary C–H bonds. 
 
When the auxiliary was switched to picolinamide-based systems 99 and 100, γ-arylated 
products could be accessed (Scheme 32). In contrast to 8-aminoquinoline-derived auxiliaries, 
primary bonds reacted faster than secondary bond and produced only the monoarylated 
products 101 and 102, illustrating excellent regiocontrol. 
 
Scheme 32. Picolinamide-directed γ-arylation of primary C–H bonds. 
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Based on mechanistic studies, the picoliniamide and 8-aminoquinoline-derived auxiliaries 
were proposed to go through the intermediates presented in Scheme 33. Auxiliary 103 
undergoes complexation with Pd(OAc)2 to form  Pd(II) intermediate 104. Rapid 
cyclometalation of 104 followed by oxidative addition generates Pd(IV) bidentate chelate 105. 
Reductive elimination then liberates Pd, rendering arylated product 106. The formation of the 
double five-membered ring chelate observed in 105 helps to stabilize the high energy 
Pd(IV)species.61 Additionally, by completely saturating coordination sites on Pd, the 
formation of by-products resulting from β-hydride elimination can be prevented. 
 
Scheme 33. Proposed mechanism for picolinamide- and 8-aminoquinoline-derived auxiliaries. 
 
 
In 2010, Daugulis also showed that 2-thiomethylaniline 107 also functioned as a good 
directing group for arylating primary sp3 C-H bonds.53 Auxiliary 107 was later applied to the 
synthesis of phenylalanine derivatives such as 108, which could be accessed in good 
enantioselectivity (Scheme 34). 62 
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Scheme 34. Use of 2-thiomethylaniline as a cleavable auxiliary. 
 
Although the Daugulis group developed three exceptional auxiliaries that could arylate 
primary and secondary sp3 bonds preferentially, these auxiliaries required installation and 
removal, decreasing the synthetic efficiency for these processes. 
As an alternative, the Yu group offered a more straightforward approach utilizing 
simple carboxylic acids such as 109. This method also allowed for β-arylation using aryl 
iodides; however, selectivity was a factor and mixtures of mono- and diarylated products (110 
and 111) were observed (Scheme 35).63 Additionally, carboxylic acids were not as reactive 
and 72% yield was the highest yield obtained. 
Scheme 35. Use of carboxylic acids for β-arylation using aryl iodides 
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To develop an improved auxiliary, the Yu group screened several N-aryl amides, and 
finally found success using electron-deficient N-aryl amide 112 (Scheme 36).64 CsF was 
selected as the base as it worked well for all substrates including those containing α−protons. 
It is worth noting that 112 does not undergo Buchwald-Hartwig N-arylation under the reaction 
conditions and that depending on the substrate, some diarylated product is still formed.30 
 
Scheme 36. Use of an electron-deficient N-aryl amide 112 as an auxiliary for β-arylation.  
 
 
 
These types of weakly-coordinating directing groups are proposed to occur via a Pd(0)-
Pd(II) catalytic cycle (Figure 19). Oxidative addition into the Ar–I bond forms Pd(II) species 
113, which can then coordinate to 114 and undergo C–H bond metalation. Reductive 
elimination from complex 115 produces Pd(0) and arylated product 116.  
 
 
Figure 19. Proposed Pd(0)-Pd(II) catalytic cycle for Yu’s auxiliary. 
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1.7.3 Oxidative Addition-Induced C–H Arylation 
 For intramolecular reactions, there is an alternative strategy that can be employed to 
achieve C–H arylation. This strategy focuses on designing substrates so that the C–H bond of 
interest is in close proximity to the metal center. Following oxidative addition and generation 
of a highly reactive Pd centre, C–H bond metalation is induced via a carboxylate-assisted, 
concerted-metalation deprotonation mechanism to render a palladacycle.  The palladacycle 
can then undergo further functionalization or reductive elimination to produce the desired 
product (Figure 20). This strategy eliminates the need to remove auxiliaries; however, it does 
require a thoughtful design of the starting material and can be synthetically restrictive. 
 
  
Figure 20. Oxidative addition-induced C–H arylation.  
 
The Fagnou group provided one of first examples utilizing oxidative addition-induced 
C–H arylation (Scheme 37). Pivalic acid was used as an additive to mediate the concerted-
metalation deprotonation step responsible for C–H abstraction.  
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Scheme 37. Intramolecular alkane arylation using pivalic acid as an additive 
 
 
 
Fagnou and Lafrance then utilized DFT calculations to explain the preference for 
primary C–H bonds in close proximity (TS-A) compared to primary C–H bonds further away 
(TS-B) (Figure 21). Through   modeling proposed transition states, a 6.1 kcalmol-1 difference 
was observed between transition state energies for 117 and 118, indicating that closer C–H 
bonds form more energetically favorable transition states. 65 
 
 
 
Figure 21. Difference in energies for transitions states based on H-atom proximity. 
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Inspired by early work by Dyker, the Baudoin group developed a carbonate-mediated 
intramolecular process to generate benzocyclobutenes via activation of primary sp3 centers 
(Scheme 38). 66,67 
 
Scheme 38. Generation of benzocyclobutenes via intramolecular Pd-catalyzed alkane 
arylation. 
 
 
 
Although this method provided access to various substitutions onto the aryl moiety, a 
quaternary center adjacent to the C–H bond of interest was required (109). No reaction was 
observed when a tertiary center was used (120) (Scheme 39). 
 
Scheme 39. Poor reactivity was observed with an adjacent tertiary center. 
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 Through DFT calculations, Baudoin et al. proposed that carbonate could abstract the 
H-atom via an intramolecular concerted-metalation deprotonation (CMD) to form palladacycle 
121 (Figure 22). 
 
 
Figure 22. Proposed catalytic cycle for formation of benzocyclobutenes based on DFT 
calculations. 
 
Ohno et al. developed a pivalate-assisted protocol where N-tert-butyl aniline 
derivatives such as 122 could be cyclized to produce indolines such as 123 in excellent yields 
(Scheme 40).68 
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Scheme 40. The use of N-tert-butyl 2-bromo anilines to produce indolines. 
 
 
 
Most importantly, the Ohno group showed that sp3 centers could be functionalized 
without an adjacent quaternary carbon (Scheme 41). As seen previously, primary C–H bonds 
were preferentially functionalized over secondary C–H bonds. This regiocontrol suggests a 
preference for six- over seven-membered palladacycles.  
 
Scheme 41. Functionalization of primary C–H bonds without an adjacent quaternary center. 
 
 
 
Trans-fused polycycle 125 could also be accessed, but required longer reaction times 
due to sterics and less reactive C–H bonds. This example illustrates the difficulty encountered 
in functionalizing secondary centers in comparison to primary C–H bonds (Scheme 42).  
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Scheme 42. Functionalization of secondary C–H centers produces trans-fused cycle 125. 
 
 
 The Fagnou group then extended Ohno’s work to include sulfonamides and amides 
(126) as viable substrates (Scheme 43). Extensive mechanistic studies including kinetics and 
DFT calculations were performed to understand the role between carbonate and pivalate, 
supporting the crucial role of pivalate as a proton shuttle (Reference Section 1.6).69 
 
Scheme 43. Use of sulfonamides and amides in intramolecular C-(sp3)–H alkane arylation. 
 
 
Subsequently, the Fagnou and Baudoin groups co-published a paper showing that aryl 
chlorides could also be used in alkane arylation reactions providing access to several different 
classes of carbocycles (Scheme 44). The three sets of reaction conditions employed a 
phosphine ligand, palladium catalyst and either K2CO3/DMF or Cs2CO3/pivalic 
acid/mesitylene, utilizing either carbonate or pivalate as the proton shuttle for the concerted-
metalation deprotonation event.69 
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Scheme 44. Generalized intramolecular alkane arylation employing various tethers, palladium, 
phopshine and K2CO3 or Cs2CO3/pivalic acid. 
 
 
 
As has been illustrated, the C–H functionalization of sp3 bonds offers a unique set of 
challenges. These obstacles can be overcome using either heteroatom-containing directing 
groups to promote the formation of palladacycles or through oxidative-addition-induced 
metalation where skillful design of starting materials can promote C–H cleavage via proximity 
effects. The next section will illustrate how these strategies can be extended to cyclopropanes. 
 
1.8 Direct Functionalization of Cyclopropanes 
Despite the great utility and applications of cyclopropanes, there is currently a lack of 
processes to directly functionalize cyclopropanes. As discussed previously (Reference 
Section 1.2), cyclopropyl C–H bonds possess increased s-character, leading to enhanced bond 
acidity; this attribute is highly desirable for developing direct methodologies. In recent years, 
there have been a growing number of papers addressing direct cyclopropyl C–H 
functionalization, exploiting heteroatom-directed arylation and oxidative addition-induced 
metalation strategies. This section will underline these important contributions utilizing these 
approaches. 
1.8.1 Heteroatom-Directed Strategies 
In 2005, the Yu group published one of the first examples of cyclopropyl C–H 
functionalization involving a direct iodination procedure utilizing oxazoline 127 as a directing 
group (Scheme 45).70 
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Scheme 45. Direct iodination of oxazoline-substituted cyclopropane 127. 
 
 
 
Yu’s process required long reaction times, although could be performed at room 
temperature. The resulting diastereomers 128 could then be hydrolyzed to produce the 
corresponding enantiomers as carboxylic acids in >99% ee.70 Of interest, the cyclopropyl C–H 
bond was favored over the substituted methyl group. It is also worth noting that an adjacent 
quaternary center was required for reactivity, paralleling the results reported from other sp3 
methodologies   (Reference Section 1.7).  
Yu et al. later developed an intermolecular direct alkylation using boronic acids as 
coupling partners and cyclopropyl-substituted O-methyl hydroxamic acid 129. Silver oxide 
and benzoquinone were used as oxidants. Air could also substitute as an environmentally 
friendly and inexpensive oxidant without detrimentally affecting conversions (Scheme 46).71 
 2,2,5,5-tetramethyltetrahydrofuran was used as a solvent, which was proposed to 
prevent β-elimination and homocoupling by-products; however this solvent is not readily 
available. 72 
 
Scheme 46. Use of alkylboronic acids as coupling partners. 
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 Inspired by the challenge of achieving selective C–H activation of sp3 centers over sp2 
centers, Yu et al. also devised a direct olefination procedure. A key part of developing this 
protocol involved utilizing an intensely electron-deficient directing group, pentafluorophenyl 
acetamide as observed in substrates 130 and 133. Using Cu (I) as an oxidant, Yu was able to 
directly olefinate cyclopropanes to give intermediate 131, which immediately underwent 1,4 
addition, generating lactams 132, 134 and 135. However, regioselectivity issues were 
observed. Although the methyl group in substrate 130 did not undergo olefination, the aryl 
group in substrate 133 did compete, resulting in a mixture of five- and six-membered lactams 
(134 and 155). It is worth noting, however, that the cyclopropyl C–H was favored (Scheme 
47).73 
Scheme 47. Direct olefination and its regioselectivity issues. 
 
This methodology was also expanded to include an example of carbonylation using a 
similar directing group (136) (Scheme 48). In this case, cyclopropyl C–H bonds could be 
activated preferentially compared to aryl and methyl C–H bonds, producing corresponding 
succinamides 137.74 
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Scheme 48. Direct carbonylation provides good regiocontrol. 
 
 
 The Sanford group also developed a aerobic direct olefination protocol similar to Yu, 
using 3-picoline as a directing group (138), albeit with lower yields (Scheme 49).75 This low 
reactivity could be partially related to the lack of an adjacent quaternary center. The 
cyclopropyl C–H bonds were functionalized preferentially over primary C–H bonds. 
 
Scheme 49. Direct olefination protocol using 3-picoline. 
 
 Sanford and Kubota also attempted to acetoxylate and iodinate cyclopropanes 
containing oxazoline, oxime ether and pyridines as directing groups; however, none of these 
attempts were successful and led to cyclopropyl ring opening in low yields. 76  
Up to this point only a few examples of C–H functionalization were observed; 
however, in 2011, Yu published a complete methodology paper focusing on enantioselective 
C–H activation of cyclopropanes using protected amino acid ligands (Scheme 50). As 
observed previously, an adjacent quaternary center was required; low yields were reported 
without α-substitution. Various cis-substituted cyclopropanes could be accessed, and these 
products could undergo further direct arylation to give cis-1,2,3-substituted cyclopropanes, 
albeit in low yields (20-38%). For the ligand, a free carboxylic acid group was crucial for good 
enantioselectivities and carbamates were the best protecting groups for the amino group. The 
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reaction temperatures could also be lowered to provide good conversions while producing 
good ee’s. 
 
Scheme 50. First example of enantioselective intermolecular C-H activation of cyclopropanes 
 
 
  
 Yu also published a follow-up paper showing an example of arylation using aryl 
iodides in which cis-diastereomer 139 was solely obtained (Scheme 51). 2-
isobutoxylquinoline was selected as the optimal ligand after screening other substituted 
pyridine and quinoline substrates.77 
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Scheme 51. Follow-up to Yu’s original methodology. 
 
 
 
1.8.2 Oxidative Addition-Induced C–H Arylation of Cyclopropanes 
 There have also been a few examples of intramolecular C–H arylation methodologies 
geared towards cyclopropanes. Rousseaux et al. reported the first example of intramolecular 
C–H functionalization of cyclopropanes using cyclopropyl carbamates 140 and 141.78 Despite 
further mechanistic studies indicated that the cyclopropyl C–H bond was being activated, ring 
opening occurred, producing unstable intermediates such as 142 (Scheme 52).  
 
Scheme 52. Intramolecular C–H functionalization of cyclopropanes involving ring-opening. 
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Intermediates such as 142 could be either oxidized to generate useful quinine 
derivatives such as 143 or reduced to produce dihydroquinolines such as 144. This 
methodology will be addressed in more detail in Chapter 3 (Scheme 53). 
 
Scheme 53. Oxidation and reduction protocols to post-functionalize unstable intermediates. 
 
 
 
The Cramer group published an process for the enantioselective intramolecular C–H 
arylation of cyclopropanes to form tetrahydroquinolines such as 145 using a phosphoramidite 
ligand (Scheme 54).79 Various tetrahydroquinolines could be obtained in good 
enantioselectivities with low catalyst loadings. 
 
Scheme 54. Saget and Cramer’s intramolecular enantioselective C–H arylation of 
cyclopropanes 
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Reactivity was also observed when the α-position was not blocked (146), producing 
spiroindoline 147 (Scheme 55). Of note, no six-membered ring by-product was observed, 
indicating a preference for the tertiary sp3 center over the secondary center, possibly due to the 
preference to form six-membered palladacycles over seven-membered palladacycles. 
 
Scheme 55. Formation of the five-membered ring occurs preferentially.  
 
 
 
This result was expanded into a paper in which various spiroindolines such as 148 
could be accessed to good to excellent yields (Scheme 56). 80 
 
Scheme 56. Synthesis of spiroindolines using pivalate-assisted conditions. 
 
 
 
Using substrate 149, further functionalization was possible via intermolecular Suzuki 
couplings with aryl boronic acids or via intermolecular heterocycle C–H arylation using 
substituted-thiophenes, benzothiophenes, thiazoles and furans (Scheme 57). 
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Scheme 57. Domino cyclopropyl C–H functionalization and intermolecular Suzuki coupling 
or intermolecular heterocycle C–H arylation. 
 
 
 
As has been demonstrated in this section, the chemical community has observed a rise 
in interest towards the C–H functionalization of cyclopropanes. Although there has been some 
progress in this field, there are still several direct transformations to be explored with 
cyclopropanes, which could offer interesting mechanistic insights and a myriad of valuable 
products.  The rest of this thesis will detail our contributions to the field through two examples 
of intramolecular C–H functionalization of cyclopropanes utilizing an oxidative-addition-
induced approach. 
1.9 Conclusions and Research Goals 
 With continuous momentum to push towards greener, more efficient and catalyst-
based processes, it is apparent that searching for superior methods to directly functionalize 
compounds can be highly beneficial. Due to their enhanced C–H bond acidity and privileged 
structures, cyclopropanes are highly desirable targets for such direct functionalization 
processes. 
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Direct functionalization has come a long-way from its origins in organometallic 
chemistry. Since these humble beginnings, chemists have improved upon earlier examples and 
adopted new strategies to target more “inert” C–H bonds. This has led to the development of 
novel processes applicable for various substrates, providing novel and easier disconnections 
and enhancing the synthetic toolbox. A significant amount of efforts has also been devoted to 
investigating the role of acetate, carbonate and pivalate in mediating C–H cleavage. 
The work presented in this thesis will describe our contributions to field of 
intramolecular direct C–H functionalization of cyclopropanes. Unlike the methods presented 
in Section 1.8, both processes utilize cationic silver to generate a highly reactive palladium 
center to promote C–H bond metalation. This work represents the first of its kind to employ 
cationic silver-mediated conditions in the intramolecular direct functionalization of 
cyclopropanes. 
Chapter Two will discuss the synthesis of valuable spiro 3,3’-cyclopropyl oxindoles 
from easily accessible 2-bromoanilides. The mechanistic studies presented will illustrate that 
this transformation proceeds via a direct arylation manifold, and will disprove the formation of 
a putative enolate.  
Chapter Three will build upon the findings in Chapter Two. By subtly changing from 
anilides to carboxamide substrates, a striking change in reactivity is observed. Ligand 
selection plays a significant role in product distribution. By changing to a slightly more 
hindered phosphine, cyclopropyl ring-opened products are favored.  Mechanistic experiments 
support that cyclopropyl C–H cleavage occurs prior to ring opening.  
This work will conclude with a comparison between these complementary 
methodologies and provide insights regarding the development of novel direct processes 
targeting cyclopropanes.  
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Chapter 2 
Silver-Mediated, Palladium-Catalyzed  
Direct Arylation of 2-Bromoanilides 
2.1 Introduction 
The spiro 3,3’-cyclopropyl oxindole core is a recurring structural motif present in 
several agrochemically and pharmaceutically active compounds, including herbicides, 
inhibitors, and antagonists for treating cancer, mood disorders, and HIV (Figure 23).81-84 
 
Figure 23. Pharmaceutically and agrochemically active compounds containing the spiro 3,3’-
cyclopropyl oxindole moiety. 
 
In addition to their diverse pharmacological profile, spiro 3,3’-cyclopropyl oxindoles 
have demonstrated synthetic utility as intermediates toward accessing relevant oxindole 
alkaloids.85 For example, in studies towards the total synthesis of welwitindoline C, the Wood 
group utilized α-diazoketone 150 as a key intermediate to produce intermediate 151 via a 
Rh(II)-mediated O–H insertion/cyclopropane ring-opening sequence (Scheme 58).86 Further 
functionalization of 152 gave access to the welwitindolinone core. 
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Scheme 58. O-H insertion/ring-opening sequence to produce key intermediate 151. 
 
 
The Carreira group has also shown a vested interest in exploiting these compounds to 
construct spiro [pyrrolidin-3,3’-oxindole] ring systems via a MgI2-catalyzed cyclopropane 
ring-expansion. In this methodology, MgI2 acts as a bifunctional catalyst to ring-open the 
cyclopropyl unit, producing intermediate 152 (Scheme 59).87 Two mechanistic pathways are 
feasible.  For path A, intermediate 153 could form, which would then cyclize via N-alkylation. 
By path B, a nucleophilic imine could attack 152 to form enolate 154 and then cyclize to give 
product 155. Path A is most likely favored for electrophilic imines, whereas path B is 
proposed to favor N-alkylimines. 
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Scheme 59. Proposed pathways for MgI2-ring-expansion reaction. 
 
Carreira et al. have applied this ring-expansion strategy towards the total synthesis of 
several complex spiro[pyrrolidin-3,3’-oxindole] alkaloids including (-)-horsfiline, 
strychnofoline and spirotryprostatin B  (Figure 24).88-93 
 
Figure 24. Ring-expansion of cyclopropyl oxindoles provides access to complex architectures 
such as oxindole alkaloids. 
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Given the biological and synthetic potential for spiro 3,3’-oxindole compounds, it is 
not surprising that the number of reports regarding spirooxindole syntheses has increased over 
the past decade, suggesting a demand for novel and more efficient routes for preparing these 
systems.94 
Some common routes to obtain spiro 3,3’cyclopropyl oxindoles involve 
functionalization of enolizable 2-oxindoles via alkylation strategies such as Michael-initiated 
ring closure and bis-alkylations (Figure 25).95-97 3-Alkylidene oxindoles can also be 
functionalized via the addition of sulfur or phosphorus ylides.98,99 Other disclosed methods 
involve Ru(II)-, Hg(II)- or Au(II)-catalyzed decomposition of carbene precursors such as 
diazo species and subsequent formal [2+1] cycloaddition with alkenes to form 
cyclopropanes.100-104  
 
 
Figure 25. Routes to access 3,3’-spiro-cyclopropyl oxindoles. 
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Some drawbacks to these methods involve the use of hazardous reagents such as diazo 
compounds and stoichiometric organometallic reagents, and additional synthetic steps required 
in accessing the required precursors. Alternatively, an intramolecular arylation strategy 
involving a direct functionalization of C-(sp3)–H from cyclopropyl anilides would permit 
exploitation of readily accessible, easier-to-handle starting materials, thus, circumventing the 
use of the above-mentioned reagents.  
2.2 Palladium-Catalyzed Intramolecular α-Arylation of Amides 
 In 1998, Hartwig and Shaughnessy developed a protocol for the intramolecular 
palladium-catalyzed α-arylation of amides (Scheme 60).105  
Scheme 60. Intramolecular palladium-catalyzed α-arylation of 2-bromoanilides. 
 
 
 Compared to previous palladium-catalyzed ketone α−arylation methodologies, amides 
posed a greater challenge due to their higher pKa values. Consequently, a strong base such as 
NaOtBu was required and Cs2CO3 gave no conversion under these reaction conditions. A 
ligand screen indicated bidentate ligands such as dppf and BINAP gave superior reactivity. 
Various electron-withdrawing and electron-donating groups on the aryl moiety were tolerated 
and spirocycle 156 was formed in excellent yield. 
This methodology was later improved when Hartwig and Lee published a lower 
temperature and higher yielding protocol using tricyclohexylphosphine that included an 
expanded substrate scope featuring aryl chlorides (Scheme 61).106 
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Scheme 61. Improved protocol for intramolecular α-arylation.  
 
 
During the ligand screen, the authors discovered steric limitations for the 2-
bromoanilide substrates.  Tricyclohexylphosphine was selected, as it was less sterically- 
demanding compared to other hindered phosphines, while bidentate ligands required higher 
temperatures.  A combination of Pd(dba)2/PCy3 gave lower conversions but reacted faster 
compared to Pd(OAc)2/PCy3. This observation was proposed to result from the extra effort 
required to reduce Pd(II) to Pd(0) for Pd(OAc)2. 
Hartwig and Lee also conducted mechanistic studies to further study this 
transformation. The authors synthesized palladium complexes and deduced relative rates for 
oxidative addition, formation of the enolate species and reductive elimination. Based on these 
experiments, oxidative addition into the aryl–bromide bond of 149 was determined to be the 
rate-determining step and the deprotonation of 150 was found to be rapid. These observations 
led to the proposed catalytic cycle shown in Figure 26.  
X
N
R1
O
R2
R3R4
Pd(OAc)2 (5 mol%)
PCy3 (5 mol %)
NaOtBu (1.5 equiv)
dioxane, 50-70 ºC
1-24 h N
R2
R3R1
R4
O
H
X=Cl, Br
R1= CN, OMe
R2, R3= alkyl, aryl
R4= Me, Bn
X= Br, 62-99% yield
     Cl, 64-93% yield
X
N
O
Me
Pd(dba)2 (5 mol%)
PCy3 (5 mol %)
NaOtBu (1.5 equiv)
dioxane, 50 ºC
1 h N
Me
O
H
X= Br, 93% yield
     Cl, 90% yield
X=Cl, Br
66 
 
 
Figure 26. Proposed catalytic cycle for intramolecular α-arylation of 2-bromoanilides. 
 
Oxidative addition into the aryl-bromide bond of 157 generates Pd complex 158.  
Deprotonation of the α-proton by NaOtBu, produces the enolate species which cyclizes to 
produce palladacycle 159.  Reductive elimination produces oxindole product 160.  
The palladium-catalyzed α-arylation of amides represents another important catalytic 
method to access oxindole species. However, it is worth noting that these reactions proceed 
via palladium-enolate intermediates where oxidative addition is the rate-determining step and 
deprotonation of the α-proton is rapid. These mechanistic details contrast direct 
functionalization reactions whereby deprotonation is the rate-determining step. 
The focus for this chapter is the direct arylation of cyclopropyl 2-bromoanilides. 
Although this topic may appear similar to Hartwig’s methodologies, we will demonstrate that 
our reaction does not proceed via an enolate intermediate, but instead undergoes proton 
abstraction via a concerted-metalation deprotonation event (CMD) representative of a direct 
arylation manifold. 
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2.3 Project Origins and Research Goals 
 The project was conducted in collaboration with Daniela Sustac Roman who 
synthesized the starting materials for the aryl cyclopropyl scope (Scheme 63), and performed 
the KIE study and epimerization studies (Reference Section 2.6). She also proposed the initial 
project to develop a Ni-catalyzed, radical-based intramolecular cyclization of 2-bromoanilides.  
 Initially, inspired by Beckwith and Storey’s reports on homolytic aromatic substitution 
and our group’s work on the metal-free synthesis of phenanthroquinolines (161), we began 
developing an intramolecular Ni-catalyzed reaction using 2-iodoanilide 162.107-109 However, 
after various attempts, all such efforts were futile towards accessing desired cyclized product 
163 (Scheme 62).  
Scheme 62. Initial project based on previous work. 
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Radical-based approaches were then abandoned and the catalyst was switched Ni to 
Pd, focusing on accomplishing the direct functionalization of cyclopropanes using these 
systems. Soon thereafter, it became apparent that 2-haloanilide systems were ripe for direct C-
(sp3)–H functionalization. 
2.4 Reaction Optimization and Development 
 Initially, Fagnou-style conditions using pivalic acid as an additive were employed with 
2-iodoanilide 162, which gave no conversion (Table 3, Entry 3).   
Table 3. Conditions utilizing pivalic acid as an additive with 2-haloanilides. 
 
  
 
Silver additives have had a history of success within palladium systems, especially in 
Heck and cross-coupling chemistry.110 In most cases, silver sources have been used to 
sequester halides and form reactive cationic palladium species, and have also been utilized as 
oxidants in Pd (II)-Pd(IV) and Pd(II)-Pd(0) catalytic cycles. 38,55,111-114 Based on the literature 
precedence, it was initially thought that the Pd catalyst was being poisoned due to excess 
iodide.  Consequently, 1 equivalent of cationic Ag was added as a sequestration agent, which 
gave moderate conversions (48%) and dehalogenation (Table 4, Entry 3). Upon replacing 2-
iodoanilide 162 with 2-bromoanilide 164, the desired product 163 was obtained in excellent 
yield (Table 4, Entry 2). Of note, good conversion was also observed when bromo substrate 
164 was cyclized under pivalate conditions (Table 3, Entry 2). 
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Table 4. Conditions utilizing silver carbonate as an additive with 2-haloanilides. 
 
The chloro analogue 165 was also synthesized and cyclized under both sets of conditions, 
which yielded no conversion under silver conditions (Table 4, Entry 1) but good yields were 
obtained using pivalate (Table 3, Entry 1). 
As the silver conditions produced slightly better conversions, we decided to study this 
reaction.  Various conditions were then screened to obtain a better understanding of the 
reaction and its mechanism.  A catalyst screen demonstrated that Pd(0) sources were also 
viable, in addition to other Pd (II) catalysts (Table 5).  
Table 5. Catalyst screen for the intramolecular direct arylation of 2-bromoanilide 164. 
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In parallel to Hartwig and Lee’s findings, steric limitations were also observed for 2-
bromoanilide 164. Sterically-hindered phosphines gave no conversion (Table 6, Entry 6), 
while bidentate ligands such as rac-BINAP and dppf were poor yielding. PCy3 was the ideal 
ligand as it was not too sterically demanding, yet was also sufficiently electron-deficient.  
 Table 6. Ligand screen for the intramolecular direct arylation of 2-bromoanilide 164. 
 
 An assortment of bases was also screened and it was discovered that strong bases such 
as NaOtBu led to ring-opening and severe decomposition of starting material 164 (Table 7, 
Entry 3).  Other weaker inorganic and organic bases gave incomplete conversion (Table 7, 
Entry 2, 4-6). Cs2CO3 (Table 7, Entry 1) gave similar conversion to K2CO3; however, K2CO3 
was chosen as the base as it is inexpensive and practical. 
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Table 7. Base screen for the intramolecular direct arylation of 2-bromoanilide 164. 
 
Other silver sources containing nitrate, sulfate, carbonate and phosphate ions were also 
effective (Table 8). AgOTf and AgBF4 gave trace amounts of product (155) while AgOAc, 
AgOBz and Ag2O gave poor to moderate conversions. These results can be partially attributed 
to solubility issues, while also suggesting that the coordinating ability of the counter ion may 
have some influence on reactivity. 
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Table 8. Silver source screen for the intramolecular direct arylation of 2-bromoanilide 164. 
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Arene solvents such as xylenes and benzene gave the best conversions (Table 9, Entry 
1-2), while polar solvents gave poor conversions (Table 9, Entry 4-5). The use of DMF 
caused decomposition of the starting material.  
Table 9. Solvent screen for the intramolecular direct arylation of 2-bromoanilide 164. 
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A temperature screen was also conduced and good yields could still be achieved over 
110 ºC (85%) (Figure 27).  The reaction temperature could also be slightly decreased from 
135 ºC to 130 ºC while maintaining 90% yield. 
 
Figure 27. The effect of temperature on product yield. 
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Catalyst and ligand loadings were also investigated and catalyst and ligand loadings 
could be reduced to 5 mol %.  When ligand loading was studied an optimal ligand to catalyst 
ratio was determined to be 1:1 (Figure 28). Although it may be argued that excess ligand is 
needed to reduce Pd(II) to Pd(0), other Pd(II)-catalyzed systems such as Suzuki couplings, 
ketone arylation and amination reactions have observed increased reaction rates using a 1:1 
ratio of ligand to catalyst.105 
 
Figure 28. The effect of ligand loading on product yield. 
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Silver loading studies were also performed which indicated that the reaction demanded 
exactly 1.0 equivalent of cationic silver. When greater than or less than 1.0 equivalent of 
cationic silver was used, the reaction was significantly inhibited (Figure 29).  In other 
methodologies where silver has been used as an oxidant to produce Pd(II) species, increasing 
the amount of silver has contributed to increased conversions.55,114 However, in the case of the 
reaction of interest, excess silver impedes reactivity, suggesting silver is not acting as an 
oxidant.  
 
Figure 29. Stoichiometric dependence of silver carbonate. 
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 A series of controls were also conducted (Table 10), which confirmed the stability of 
the starting material and indicated that both a silver source and base were required in 
combination with a Pd catalyst and ligand for the reaction to function.  
Table 10. Control experiments for the intramolecular direct arylation of 2-bromoanilide 164. 
 
After an extensive optimization, the followed optimal conditions were achieved 
(Scheme 63). Much to our delight, the reaction times could be significantly reduced from 16 
hours to only 3 hours, indicating the accelerating effect of silver and efficiency of our 
reaction.115 
Scheme 63. Optimized conditions for the intramolecular direct arylation.  
 
N
O
Pd(OAc)2 (5 mol %) 
PCy3 (5 mol %)
K2CO3 (1.5 equiv)
Ag3PO4 (0.33 equiv)
Br
Me
N
Me
O
toluene (0.5 M), 
130°C, 3 h
H
90% isolated yield
78 
 
2.5 Scope of the Reaction 
 Using optimized conditions, we explored the effect of substitution on the aryl ring 
containing the halide (Scheme 64). A range of functional groups was tolerated. Electron- 
donating substituents furnished desired products 167-169 in good yields. Improved yields 
were obtained from substrates bearing electron-withdrawing groups, affording products 170-
174, presumably due to the increased ease of oxidative insertion to the aryl halide bond. 
Notably, chloro-substituted product 174 was also viable, allowing for further potential 
structural modifications. 
Scheme 64. Effect of aromatic substitution. a 
 
We also varied the protecting group on the nitrogen atom; 175 and 176 gave trace 
conversions, while 177 produced only 55% yield (Scheme 65). The low reactivity of 175-177 
was rationalized to be a consequence of steric hindrance, as these protecting groups are bulky. 
It is worth noting that no benzylic or aryl insertion products were observed, indicating a 
preference for cyclopropyl C-(sp3)–H bonds. 
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Scheme 65. Effect of N-protecting group on reactivity. a,b 
 
The next step was to investigate the effect of aromatic substitution on the cyclopropane 
unit (Scheme 66). The trans-racemic starting materials were easily accessible via the Corey-
Chaykovsky reaction and under optimized reaction conditions resulting spiro 3,3’-cyclopropyl 
oxindoles were produced as a mixture of major and minor diastereomers. Ortho- and meta-
substitution provided products 178 and 179 in high yield, suggesting that steric hindrance does 
not negatively impact the process. In addition, para-substituted electron-donating (180-181) 
and electron-withdrawing substrates (182-184) were both tolerated, producing excellent 
yields, although electron-donating groups gave slightly better diastereoselectivities. 
Heterocyclic substitution (185-186) was also viable.  
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Scheme 63. Effect of cyclopropane substitution using trans-racemic starting materials.a,b,c 
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The configuration for both diastereomers was confirmed via X-ray crystallography using 
products 182 and 184 and were assumed to be identical for the remaining scope (Figure 30). 
 
Figure 30. X-ray crystal structure for major and minor diastereomers. 
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2.6 Mechanistic Studies 
2.6.1 Epimerization Studies 
To probe whether the cyclization occurs via an enolate-like mechanism or direct 
arylation scaffold, we performed the reaction using enantioenriched cis- and trans- starting 
materials 187 and 188. In both cases, the reaction proceeded with little erosion of ee for the 3-
hour reaction time (Scheme 67), supporting the possibility of a direct arylation mechanism. It 
is worth noting that the reaction is stereospecific for both cis- and trans isomers  (189-190). 
Scheme 67. Epimerization studies for both cis and trans starting materials. 
 
2.6.2 Kinetic Isotope Study 
We also determined the KIE to be 3.9, identifying C–H cleavage as the rate-
determining step (Scheme 68).  For palladium-catalyzed α-arylations involving enolate 
species, Hartwig and Lee determined that oxidative addition was the rate-determining step.106. 
Based on the reaction’s KIE and the literature (Reference Section 1.6), it suggests that our 
reaction does proceed via a direct arylation manifold and does not form an enolate species. 
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Scheme 68. Intramolecular parallel KIE study. 
 
2.6.3 Proposed Catalytic Cycle 
We next considered the role of acetate, carbonate and silver on the reaction. As 
observed during the catalyst screen (Reference Section 2.3), the reaction was not impeded by 
the absence of acetate ion as other acetate-free Pd-sources such as Pd2(dba)3 and PdBr2gave 
excellent conversions (92% yield and 81% yield, respectively). These results indicate that 
carbonate, not acetate functions as the external base to facilitate the concerted-deprotonation 
metalation pathway.  
Based on these experimental findings, we propose the following mechanism (Figure 
31). Oxidative addition of Pd(0) into the Ar–Br bond of 164 generates intermediate 191. 
Silver(I) abstracts bromide forming highly reactive cationic Pd species 192. Carbonate acts as 
an external base to mediate concerted-metalation deprotonation event 193, and subsequently, 
causes irreversible deprotonation to produce six-membered palladacycle 194. Reductive 
elimination regenerates Pd(0) and yields 163. 
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Figure 31. Proposed mechanism for formation of spiro 3,3’-cyclopropyl oxindoles. 
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2.7 Summary 
 In conclusion, this project demonstrated a novel example of cyclopropane direct 
arylation via an efficient and high-yielding Pd-catalyzed, Ag-mediated reaction. Simple and 
easily accessible starting materials are used to directly synthesize a vast array of spiro 3,3’-
cyclopropyl oxindoles in excellent yields and moderate drs. Epimerization studies showed 
retention of ee for both enantioenriched cis- and trans-starting materials, indicating that an 
enolate intermediate was not being formed. A direct arylation manifold was further supported 
by a KIE of 3.9, indicating that C–H cleavage was the rate-determining step. Other 
optimization results showed that Pd(0) sources were also viable and that acetate was not 
required for reactivity, suggesting that carbonate was responsible for assisting with the 
concerted-metalation deprotonation step.  
This project revealed that silver could act as a powerful tool to generate a sufficiently 
reactive Pd species to undergo insertion into the cyclopropyl C–H bond. These findings 
revealed new opportunities for direct functionalization reactions utilizing silver-mediated, 
palladium-catalyzed processes, which will be elaborated on in Chapter 3. 
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Chapter 3  
Palladium-Catalyzed, Silver-Mediated Ring-Opening of 
Cyclopropyl Benzamides  
3.1 Introduction 
 Benzazepine-type rings represent a privileged motif found in numerous biologically 
active compounds and pharmaceutical drugs (Figure 32).116-118 Despite not being as 
commonly known, benzazepinones hold their own importance as precursors to other 
benzazepine-containing structures who themselves possess a unique pharmacological 
profile.119-124 
 
Figure 32. Biologically active compounds containing benzazepine-type rings.  
Pink= benzazepinone-type structures, Blue= benzazepine-containing structures 
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As Scheme 69 illustrates, a synthetic sequence involving C–H functionalization and ring 
opening of cyclopropyl benzamides could provide a novel route towards accessing 
benzazepinone-type systems. The synthesis of benzazepinones via this proposed strategy will 
be the focus for Chapter Three.  
 
Scheme 69.  Cyclopropyl benazamides as precursors for benzazapinone-type stuctures. 
 
 
3.2 Palladium-Catalyzed Ring-Opening of Cyclopropanes 
Cyclopropane ring-opening reactions are a class of transformations that can lead to 
novel and difficult-to-access substrates.93,125 As a catalyst, palladium has played a major role 
in expanding these methodologies. For example, Nakamura and Kuwajima first illustrated the 
synthetic utility of cyclopropyl derivatives such as 195 as homoenolate precursors, which can 
be utilized as the inverse-polarity synthons of Michael acceptors 196  (Figure 33).126 
 
 
 
Figure 33. The use of cyclopropane 195 as an inverse-polarity synthons for 196. 
 
Nakamura and Kuwajima’s protocol involved utilizing aryl triflates, palladium catalyst 
and ligand to achieve direct arylation of siloxycyclopropane 197, producing β-arylated 
carbonyl such as 198. Of note, aryl halides were unreactive, indicating the important role of 
the aryl triflates in generating a highly reactive cationic Pd(II) species (Scheme 70). 
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Scheme 70. Generation of homoenolates from siloxycyclopropanes and functionalization with 
aryl triflates. 
. 
 
 
 In 2000, Park and Cha developed a palladium (II)-catalyzed ring-opening of 
cyclopropanols such as 199 to product various monosubstituted olefins such as 200 (Scheme 
71). 
Scheme 71. Pd(II)-catalyzed ring-opening of cyclopropanols  
 
 
 
In contrast to the work of Nakamura, whereby ring opening of siloxycyclopropanes 
occurs via “corner attack” by an electrophilic palladium species, Park and Cha proposed that 
Pd(II) coordinates to the in-situ formed cyclopropyl alkoxide to generate 201.  Alkoxide 
palladium species 201 then undergoes ring-opening of the less-substituted C-C bond (B) to 
generate alkylpalladium species 202 preferentially over 203.   β-hydride elimination produces 
olefin 200 and either a Pd(II)–H or Pd(0) species, of which is then re-oxidized to Pd(II) 
(Figure 34). 127  
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Figure 34. Formation of monosubstituted olefins via Pd-mediated ring-opening of 
cyclopropanols. 
 
 Rosa and Orellana developed a protocol to exploit siloxycyclopropanes such as 204 as 
homoenolate precursors in combination with direct arylation to access α-indanones such as 
205 (Scheme 72).128 
 
Scheme 72. Formation of homoenolates and subsequent direct arylation produces α-indanone 
205.  
 
 
 
This example provides a case whereby ring-opening to generate the homoenolate occurs prior 
to C–H functionalization. Figure 34 illustrates the catalytic cycle for this transformation. 
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Figure 35. Proposed catalytic cycle for formation of α-indenones from homoenolates. 
 
 Coordination of Pd (II) to cyclopropyl alkoxide 207, followed by oxidative 
rearrangement generates homoenolate 208. Species 208 then undergoes aryl C–H cleavage via 
a concerted-metalation deprotonation event mediated by acetate, and subsequent palladation to 
give six-membered palladacycle 209. Reductive elimination produces cyclized product 210 
and Pd(0) is then re-oxidized to Pd(II). 
 As previously discussed (Reference Section 1.8), Rousseaux et al. published one of 
the first examples of cyclopropyl C–H functionalization using an oxidative-induced metalation 
approach; however, the unstable intermediate underwent ring opening to give unstable 1,4-
dihydroquinolines.78 To prove that cyclopropyl C–H cleavage occurred prior to ring-opening 
and that a homoenolate was not forming instead, a set of mechanistic experiments were 
conducted (Scheme 73). First, the process was confirmed to be pivalate-mediated as starting 
material 211 failed to produce desired product 212 in the absence of pivalate. Secondly, the 
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authors independently synthesized cyclopropyl product 213 and subjected this substrate to the 
reaction conditions at 140 ºC to investigate if 213 was an intermediate and that Pd-insertion 
into 213 was responsible for generating the ring-opened product 212. As both results failed to 
produce 212, this supported the conclusion that cyclopropyl C–H cleavage was mediated by 
pivalate and was indeed occurring prior to cyclopropyl ring-opening. 
 
Scheme 73. Mechanistic studies by Rousseaux et al.  
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Figure 36. Catalytic cycle for formation of 1,4-dihydroquinolines. 
 
 
 
Figure 36 illustrates the proposed catalytic cycle for the reaction. Pd(0) undergoes oxidative 
addition into the aryl–halide bond of substrate 214 , followed by ligand exchange with pivalate 
to generate complex 215. Subsequent cyclopropyl C–H cleavage via pivalate-mediated 
concerted-metallation deprotonation event 216 generates a six-membered palladacycle 217. 
Ring opening of 217 produces seven-membered palladacycle 218, which after deprotonation 
and reductive elimination, generates product 212. If ring-opening does not occur, reductive 
elimination occurs after concerted-metalation deprotonation to produce product 213. 
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3.3 Project Origins and Research Goals 
 The work presented in this chapter was initiated as a consequence of the work 
presented in Chapter Two. Of note, this project was also done in collaboration with Daniela 
Sustac Roman who performed the initial ligand and silver source screen, controls and pivalate-
assisted conditions, and replicated the mechanistic studies performed by Rousseaux et al.  
Instead of cyclopropyl anilides, cyclopropyl benzamide 219 was subjected to the Pd-catalyzed 
conditions presented in Chapter Two, which gave rise to four different products: two 
benzazepinone isomers, 220 and 221, six-membered ring 222 and a small amount of five-
membered ring 223 (Scheme 70). The structures for products 220-223 were elucidated using 
1D NOE experiments in addition to 1H NMR, 13C and GCMS. Of note, benzamides favor 
cyclopropyl C–H functionalization at the β−position, whereas anilides show a preference for 
the α−position. 
Scheme 74. Comparison of reactivity between cyclopropyl anilide and benzamide systems.  
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3.4 Reaction Optimization and Development 
We first conducted a ligand screen to determine if the reaction could be tuned to favor 
only one of products 220-223 (Table 11).129 Unlike our previous methodology (Reference 
Chapter Two), good yields could be obtained using other ligands, indicating that the ligand 
had a large influence on the product distribution.  
Table 11. Ligand screen and effect on product distribution. a 
 
Despite the goal was to obtain either product 222 or 223 with the cyclopropane ring 
intact, when slightly more hindered ligand PtBu3•HBF4 was employed, the reaction favored 
only benzazepinone products 220 and 221 (Scheme 75). As these were medicinally and 
synthetically interesting compounds and isomers 220 and 221 could be easily separated, we 
decided to study this transformation. Of note, temperatures could be reduced by 10 ºC (125 ºC 
from 135 ºC). 
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Scheme 75. Switching to a more hindered ligand favored seven-membered rings. 
 
 Substrate 219 was also subjected to both pivalate-assisted conditions published by 
Rousseaux et al. and all four products 220-223 were observed (Scheme 76). In parallel with 
silver-conditions, the use of pivalate also favored C–H functionalization at the β−position. 
However, unlike silver-conditions, pivalate-assisted conditions gave predominately 222 
instead of ring-opened products 220 and 221, indicating the difference between silver and 
pivalate additives in enhancing reactivity. 
Scheme 76. Product distribution using pivalate-assisted conditions. 
 
As an extensive optimization from the previous project was already conducted 
(Reference Section 2.3), key conditions were screened that could provide mechanistic 
insights. Control experiments were first performed and it was discovered that although silver 
and palladium were both required, some product formation does occur without a ligand (Table 
12).  K2CO3 was also required for the reaction to reach completion. 
 
 
N
Me
O
Br
Pd(OAc)2 (5 mol %)
PtBu3•BF4 (5 mol %)
Ag3PO4 (0.33 equiv)
K2CO3 (1.1 equiv)
toluene, 125°C, 16 h
N
O
Me
N
O Me
(220)
66% yield
(221)
26% yield
92% yield total
(219)
N
Br
O
Me
Pd(OAc)2 (5 mol %)
PCy3 (10 mol %)
PivOH (0.3 equiv)
Cs2CO3 (1.1 equiv)
PhMe, 135°C, 16 h
N
O
Me
N
O Me
N
O
Me
N
O
Me
H
H (220)
5% yield
(221)
15% yield
(222)
47% yield
(223)
14% yield
(219)
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Table 12. Control reactions for synthesis of 220 and 221.a 
 
In parallel to previous results (Reference Chapter Two), it was observed that silver 
was required and that its stoichiometry mattered; too much or too little silver led to incomplete 
conversion. However, as the amount of silver was increased, an increase in major isomer 220 
over minor isomer 221 was also observed, suggesting that silver may play a role in mediating 
the isomerization process (Figure 37). 
  
Figure 37. Yield and product ratio dependence on silver stoichiometry. 
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 Other silver sources were also screened and it was discovered that AgOAc and Ag2CO3 
(Entry 3) gave moderate yields. In parallel with previous results (Chapter Two), AgOTf 
exhibited no reactivity (Entry 3). Of interest, AgBr  (Entry 4) still gave decent conversion, 
indicating that excess bromide was not hindering the reaction significantly.  
Table 13. Silver source screen for synthesis of 220 and 221.a 
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3.5 Scope of the Reaction 
Iodo and chloro analogues 224 and 225 were also synthesized to test if the reactivity 
paralleled previous work (Reference Chapter 2). Indeed, the same trend was observed; iodo 
analogue 224 gave good conversions; however, chloro substrate 225 failed to produce any 
product (Scheme 77). This is probably because it is much more difficult for silver to abstract 
chloride compared to bromide and iodide based on relative bond strengths. 
 
Scheme 77. Effect of halide on product yields. 
 
 
 
 Other protecting groups were also tested. As anticipated methyl carbamate 226 was 
highly labile; only 53% of the major de-protected isomer 227 could be obtained along with an 
unidentifiable mixture of alkenes (Scheme 78). 
 
Scheme 78. Reactivity of methyl carbamate analogue 226. 
 
 
 
 
N
Me
O
I
Pd(OAc)2 (5 mol %)
PtBu3•BF4 (5 mol %)
Ag3PO4 (0.33 equiv)
K2CO3 (1.1 equiv)
toluene, 125°C, 16 h
N
O
Me
N
O Me
(220)
48% yield
(221)
29% yield
92% yield total
N
Me
O
Cl
Pd(OAc)2 (5 mol %)
PtBu3•BF4 (5 mol %)
Ag3PO4 (0.33 equiv)
K2CO3 (1.1 equiv)
toluene, 125°C, 16 h
(224)
(225)
N
O
Me
N
O Me
(220) (221)
N
CO2Me
O
Br
Pd(OAc)2 (5 mol %)
PtBu3•BF4 (5 mol %)
Ag3PO4 (0.33 equiv)
K2CO3 (1.1 equiv)
toluene, 125°C, 16 h
NH
O
mixed alkenes
(227)
53% yield
(226)
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Benzyl moiety 228, however, did produce the desired products 229 and 230 in 
excellent yield (Scheme 79). Of interest, C–H bond metalation is selective towards the 
cyclopropyl moiety; no products resulting from benzyl C–H insertion was detected by NMR 
or GCMS.  
 
Scheme 79. Benzyl-protected carboxamide 228 gives exclusively 229 and 230. 
 
 
A small scope was then synthesized to study the generality of our reaction and 
functional group tolerance, and resulting products 231-246 were formed in excellent yields 
(Scheme 80). Substitutions onto to the aryl ring were well-tolerated, as both meta and para 
substitutions gave excellent yields. Mono- and di-fluorinated products 235-238 and 245-246 
were also accessible in good yields. The dimethyl substrate also gave good conversions (243-
244), indicating that steric hindrance adjacent to the bromide does not impede the reaction. 
Methoxy substitution also furnished the desired products in good yield (239-240). Only the 
trimethoxy-substituted substrate gave poor conversion (27% yield) (231-232), with unreacted 
starting material and dehalogenation observed.  
 
 
 
 
 
 
 
 
 
N
O
Br
Pd(OAc)2 (5 mol %)
PtBu3•BF4 (5 mol %)
Ag3PO4 (0.33 equiv)
K2CO3 (1.1 equiv)
toluene, 125°C, 16 h(228)
N
O
N
O
(229)
59% yield
(230)
37% yield
96% yield total
Ph Ph Ph
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Scheme 80. Reaction scope for benzo[c]azepine-1-ones. 
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Aryl substitution onto the cyclopropyl moiety was also attempted; however, substrate 
247 had low reactivity and gave poor conversions even after heating for 3 days (Scheme 81). 
This is possibly due to steric hindrance from the bulky aryl ring impeding the reaction. 
 
Scheme 81. Installation of aryl substituents onto the cyclopropyl moiety. 
 
 
As a practical application, substrates 220 and 221 can also be hydrogenated to generate 
a single seven-membered benzolactam-type product in excellent yield (Scheme 82).  
 
Scheme 82. Hydrogenation of isomers to give a single benzolactam-type product. 
 
 
 
3.6 Mechanistic Studies 
After the reaction development and scope, further investigations were warranted. 
Firstly, the isomerization of benzazepinones 220 and 221 required more understanding. The 
second goal was determining the role of the reagents. Finally, the catalytic cycle needed to be 
established. 
 
 
 
Br
O
N
Me
Me
Pd(OAc)2 (5 mol %)
PtBu3•HBF4 (5 mol %)
Ag3PO4 (0.33 equiv)
K2CO3 (1.1 equiv)
PhMe, 125°C, 16 h
N
O Me
N
O Me
+  isomers
15% (total yield)
44% (after 3 days at 120°C)
Me
(247) (248) (249)
Me
N
O Me
N
O Me
+
Pd/C (10 mol%)
H2 (1 atm)
N
O Me
MeOH, rt, 16 h
(250)
93% yield
(220) (221)
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3.6.1 Isomerization Studies 
To identify the thermodynamic product and the kinetic product from both isomers 220 
and 221, time-dependent isomerization studies were conducted (Figure 38). Over a 16-hour 
period, the formation of isomer 221 was observed in the first 30 minutes; however, isomer 220 
emerged as the dominant product after 30 minutes. This observation supported the assertion 
that isomer 221 was the kinetic product as it formed the fastest, while isomer 220 was the 
more stable thermodynamic product. At the end of the 16-hour period, the ratio between 
isomers 220 and 221 stabilized at 3:1, indicating this is where the equilibrium lies for the 
reaction. 
 
 
Figure 38. Isomerization experiments over 16 h. 
 
Additionally, minor isomer 221 re-subjected to the reaction conditions, which partially 
isomerized to major isomer 220 (Scheme 79). As noted with the time-trials, a 3:1 ratio 
between isomers 220 and 221 was also detected. In contrast, when major isomer 220 was re-
subjected to the reaction conditions, no isomerization was observed suggesting 220 was the 
more stable product. 
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Scheme 83. Other isomerization experiments. 
 
 
 
3.6.2 Determining the Role of Reagents and the Catalytic Cycle 
The next objective was determining the sequence of events in the catalytic cycle. To 
achieve this goal, a similar experiment to the work of Rousseaux et al. was conducted. 6-
membered ring product 222 was heated in the presence of the reaction conditions and 
observed no ring-opening, indicating that this was not an intermediate leading towards ring-
opened products 220 and 221 (Scheme 80). 
 
Scheme 84. Determining the order of mechanistic events. 
 
 
 
The starting material 219 was also shown to be highly stable based on control 
experiments; no product was formed in the absence of silver or palladium. These results 
suggested that cyclopropyl C–H cleavage does occur prior to ring-opening and that the 
reaction was not proceeding via a homoenolate-type intermediate. 
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The final task was to establish whether acetate or carbonate was responsible for 
mediating the concerted-metalation deprotonation process. A Pd(0) source was initially 
employed and it was found that yields were significantly reduced (Table 14). To determine if 
this was due to the absence of acetate or lack of a Pd(II) catalyst, Pd(dba)2 was reacted with 
KOAc instead of K2CO3.130 Interestingly enough, the reactivity was restored (63% yield) when 
acetate was added, leading to the conclusion that acetate not carbonate was mediating the 
concerted-metalation deprotonation process and that the reaction was proceeding via a Pd(0)-
Pd(II) catalytic cycle.   
 
Table 14. Determining the role of reagents. 
 
 
 
3.6.3 Proposed Catalytic Cycle 
Based on the mechanistic investigations, the following catalytic cycle was proposed 
(Figure 39). Pd(0) undergoes oxidative addition into the aryl–bromide bond of substrate 219 
to form Pd (II) species 251. Silver then abstracts the bromide, generating reactive cationic Pd 
species 252.  Cleavage of the cyclopropyl C–H bond occurs via acetate-mediated concerted-
metalation deprotonation 253 to give palladacycle 254. If PCy3 is used as a ligand, the 6-
membered ring product 222 can form via reductive elimination from palladacycle 254. With 
PtBu3•HBF4, palladacycle 254 undergoes ring-opening to generate eight-membered 
palladacycle 255. Deprotonation and subsequent reductive elimination from palladacycle 255 
produces 220 and 221. 
105 
 
 
 
 
Figure 39. Proposed catalytic cycle for formation of products 220-222. 
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3.7 Summary 
This chapter demonstrated the dramatic change in reactivity from switching from 
cyclopropyl anilides to cyclopropyl benzamides. Cyclopropyl anilides exhibited a preference 
for cleavage of the cyclopropyl α-proton, whereas cyclopropyl benzamides favored 
functionalization of the cyclopropyl β-proton.  Ligand selection played an important role in 
product distribution and by using PtBu3•HBF4 as a sterically hindered phosphine, 
benzoazepinones could be accessed in good to excellent conversions. As a practical 
application, benzoazepinones could also be hydrogenated to produce benzolactam-type 
systems in excellent yield. Isomerization studies distinguished the thermodynamic product 
from the kinetic product. Finally, mechanistic studies confirmed that ring-opening occurred 
after cyclopropyl C–H cleavage, and prior to ring-opening, paralleling the results reported by 
Rousseaux et al. Other experiments indicated that acetate, not carbonate was responsible for 
the concerted-metalation deprotonation event. Overall, this project illustrated how subtle 
changes in reaction conditions such as additives, ligands, and switching from anilides to 
benzamides can effect product distribution and cyclopropyl C–H bond reactivity, while 
providing access to three different products: two separable benzazepinone isomers and the 
dehydrogenated product. 
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Chapter 4 Concluding Remarks 
The field of direct C–H functionalization has produced several elegant and highly 
practical methodologies possessing widespread benefits and applications. This thesis has 
focused on a largely unexplored aspect: the intramolecular C–H functionalization of 
cyclopropanes. Both methodologies presented center on offering an alternative to pivalate-
assisted methodologies by utilizing a silver source as a way to access a highly reactive cationic 
palladium species via halide abstraction. 
 In the second chapter, a facile and efficient process to access valuable spiro 3,3-
cyclpropyl oxindoles from easily synthesized 2-bromoanilides was presented. The reaction is 
highly efficient and is tolerant towards a variety of electronically and sterically different 
functional groups. To disprove the formation of a putative enolate, epimerization experiments 
were conducted using enantiopure-starting materials. As little to no erosion in ee’s was 
observed, this finding supports that the reaction does not proceed via a palladium-enolate 
intermediate. A KIE of 3.9 provided additional evidence for a direct arylation manifold, 
identifying cyclopropyl C–H cleavage as the rate-determining step. Other investigations 
indicated that the reaction goes through a Pd(0)-Pd(II) catalytic cycle, and that carbonate 
participates in the concerted-metalation deprotonation (CMD) event.  
 Based on the findings of Chapter Two, Chapter Three examined the reactivity of 
cyclopropyl benzamides, which closely paralleled the work of Rousseaux et al. In contrast to 
Chapter Two, we observed a strong ligand effect on product distribution. Switching to a 
slightly more sterically encumbered ligand produced benzazepinones as two separable isomers 
in excellent yields; benzolactam-type systems could also be easily accessed via hydrogenation. 
Isomerization experiments allowed for identification of the kinetic and thermodynamic 
products. Evidence was provided to establish that cyclopropyl C–H cleavage occurs prior to 
ring-opening and upon further investigation, it was demonstrated that unlike the first project 
(Chapter Two), acetate not carbonate is required to mediate the concerted-metalation 
deprotonation (CMD) event.  
Both projects offer unique insights into the direct functionalization of cyclopropanes 
where silver acts as an important additive to generate a highly reactive cationic palladium 
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species. Upon realizing that the direct functionalization of cyclopropanes is possible, 
researchers have begun to focus on targeting these pharmacologically valuable, and 
chemically interesting systems. The work presented in this thesis represents the first examples 
of intramolecular C–H functionalization of cyclopropanes using silver additives to form 
reactive cationic palladium species. There are several transformations and areas in which the 
direct functionalization of cyclopropanes can be explored. Such pathways will be pursued in 
more detail over the next few years and the results will be reported in a forthcoming doctoral 
dissertation. 
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“If I were to wish for anything, I should not wish for wealth and power, but for the 
passionate sense of the potential, for the eye which, ever young and ardent, sees the possible. 
Pleasure disappoints, possibility never.  
And what wine is so sparkling, what so fragrant, what so intoxicating, as possibility!”  
-Søren Kierkegaard 
 
 
 
 
 
 
 
 
 
 
 
110 
 
Chapter 5 Experimental Section 
All non-aqueous reactions were run under argon atmosphere with flame-dried 
glassware using standard techniques for manipulating air-sensitive compounds.129 Anhydrous 
solvents were obtained by filtration through drying columns or by distillation over sodium or 
calcium hydride. Commercial reagents were used as supplied or purified by standard 
techniques where necessary.1 The reported yields represent the yields of products isolated 
following distillation, flash chromatography, or preparative TLC. 
Flash column chromatography was performed using 230-400 mesh silica and Merck 
type E basic alumina (pH ~ 10-11) by as per the method developed by Still or performed on an 
automatic purification system using the indicated solvent system (Teledyne Isco Combiflash® 
Rf or Sq16x). Pre-packed normal phase silica gel columns were used for separation of 
products using Teledyne Isco RediSep® Rf High Performance Gold or Silicycle SiliaSepTM 
High Performance columns (12g, 24g, 40g, or 80g).  
Analytical thin-layer chromatography (TLC) was performed on pre-coated, glass-
backed silica gel plates (Merck 60 F254) and visualized by UV absorbance (254 nm), and/or 
ceric ammonium molybdate (CAM), and potassium permanganate (KMnO4).   
Nuclear magnetic resonance spectra were recorded on an Avance AV400 MHz, 
Avance AV 300 MHZ, or DRX 400 MHz (1H,13C, 19F, 1D NOESY) spectrometer. Chemical 
shifts for 1H NMR spectra are recorded in parts per million (ppm) from tetramethylsilane 
(TMS) with the solvent resonance as the internal standard (CHCl3, δ = 7.26 ppm). The data 
was reported as follows: chemical shift, multiplicity (s = singlet, s (br) = broad singlet, d = 
doublet, dd = doublet of doublets, dt = doublet of triplets, td = triplet of doublets, ddd = 
doublet of doublets of doublets, t = triplet, q = quadruplet, m = multiplet, br m= broad 
multiplet), coupling constant in Hz and integration. Chemical shifts for 13C NMR spectra were 
recorded in parts per million from tetramethylsilane using the central peak of CDCl3 (77.16 
ppm) as the internal standard. All 13C NMR spectra were obtained with complete proton 
decoupling. The 2-haloanilides and 2-carboxamides were reported as a mixture of 
rotamers.130,131 
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Infrared spectra were taken on a Bruker Vertex Series FTIR (neat) with the important 
vibrations reported in reciprocal centimeters (cm–1). Melting points were obtained using a 
Thomas Hoover melting point apparatus and are uncorrected. 
Analytical supercritical fluid chromatography was performed with a Berger SFC 
fashioned with a UV diode detector. SFC results are reported as follows: (column type, eluent, 
retention time (tr).  
High-resolution mass spectra were performed by the Centre régional de spectroscopie 
de masse de l’Université de Montréal using either ESI, or APPI ionization modes. X-ray 
structures were obtained though Laboratoire de diffraction des rayons-X de l’Université de 
Montréal using an Enraf-Nonius CAD-3 or CAD-4 apparatus.  
Experimental protocols and characterization data for new compounds and selected 
known compounds presented in this thesis are described in the following Annex, as are data 
obtained from x-ray analysis.  
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II 
 
 
 
Experimental Section for Chapter 2 
 
Synthesis of Starting Materials 
 
Starting materials not listed below were obtained commercially and the reagents were used 
without further purification.  
 
Synthesis of 2-bromoanilines  
 
The following 2-bromoanilines were obtained via bromination from their corresponding 
anilines according to literature procedure: 2-bromo-4-methylaniline,1 4-amino-3-
bromobenzaldehyde,2 2-bromo-4-(trifluoromethyl)aniline,3 4-amino-3-bromobenzonitrile,4 
and 2-bromo-4-chloroaniline,5 ethyl 4-amino-3-bromobenzoate,6 2-bromo-3,4-
dimethoxyaniline7 and 2-bromo-4-methoxyaniline.8 
 
 
 
 
 
 
 
                                                
1 Das, B.; Venkateswarlu, K.; Majhi, A.; Siddaiah, V.; Reddy, K.R. J.Mol.Cat.A:Chem. 2007, 267, 30. 
2 Das, B.; Venkateswarlu, K.; Majhi, A.; Siddaiah, V.; Reddy, K.R. J.Mol.Cat.A:Chem. 2007, 267, 30. 
3 Das, B.; Venkateswarlu, K.; Majhi, A.; Siddaiah, V.; Reddy, K.R. J.Mol.Cat.A:Chem. 2007, 267, 30. 
4 Roche,D.; Prasad,K.; Repic,O.; Blacklock,T.J. Tetrahedron. Lett. 2000, 41, 2083. 
5 Roche,D.; Prasad,K.; Repic,O.; Blacklock,T.J. Tetrahedron. Lett. 2000, 41, 2083. 
6 Tobe,Y.; Utsumi,N.; Kawabata,K.; Nagano,A.; Adachi,K.; Araki,S.; Sonoda,M.; Hirose,K.; Naemura,K. J. Am. Chem. 
Soc. 2002, 124, 5350. 
7 Peat, A.J.;  Buchwald,S.L. J. Am. Chem. Soc. 1996, 118, 1028. 
8 Peat, A.J.;  Buchwald,S.L. J. Am. Chem. Soc. 1996, 118, 1028. 	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General Synthesis of 2-bromoanilides (1a-1i) (example for 1a shown below) 
 
 
To a 100-mL round bottom flask flame dried over argon was added 2-bromoaniline (2.47 g, 
14.4 mmol) dissolved in 40 mL THF. To this was added cyclopropanecarbonyl chloride (1.4 
mL, 15.8 mmol, 1.1 equiv) dropwise, forming a cloudy off-white solution. This mixture was 
then stirred overnight (16 h) at ambient temperature. 40 mL of EtOAc was then added and the 
opaque solution was transferred to a 125-mL separatory funnel. The solution was then washed 
with saturated NaHCO3 solution (3x’s, 40 mL), and brine (2x’s 40 mL). The combined 
organics were then dried over anhydrous Na2SO4, filtered and concentrated in vacuo to give a 
white solid, which was used crude in the subsequent methylation step.  
This intermediate was dissolved in 40 mL of THF, cooled to 0°C, and NaH (0.52 g, 
22.2 mmol, 1.5 equiv) was added  forming a grey solution. After 15 minutes, MeI was added 
dropwise (0.70 mL, 107 mmol, 7.0 equiv). The reaction was then warmed to ambient 
temperature and stirred overnight (16 hours). It was then quenched with water (40 mL), 
EtOAc was added (40 mL), and transferred to a 250-mL separatory funnel. The layers were 
separated, and the aqueous layer was extracted with EtOAc (3x’s, 50 mL). The combined 
organics were washed with brine (50 mL), dried over anhydrous Na2SO4, filtered and 
concentrated in vacuo to give the desired product as a brown oil. The crude was then purified 
via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent gradient 
NH2
Br O
Cl
THF, rt, 16 h
N
H
OBr
NaH, THF
MeI, 0°C to rt,
16 h
N
OBr
Me
R1
R1
R1
1a-1i
IV 
 
of 10% to 50% EtOAc : Hex. (Rf: 0.31 (1:1 Hex :EtOAc). The desired product was isolated as 
a golden oil (3.30 g, 13 mmol, 90% yield over two steps). 
 
 
 
N-(2-bromophenyl)-N-methylcyclopropanecarboxamide (1a) 
 
The observed characterization data (1H NMR) was consistent with that previously reported in 
the literature.9 1H NMR (CDCl3, 400 MHz): δ 7.71-7.69 (m, 1H), 7.42-7.35 (m, 2H), 7.27-
7.22 (m, 1H), 3.21 (s, 3H), 1.23-0.95 (m, 3H), 0.69-0.54 (m, 2H). 
 
 
 
N-(2-bromo-4-methylphenyl)-N-methylcyclopropanecarboxamide (1b) 
 
The title compound 1b was prepared by the general synthesis on a 7.07 mmol scale and then 
purified via column chromatography (20:1 Hex : EtOAc) to give a brown oil in 65% yield 
(1.23 g, 4.60 mmol) over two steps: Rf: 0.32 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): 
δ  7.53 (s, 1H), 7.27 (d, J = 7.9 Hz, 1H), 7.23-7.21 (m, 1H), 3.20 (s, 3H), 2.40 (s, 3H), 1.27-
1.19 (m, 1H), 1.05-0.96 (m, 2H), 0.65-0.56 (m, 2H); 13C NMR (CDCl3, 75MHz): δ 173.1, 
139.78, 139.65, 133.7, 129.3, 123.0, 35.6, 20.5, 11.8, 8.1, 7.6;  FTIR (cm-1) (neat): 3011, 
1655, 1493, 1390, 1283, 1058, 823, 577; HRMS (ESI, Pos) calcd for C12H14BrNNaO  
(M+Na)+ : 290.0151, found: 290.0144 m/z. 
 
                                                
9 Beckwith, A.L.J.; Storey,J.M.D. Chem. Commun.1995, 977. 	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N-(2-bromo-4-methoxyphenyl)-N-methylcyclopropanecarboxamide (1c) 
 
The title compound 1c was prepared by the general synthesis on a 7.46 mmol scale and then 
purified via column chromatography (20:1 Hex: EtOAc) to give a dark purple oil in 70% yield 
(1.49g, 5.25 mmol) over two steps. Rf: 0.45 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): 
δ 7.282-7.279 (m, 1H), 7.23 (d, J = 2.8 Hz, 1H), 6.92 (dd, J = 8.7, 2.8 Hz, 1H), 3.85 (s, 3H), 
3.20 (s, 3H), 1.24-1.18 (m, 1H), 1.08-0.95 (m, 2H), 0.69-0.55 (m, 2H); 13C NMR (CDCl3, 
75MHz): δ 173.7, 159.4, 135.5, 130.3, 124.0, 118.5, 114.5, 55.7, 36.1, 12.0, 8.4, 7.9; FTIR 
(cm-1) (neat): 3009, 1653, 1493, 1390, 1031, 890, 605; HRMS (APPI, Pos) calcd for 
C12H15BrNO2 (M+H)+ : 284.0281 , found: 284.0272 m/z. 
 
 
 
N-(2-bromo-4,5-dimethoxyphenyl)-N-methylcyclopropanecarboxamide (1d) 
 
The title compound 1d was prepared by the general synthesis on a 3.13 mmol scale and then 
purified via column chromatography (20:1 Hex: EtOAc) to give a dark purple solid in 80% 
yield (0.782 g, 2.49 mmol) over two steps. mp: 75-78°C; Rf: 0.55 (1:1 Hex : EtOAc); 1H 
NMR (CDCl3, 400MHz): δ 7.06 (s, 1H), 6.81 (s, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.14 (s, 3H), 
1.22-1.14 (m, 1H), 1.00-0.89 (m, 2H), 0.62-0.52 (m, 2H); 13C NMR (CDCl3, 100MHz); δ 
173.7, 149.16, 149.06, 135.2, 115.3, 113.6, 112.2, 56.23, 56.19, 35.9, 12.0, 8.4, 7.9; FTIR 
(cm-1) (neat): 2937, 1648, 1525, 1382, 1070, 898, 875, 637; HRMS (ESI, Pos) calcd for 
C13H16BrNNaO3 (M+Na)+ : 336.0206, found: 336.0207 m/z. 
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N-(4-acetyl-2-bromophenyl)-N-methylcyclopropanecarboxamide (1e) 
 
The title compound 1e was prepared by the general synthesis on a 5.18 mmol scale and then 
purified via column chromatography (20:1 Hex: EtOAc) to give an orange oil in 65% yield 
(1.04 g, 3.39 mmol) over two steps. Rf: 0.35 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 300MHz): 
δ 8.27 (d, J = 1.9 Hz, 1H), 7.97 (dd, J = 8.1, 1.9 Hz, 1H), 7.47 (d, J = 8.1 Hz, 1H), 3.22 (s, 
3H), 2.63 (s, 3H), 1.13-0.98 (m, 3H), 0.68-0.58 (m, 2H); 13C NMR (CDCl3, 100MHz): δ 
195.6, 173.0, 146.9, 137.9, 133.8, 130.4, 128.7, 124.4, 35.9, 26.7, 12.6, 8.8, 8.4 ; FTIR (cm-1) 
(neat): 3010, 1768, 1687, 1655, 1424, 1264, 1127, 1085, 604; HRMS (ESI, Pos) calcd for 
C13H14BrNNaO2 (M+Na)+ : 318.0100, found: 318.0099 m/z. 
 
 
Ethyl 3-bromo-4-(N-methylcyclopropanecarboxamido)benzoate(1f) 
 
The title compound 1f was prepared by the general synthesis on a 4.07 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give a light yellow solid in 66% yield (0.881 g, 2.70 
mmol) over two steps. mp: 68-72°C; Rf: 0.42 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 
400MHz): δ  8.29 (d, J = 1.9 Hz, 1H), 8.00 (dd, J = 8.1, 1.9 Hz, 1H), 7.39 (d, J = 8.1 Hz, 1H), 
4.34 (q, J = 7.1 Hz, 2H), 3.15 (s, 3H), 1.34 (dd, J = 9.2, 5.1 Hz, 3H), 1.06-0.89 (m, 3H), 0.61-
0.50 (m, 2H).; 13C NMR (CDCl3,100MHz): δ 172.0, 163.4, 145.7, 133.9, 130.7, 129.11, 
128.97, 122.9, 60.6, 34.9, 13.3, 11.5, 7.7, 7.3; FTIR (cm-1) (neat): 3013, 1715, 1649, 1592, 
Br
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1471, 1280, 1121, 753; HRMS (ESI, Pos) calcd for C14H16BrNNaO3 (M+Na)+: 348.0206 , 
found: 348.0206 m/z. 
 
 
 
N-(2-bromo-4-cyanophenyl)-N-methylcyclopropanecarboxamide (1g) 
 
The title compound 1g was prepared by the general synthesis on a 4.10 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give an orange solid in 84% yield (0.949 g, 3.40 
mmol) over two steps. mp: 210-213°C; Rf: 0.37 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 
400MHz): δ  7.99 (s, 1H), 7.69 (dd, J = 8.1, 1.6 Hz, 1H), 7.48 (d, J = 8.1 Hz, 1H), 3.18 (s, 
3H), 1.07-0.93 (m, 3H), 0.70-0.56 (m, 2H); 13C NMR (CDCl3,100MHz): δ 172.9, 147.3, 
137.3, 132.6, 131.1, 124.8, 116.6, 113.6, 36.0, 12.7, 9.0, 8.6 ; FTIR (cm-1) (neat): 2927, 2229, 
1660, 1481, 1425, 1143, 610, 450; HRMS (ESI, Pos) calcd for C12H11BrN2NaO (M+Na)+: 
300.995 , found: 300.9944 m/z. 
 
 
N-(2-bromo-4-(trifluoromethyl)phenyl)-N-methylcyclopropanecarboxamide(1h) 
 
The title compound 1h was prepared by the general synthesis on a 0.922 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give a white solid in 72% yield (0.2136 g, 0.663 
mmol) over two steps. mp: 49-52°C; Rf: 0.55 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 
400MHz): δ  7.95 (s, 1H), 7.66-7.64 (m, 2H), 7.49 (d, J = 8.0 Hz, 1H), 3.19 (s, 3H), 1.08-0.96 
(m, 3H), 0.67-0.57 (m, 2H); 13C NMR (CDCl3,75MHz): 173.1, 146.3, 131.7 (q, J = 33.5 Hz), 
131.1 (q, J= 3.9 Hz), 130.7, 126.0 (q, J= 3.5 Hz), 122.8 (q, J= 273 Hz), 35.9, 12.6, 8.9, 8.4;  
Br
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19F NMR (282 MHz, CDCl3): δ -62.7; FTIR (cm-1) (neat): 2935, 1783, 1657, 1428, 1157, 
935, 680, 648, 484; HRMS (ESI, Pos) calcd for C12H11BrF3NNaO (M+Na)+: 343.9868 , 
found: 343.9868 m/z. 
 
 
 
N-(2-bromo-4-chlorophenyl)-N-methylcyclopropanecarboxamide(1i) 
 
The title compound 1i was prepared by the general synthesis on a 6.55 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc :Hex to give a light pink solid in 63% yield (1.18 g, 4.08 
mmol) over two steps. mp: 61-63°C; Rf: 0.53 (1:1 Hex :EtOAc); 1H NMR (CDCl3, 300MHz): 
δ  7.70 (d, J = 2.3 Hz, 1H), 7.37 (dd, J = 8.4, 2.3 Hz, 1H), 7.30 (d, J = 8.4 Hz, 1H), 3.18 (s, 
3H), 1.15-0.95 (m, 3H), 0.68-0.57 (m, 2H).; 13C NMR (CDCl3,75MHz): δ 173.5, 141.8, 134.8, 
133.6, 131.0, 129.3, 124.6, 36.1, 12.5, 8.9, 8.4 ; FTIR (cm-1) (neat): 2932, 1655, 1556, 1285, 
1034, 894, 579; HRMS (APPI, Pos) calcd for C11H12BrClNO  (M+H)+: 287.9785 , found: 
287.9776 m/z. 
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Synthesis of trans-rac-2-arylcyclopropanecarboxylic acids 
 
The ethyl-(E)-3-arylacrylates were synthesized according to the literature procedure.10 The 
Corey-Chaykovsky cyclopropanation was performed as outlined in the literature,11 except an 
acidic work up was added to isolate the carboxylic acid. All the intermediates have been 
previously synthesized and match reported literature data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                
10 Jiang, T.; Livinghouse, T.; Lovick, H.M. Chem. Commun. 2011, 47, 12861-12863.  
11 Corey, E.J.; Chaykovsky, M. J. Am. Chem. Soc. 1965, 87, 1353-1364.	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Synthesis of 2-bromoanilides (1j-1r)   
Route A 
 
The cyclopropanecarboxylic acid (1 equiv) was dissolved in THF (10 mL) in a 50-mL round-
bottomed flask flame-dried and cooled over argon. Catalytic DMF (2-3 drops) was added to 
the solution. Oxalyl chloride (1.1 equiv) was then added dropwise over 30 min. The reaction 
was stirred for an additional 30 min at ambient temperature (or until complete by TLC) and 
then concentrated in vacuo to remove excess oxalyl chloride. The residue was re-dissolved in 
THF (10 mL). 2-Bromoaniline (0.95 equiv), then Et3N (1.0 equiv) were both added dropwise. 
The reaction was stirred at ambient temperature for a further 16 h. It was then quenched with 
water (10 mL), and the aqueous layer was extracted with EtOAc (2x’s, 25 mL). The combined 
organic layers were washed with saturated NaHCO3 solution (20 mL), brine (10 mL), dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude was then dissolved in 
THF (10 mL) in a 25-mL round-bottomed flask under argon and cooled in an ice bath. NaH 
(60%, 1.1 equiv) was added portionwise. The reaction was stirred for an additional 10 min, 
then MeI (1.5 equiv) was added. The reaction was allowed to warm up to ambient temperature 
and stirred for 16 h. Then, the reaction was quenched with water (10 mL) and extracted with 
EtOAc (3x’s, 20 mL). The combined organic layers were washed with brine (10 mL), dried 
over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash 
chromatography. As indicated, the desired products were trans-racemic. 
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Route B 
 
The cyclopropanecarboxylic acid (1.0 equiv) was dissolved in THF (10 mL) in a 50 mL 
round-bottomed flask, flame-dried and cooled under argon. DMF (2-3 drops) was then added 
to the solution. Oxalyl chloride (1.1 equiv) was then added dropwise over 30 min. The 
reaction was stirred for an additional 30 min at ambient temperature (or until complete by 
TLC). The reaction was then concentrated in vacuo to remove excess oxalyl chloride, and the 
residue was re-dissolved in THF (10 mL). 2-Bromo-N-methylaniline12 (0.95 equiv), then Et3N 
(1.0 equiv) were both added dropwise. The reaction was stirred at ambient temperature for a 
further 16 h. It was then quenched with water (10 mL), and the aqueous layer was extracted 
with EtOAc (2x’s, 25 mL). The combined organic layers were washed with saturated NaHCO3 
solution (20 mL) and brine (10 mL), and then dried over anhydrous Na2SO4. After filtering 
and concentrating in vacuo, the residue was purified by flash chromatography or re-
crystallization to give trans-racemic products.  
 
trans-rac-N-(2-bromophenyl)-N-methyl-2-(o-tolyl)cyclopropanecarboxamide (1j) 
Synthesized according to route B on an 1.9-mmol scale. The residue was purified by flash 
chromatography (5-20% EtOAc : Hex), affording the title compound as clear oil in 94% yield 
(618 mg, 1.80 mmol). Reported as a 1:1 mixture of rotamers. mp: 91-93 °C; Rf: 0.44 (1:1 
Hex :EtOAc);  1H NMR (CDCl3, 400 MHz): δ 7.71-7.66 (m, 1H), 7.40-7.37 (m, 2H), 7.27-
7.21 (m, 1H), 7.12-7.06 (m, 2H), 7.02-6.97 (m, 1H), 6.74-6.66 (m, 1H), 3.29 (s, 3H), 2.70-
                                                
12 Wurtz, S.; Lohre, C.; Frohlich, R.; Bergander, K.; Glorius, F. J. Am. Chem. Soc. 2009, 131, 8344. 	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2.56 (m, 1H), 2.39 (d, 3H, J = 9.0 Hz), 1.69-1.53 (m 1H), 1.46-1.41 (m, 1H), 1.12-0.99 (m, 
1H); 13C NMR (CDCl3, 100 MHz): δ 172.5, 172.4, 142.7, 142.6, 138.4 (2C), 138.3, 137.9, 
134.0 (2C), 130.3, 130.1, 129.8, 129.7, 129.0 (2C), 126.4, 126.1, 126.0, 125.5, 123.9, 36.2, 
36.1, 24.5, 24.4, 21.4, 19.8, 19.7, 16.3, 15.8; FTIR (cm–1)(neat): 2939, 1644, 1580, 1477, 
1358, 1270, 1059, 1029, 767, 752, 723; HRMS (ESI, Pos) calcd for C18H19BrNO [M+H]+: 
344.0645 m/z, found 344.0644 m/z.  
  
trans-rac-N-(2-bromophenyl)-N-methyl-2-(m-tolyl)cyclopropanecarboxamide(1k) 
Synthesized according to route A, on a 3.0 mmol scale. The residue was purified by flash 
chromatography (5-20% EtOAc : Hex), affording the title compound as an off-white solid in 
74% yield (764 mg, 2.22 mmol). Reported as a 1:1 mixture of rotamers. mp: 87-88 °C; Rf: 
0.49 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.72-7.62 (two br d, 1H, J = 7.3 Hz), 
7.41-7.40 (m, 1H), 7.32-7.27 (m, 1H), 7.24-7.21 (m, 1H), 7.10-7.07 (m, 1H),  6.97-6.96 (d, 
1H, J = 7.2 Hz), 6.86-6.71 (m 2H),  3.28 (s, 3H), 2.63-2.50 (m, 1H), 2.27 (s, 3H), 1.72-1.59 (m 
1H), 1.47-1.41 (m, 1H), 1.15-1.04 (m, 1H); 13C NMR (CDCl3, 100 MHz): δ 172.2, 172.1, 
142.7, 142.6, 140.6, 140.5, 137.8, 137.7, 133.9 (2C), 130.4, 130.1, 129.7 (2C), 129.0, 128.9, 
128.2, 128.1, 127.9, 127.3, 126.9, 124.0, 123.8, 123.7, 123.3, 36.2, 36.1, 26.4, 26.1, 23.6, 23.0, 
21.4, 17.2, 16.2; FTIR (cm–1)(neat): 2922, 1650, 1607, 1427, 1363, 1252, 1031, 930, 730, 
697, 673; HRMS (ESI, Pos) calcd for C18H19BrNO [M+H]+: 344.0645 m/z, found 344.0647 
m/z.  
 
trans-rac-N-(2-bromophenyl)-N-methyl-2-(p-tolyl)cyclopropanecarboxamide (1l) 
Synthesized according to route B, on a 2.85 mmol scale. The residue was purified by flash 
chromatography (5-20% EtOAc : Hex), affording the title compound as an off-white solid in 
77% yield (769 mg, 2.30 mmol). Reported as a 1:1 mixture of rotamers. mp: 98-99 °C; Rf: 
0.40 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.69-7.59 (two d, 1H), 7.38-7.36 (m, 
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1H), 7.28-7.26 (m, 1H), 7.22-7.17 (m, 1H), 7.00-6.97 (m, 2H), 6.89 (dd, 1H, J = 8.0, 1.5 Hz), 
6.80 (dd, 1H, J = 8.0, 1.5 Hz), 3.25 (s, 3H), 2.60-2.47 (m, 1H), 2.26 (s, 3H), 1.67-1.54 (m 1H), 
1.41-1.34 (m, 1H), 1.11-0.99 (m, 1H); 13C NMR (CDCl3, 100 MHz): δ 172.4, 172.2, 142.7, 
142.6, 137.6 (2C), 135.7 (2C), 133.9 (2C), 130.4, 130.1, 129.8, 129.7, 129.0 (2C), 128.9, 
126.8 (2C), 126.3, 124.0, 123.7, 36.2 (2C), 26.2, 25.9, 23.5, 23.0, 21.1 (2C),17.2, 16.3; FTIR 
(cm–1)(neat): 3082, 3024, 1644, 1581, 1475, 1423, 963, 871, 671, 527; HRMS (ESI, Pos) 
calcd for C18H19BrNO [M+H]+: 344.0647 m/z, found 344.0645 m/z. 
 
trans-rac-N-(2-bromophenyl)-2-(4-methoxyphenyl)-N-methylcyclopropanecarboxamide 
(1m) 
Synthesized according to route B on a 2.37-mmol scale. The residue was purified by flash 
chromatography (5-20% EtOAc : Hex), affording the title compound as a clear oil in 74% 
yield (632 mg, 1.75 mmol). Reported as a 1:1 mixture of rotamers. Rf: 0.44 (1:1 Hex : 
EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.71-7.61 (two br d, 1H), 7.42-7.37 (m, 1H), 7.31-
7.27 (m, 1H), 7.23-7.19 (m, 1H), 6.94 (d, 1H, J = 8.4 Hz), 6.86 (d, 1H, J = 8.5 Hz), 6.73 (dd, 
2H, J = 8.8, 2.5 Hz), 3.75 (s, 3H), 3.27 (s, 3H), 2.60-2.47 (m, 1H), 1.68-1.55 (m, 1H), 1.39-
1.32 (m, 1H), 1.10-0.99 (m, 1H); 13C NMR (CDCl3, 100 MHz): δ 172.4, 172.3, 158.1 (2C), 
142.7, 142.6, 133.9 (2C), 132.7, 132.6, 130.4, 130.2, 129.8, 129.7, 129.0, 128.9, 128.0, 127.5 
(2C), 124.0, 123.7, 113.8, 55.3 (2C), 36.2, 36.1, 25.9, 25.6, 23.5, 23.0, 17.0, 16.1; FTIR    
(cm–1) (neat): 28344, 1651, 1611, 1583, 1514, 1475, 1245, 1119, 1034, 823, 671; HRMS 
(ESI, Pos) calcd for C18H18BrNNaO2 [M+Na]+: 382.0413 m/z, found 382.0407 m/z. 
 
trans-rac-N-(2-bromophenyl)-2-(4-fluorophenyl)-N-methylcyclopropanecarboxamide 
(1n) 
Synthesized according to route B, on a 3.5 mmol scale. The residue was purified by re-
crystallization from EtOAc : Hex, affording the title compound as a white solid in 78% yield 
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(931 mg, 2.68 mmol). Reported as a 1:1 mixture of rotamers. mp: 99-100 °C; Rf: 0.41 (1:1 
Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.67-7.55 (two br d, 1H), 7.37-7.36 (m, 1H), 
7.26-7.25 (m, 1H), 7.19-7.15 (m, 1H), 6.93-6.89 (m, 1H), 6.84-6.80 (m 3H), 3.23 (s, 3H), 
2.57-2.45 (m, 1H), 1.68-1.57 (m 1H), 1.38-1.32 (m, 1H), 1.07-0.97 (m, 1H); 13C NMR 
(CDCl3, 100 MHz): δ 171.8, 171.7, 162.4, 160.0, 142.4 (2C), 136.2 (d, J = 3 Hz), 136.1 (d, J = 
3 Hz), 133.8, 133.7, 130.1, 130.0, 129.7 (2C),128.9, 128.8, 128.1, 128.0, 127.6, 127.7, 123.8, 
123.5, 115.1, 115.0, 114.9, 114.8, 36.0 (2C), 25.6, 25.2, 23.6, 23.1, 16.9, 16.0; 19F NMR 
(CDCl3, 300 MHz): δ -116.6 (m);  FTIR (cm–1) (neat): 2966, 1650, 1528, 1510, 1475, 1419, 
1320, 1211, 1083, 864, 746, 671, 572. HRMS (ESI, Pos) calcd for C17H16BrFNO [M+H]+: 
348.0394 m/z, found 348.0392 m/z.  
 
 
trans-rac-N-(2-bromophenyl)-2-(4-chlorophenyl)-N-methylcyclopropanecarboxamide(1o) 
Synthesized according to route B, on a 1.9 mmol scale. The residue was purified by flash 
chromatography (5-20% EtOAc : Hex), affording the title compound as a white solid in 77% 
yield (533 mg, 1.46 mmol). Reported as a 1:1 mixture of rotamers. mp: 80-82 °C; Rf: 0.53 
(1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.69-7.57 (two br d, 1H, J = 8.3 Hz), 7.41-
7.37 (m, 1H), 7.27-7.25 (m, 1H), 7.13-7.11 (m, 2H), 6.98 (d, 1H, J = 8.1 Hz), 6.82 (d, 1H, J = 
8.1 Hz),  3.25 (s, 3H), 2.56-2.46 (m, 1H), 1.72-1.61 (m 1H), 1.40-1.33 (m, 1H), 1.11-1.00 (m, 
1H). 13C NMR (CDCl3, 100 MHz): δ 171.8, 171.7, 142.5, 142.4, 139.2 (2C), 133.9, 133.8, 
131.8 (2C), 130.2, 130.0, 129.8 (2C), 129.0, 128.9, 128.4 (2C), 128.3, 128.0, 127.7, 123.9, 
123.6, 36.2, 36.14, 25.8, 25.4, 23.9, 23.5, 17.2, 16.3. FTIR (cm–1)(neat): 2922, 2866, 1657, 
1492, 1477, 1358, 1056, 1012. HRMS (ESI, Pos) calcd for C17H16BrClNO [M+H]+: 364.0098 
m/z, found 364.0097 m/z.  
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trans-rac-N-(2-bromophenyl)-N-methyl-2-(4-
(trifluoromethyl)phenyl)cyclopropanecarboxamide(1p) 
Synthesized according to route B, on a 1.36 mmol scale. The residue was purified by flash 
chromatography (5-20% EtOAc : Hex), affording the title compound as a yellow solid in 66% 
yield (356 mg, 0.894 mmol). Reported as a 1:1 mixture of rotamers. mp: 74-75 °C; Rf: 0.44 
(1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.71-7.57 (two br d, 1H), 7.43-7.39 (m, 
3H), 7.27-7.26 (m, 1H), 7.23-7.19 (m, 1H), 7.09 (d, 1H, J = 7.9 Hz), 6.99 (d, 1H, J = 7.9 Hz),  
3.26 (s, 3H), 2.69-2.59 (m, 1H), 1.77-1.66 (m 1H), 1.49-1.42 (m, 1H), 1.18-1.06 (m, 1H); 13C 
NMR (CDCl3, 100 MHz): δ 171.6, 171.5,145.0 (2C), 142.5, 142.4, 134.0 (2C), 130.2, 
130.1,129.9(2C), 129.1, 129.0, 126.8, 126.4, 125.3-125.2 (m), 123.9, 123.7, 36.2 (2C), 26.1, 
25.7, 24.3, 23.8, 17.6, 16.6;  19F NMR (CDCl3, 300 MHz): δ -62.3 (d, J = 9.7 Hz). FTIR  
(cm–1) (neat): 2931, 1655, 1618, 1476, 1423, 1323, 162, 1116, 1067, 826, 727, 711. HRMS 
(ESI, Pos) calcd for C18H16BrF3NO [M+H]+: 398.0362 m/z, found 398.0355 m/z.  
 
trans-rac-N-(2-bromophenyl)-2-(furan-2-yl)-N-methylcyclopropanecarboxamide(1q) 
Synthesized according to route B, on a 2.85 mmol scale. The residue was purified by flash 
chromatography (5-20% EtOAc : Hex), affording the title compound as a yellow oil in 77% 
yield (707 mg, 2.21 mmol). Reported as a 1:1 mixture of rotamers. Rf: 0.48 (1:1 Hex : 
EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.66-7.59 (two br d, 1H, J = 8.0 Hz), 7.39-7.29 (m, 
2H), 7.21-7.16 (m, 1H), 7.10-7.08 (m, 1H), 6.15-6.13 (m, 1H), 5.96-5.82 (br d, 1H, J = 12.7, 
2.6 Hz), 3.21 (s, 3H), 2.54-2.44 (m, 1H), 1.59-1.46 (m, 2H), 1.16-1.06 (m, 1H); 13C NMR 
(CDCl3, 100 MHz): δ 171.5, 171.4,154.0 (3C), 142.4, 142.3, 140.8, 140.7, 133.8, 130.2, 130.0, 
129.7 (2C), 128.9 (2C), 123.9, 123.5, 110.2, 105.0, 104.8, 36.1 (2C), 32.2, 21.4, 19.5, 19.1, 
15.0, 14.4; FTIR (cm–1) (neat): 3008, 2923, 1650, 1583, 1507, 1422, 1315, 1131, 1119, 1013, 
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764, 727; HRMS (ESI, Pos) calcd for C15H14BrNNaO2 [M+Na]+: 342.0100 m/z, found 
342.0099 m/z.  
 
trans-rac-N-(2-bromophenyl)-N-methyl-2-(thiophen-2-yl)cyclopropanecarboxamide(1r) 
Synthesized according to route A, on a 2.76 mmol scale. The residue was purified by flash 
chromatography (5-20% EtOAc : Hex), affording the title compound as an off-white solid in 
67% yield (622 mg, 1.85 mmol). Reported as a 1:1 mixture of rotamers. mp: 119-121 °C; Rf: 
0.46 (1:1 Hex : EtOAc);  1H NMR (CDCl3, 400 MHz): δ 7.69-7.64 (m, 1H), 7.41-7.31 (m, 
2H), 7.24-7.20 (m, 1H), 7.00 (t, 1H, J = 4.5 Hz), 6.81-6.79 (m, 1H),  6.66-6.59 (two d, 1H, J = 
3.2 Hz), 3.25 (s, 3H), 2.72-2.53 (m, 1H), 1.73-1.62 (m 1H), 1.48-1.43 (m, 1H), 1.15-1.04 (m, 
1H); 13C NMR (CDCl3, 100 MHz): δ171.6, 171.5, 144.9, 144.8, 142.6, 142.5, 134.0 (2C), 
130.4, 130.1, 129.9, 129.8, 129.1, 129.0, 126.7, 126.6, 124.2, 124.1, 123.7, 123.6, 123.3, 
123.1, 36.2 (2C), 24.4, 24.0, 21.5, 21.3, 17.9, 17.1; FTIR (cm–1) (neat): 2923, 1643, 1582, 
1476, 1426, 1203, 1056, 923, 761, 700; HRMS (ESI, Pos) calcd for C15H15BrNO [M+H]+: 
336.0052 m/z, found 336.0050 m/z.  
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Synthesis of trans-rac-N-(2-bromophenyl)-N-methyl-2-phenylcyclopropanecarboxamide  
(1sa) 
 
 
 
 
To a solution of 2-bromoaniline (11.6 mmol, 1 equiv) in THF (25 mL) was added cinnamyl 
chloride (11.9 mmol, 1.1 equiv) under argon. The reaction was stirred at room temperature for 
16 h. Then, EtOAc (50 mL) was added and the organic phase was washed with saturated 
NaHCO3 solution (2x’s, 30 mL) and brine (15 mL). The organic phase was dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The resulting solid was dried on a 
vacuum pump, then dissolved in 25 mL of THF, purged with argon, and cooled down in an ice 
bath. NaH (60%, 15.9 mmol, 1.37 equiv) was added to the solution portionwise over a few 
minutes. The reaction was stirred for an additional 10 min at 0 °C, then MeI (17.4 mmol, 1.5 
equiv) was added to the reaction. The reaction was allowed to warm up to room temperature, 
and stirred overnight. The reaction was quenched with water (15 mL), and extracted with 
EtOAc (3x’s, 25 mL). The combined organic layers were washed with brine, dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was flashed in 5-30% 
EtOAc/Hex to give 77%( 2.8 g) of N-(2-bromophenyl)-N-methylcinnamamide as an off-white 
solid to be used in the subsequent step. 
NH2
Br O
Cl
1.THF, rt, 16 h
2.NaH, THF
MeI, 0°C to rt, 16 h
N
Br O
Me
N
Br O
Me
Me3S+OI-
NaH 
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To a solution of trimethylsulfoxonium iodide (2 equiv) in DMSO (100 mL) was added 
NaH (60%, 2 equiv) portionwise over 15 min. The reaction was allowed to stir for 30 min at 
room temperature, then a solution of N-(2-bromophenyl)-N-methylcinnamamide in 5 mL of 
DMSO was added dropwise. The reaction was allowed to stir for 16 h. Then, the reaction was 
neutralized with 2.0 M HCl, and extracted with EtOAc (2x’s, 25 mL). The combined organic 
layer was washed with brine (2x’s, 30 mL), dried over anhydrous Na2SO4 and concentrated in 
vacuo. The residue was purified by flash chromatography in 5-10% EtOAc : Hex, affording 
the title compound as a clear oil in 75% yield and as the trans-racemic product.  
Reported as a 1:1 mixture of rotamers. Rf: 0.48 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 
MHz): δ 7.69-7.57 (br d, 1H), 7.39-7.36 (m, 1H), 7.28-7.25 (m, 1H), 7.19-7.11 (m, 4H), 6.97 
(d, 1H, J = 7.7 Hz), 6.90 (d, 1H, J = 7.7 Hz), 3.25 (s, 3H), 2.62-2.49 (m, 1H), 1.70-1.57 (m, 
1H), 1.43-1.37 (m, 1H), 1.14-1.02 (m, 1H); 13C NMR (CDCl3, 100 MHz): δ 172.3, 172.2, 
142.7, 142.6, 140.8, 140.7, 134.0, 133.9, 130.4, 130.2, 129.8 (2C), 129.0 (2C), 128.4, 128.3, 
126.9, 126.4, 126.2, 124.0, 123.7, 36.3, 36.2, 26.6, 26.2, 23.8, 23.3, 17.4, 16.4; FTIR  (cm–1) 
(neat): 3002, 1647, 1583, 1457, 1423, 1358, 1312, 749, 728, 697; HRMS (ESI, Pos) calcd for 
C17H16BrNNaO [M+Na]+: 352.0308 m/z, found 352.0304 m/z. 
Synthesis of cis-rac-N-(2-bromophenyl)-N-methyl-2-phenylcyclopropanecarboxamide 
(1sb) 
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To a 250-mL round-bottomed flask flame-dried and cooled under argon was added 
[Rh(OAc)2]2 (70 mg, 0.324 mmol, 0.5 mol %). Styrene (11.0 mL) was then added, and the 
reaction was cooled to 0ºC. Ethyl diazoacetate (3.7 g, 32.4 mmol, 1.0 equiv) was then added 
over 60 min via a syringe pump. The reaction was stirred for 3 h, then filtered through a silica-
cotton plug and concentrated in vacuo. The racemic mixture was then flashed in 5-10% 
EtOAc/Hex and the cis-prodcut isolated in 28 % yield (1.7 g, 8.9 mmol). 
1.42 g (7.5 mmol) of the racemic mixture was then transferred to a 100-mL round-bottomed 
flask containing 15 mL of THF: 10 mL of MeOH. 2.0 M NaOH (19 mL, 37.4 mmol, 5.0 
equiv) was then added and the mixture was heated to 55ºC for 5 hours. The reaction was then 
cooled to ambient temperature, acidified with 30 mL of 10% HCl. This was transferred to a 
250-mL separatory funnel and extracted with benzene (3x’s, 25 mL). The combined organics 
were then washed with brine, dried over anhydrous Na2SO4 and concentrated in vacuo to give 
the desired cis-rac-cyclopropanecarboxylic acid. 
1sb was then synthesized according to route A from 1.9 mmol of the cis-rac-
cyclopropanecarboxylic acid. The residue was purified by flash chromatography (5-20% 
EtOAc/Hex), affording the cis-racemic product as a clear oil in 79% yield (494 mg, 1.50 
mmol). Reported as a 3:1 mixture of rotamers. Rf: 0.45; 1H NMR (CDCl3, 400 MHz): δ 7.72-
7.67 (two d, 1H, J = 8.0, 1.3 Hz), 7.41-7.15 (m, 7H), 6.87 (dd, 1H, J = 7.8, 1.6 Hz), 3.07 & 
3.01 (s, 3H), 2.30 & 2.06 (q, 1H, J =8.4 Hz), 1.90-1.86 & 1.81-1.77 (m, 1H), 1.73-1.66 (m, 
1H), 1.21-1.14 (m, 1H). 13C NMR (CDCl3, 100 MHz): δ 169.5, 168.4, 143.0, 142.4, 137.2, 
136.6, 133.8, 133.6, 130.6, 130.2, 129.7, 129.6, 129.5, 128.8, 128.6, 128.2, 127.8, 127.4, 
126.2, 126.1, 123.7, 123.2, 35.9, 35.8, 26.5, 25.5, 24.4, 21.0, 12.2, 11.2; FTIR (cm–1) (neat): 
3059, 3008, 1655, 1497, 1476, 1458, 1329, 1068, 1026, 728, 696, 664; HRMS (ESI, Pos) 
calcd for C17H16BrNNaO [M+Na]+: 352.0308 m/z, found 352.0305 m/z. 
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General Procedure for the Synthesis of Spiro 3,3’-cyclopropyl oxindoles (2a-2sb) 
 
To a 5.0-mL microwave vial in a glovebox was added in the following order: Pd(OAc)2 (5.6 
mg, 0.025 mmol), PCy3 (7.0 mg, 0.025 mmol), K2CO3 (104 mg, 0.75 mmol) and Ag3PO4 (0.17 
mmol, 69.1 mg). The vial was crimped shut. The 2-bromoanilide (1a-1sa) (0.50 mmol) was 
weighed into a vial, dissolved in 0.4 mL of toluene and added to the reaction vial. The vial 
containing 2-bromoanilide was rinsed with 3x’s 0.2 mL of toluene for a total volume of 1.0 
mL. This yellowish-orange solution was then heated to 130°C in an oil bath for 3 h as 
indicated by TLC. The reaction turned black within five minutes. The reaction was cooled to 
ambient temperature, filtered over a cotton-Celite® plug, and rinsed with 15 mL of ethyl 
acetate. It was then concentrated in vacuo to give the crude product. The crude was then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% Ethyl Acetate/Hexanes to give 2a-2sb.  
 
 
 
1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (2a) 
 
The title compound 2a was prepared by the general procedure on a 0.464 mmol scale to give 
an orange solid in 90% yield (72. 4 mg, 0.418 mmol). The observed characterization data (1H 
NMR) was consistent with that previously reported in the littérature.13,14 1H NMR (CDCl3, 
400 MHz): δ 7.52-7.47 (m, 1H), 7.28-7.25 (m, 1H), 7.16-7.13 (m, 1H), 7.09-7.06 (m, 1H), 
3.54 (s, 3H), 1.98-1.95 (m, 2H), 1.76-1.73 (m, 2H). 
                                                
13 Beckwith, A.L.J.; Bowry, V.W.;  Bowman,W. R.; Mann, E.; Parr, J .; Storey, J. Angew. Chem. 2004, 116, 97. 
14 Helan, V.; Mills, A.; Drewry,D.; Grant, D. J. Org. Chem. 2010, 75, 6693. 
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1',5'-dimethylspiro[cyclopropane-1,3'-indolin]-2'-one (2b) 
The title compound 2b was prepared by the general procedure on a 0.508 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give a light pink solid in 81% yield (77.2 mg, 0.412 
mmol). mp: 75-78°C; Rf: 0.42 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400MHz): δ 7.06-7.04 
(m, 1H), 6.81-6.78 (m, 1H), 6.66 (dd, J = 1.0, 0.4 Hz, 1H), 3.28 (s, 3H), 2.35 (s, 3H), 1.74-
1.69 (m, 2H), 1.50-1.46 (m, 2H); 13C NMR (CDCl3, 75 MHz): δ 177.2, 141.3, 131.6, 131.0, 
130.3, 127.1, 119.2, 107.8, 27.1, 26.7, 21.2, 19.1; FTIR (cm-1) (neat): 2918, 1691, 1493, 1392, 
1230, 890, 700, 554; HRMS (ESI, Pos) calcd for C12H13NNaO(M+Na)+: 210.0889 , found: 
210.0881 m/z. 
 
 
5'-methoxy-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (2c) 
 
The title compound 2c was prepared by the general procedure on a 0.506 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give a cream-coloured solid in 67% yield (69.4 mg, 
0.342 mmol). mp: 72-75°C; Rf: 0.62(1:1 Hex : EtOAc); 1H NMR (CDCl3, 400MHz):  δ 6.80 
(d, J = 2.1 Hz, 2H), 6.47 (t, J = 0.9 Hz, 1H), 3.80 (s, 3H), 3.29 (s, 3H), 1.75 (m, 2H), 1.49 (m, 
2H); 13C NMR (CDCl3, 75 MHz): δ 176.8, 155.9, 137.3, 132.4, 111.0, 108.3, 106.1, 56.0, 
27.5, 26.7, 19.3; FTIR (cm-1) (neat): 2930, 1694, 1370, 1210, 793 ; HRMS (APPI, Pos) calcd 
for C12H14NO2 (M+H)+: 204.1019 , found: 204.1027 m/z. 
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5',6'-dimethoxy-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (2d) 
The title compound 2d was prepared by the general procedure on a 0.5 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give a cream-coloured solid in 74% yield (86.3 mg, 
0.37 mmol). mp: 148-150°C; Rf: 0.52 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400MHz): δ 6.55 
(s, 1H), 6.45 (s, 1H), 3.92 (s, 3H), 3.85  (s, 3H), 3.27 (s, 3H), 1.69-1.66 (m, 2H), 1.45-1.42 (m, 
2H); 13C NMR (CDCl3, 75 MHz):  δ 177.5, 148.9, 145.1, 137.3, 121.6, 104.3, 94.8, 57.1, 56.7, 
27.3, 26.7, 18.7; FTIR (cm-1) (neat): 2932, 1687, 1508, 1285, 1150, 901, 777; HRMS (ESI, 
Pos) calcd for C13H15NNaO3 (M+Na)+: 256.0944, found: 256.0942 m/z. 
 
5'-acetyl-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (2e) 
The title compound 2e was prepared by the general procedure on a 0.412 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give a cream-coloured solid in 62% yield (54.9 mg, 
0.255 mmol). mp: 165-167°C; Rf: 0.27 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400MHz): δ 
7.93-7.90 (m, 1H), 7.49 (d, J = 1.3 Hz, 1H), 6.93 (dd, J = 8.1, 3.3 Hz, 1H), 3.33 (s, 3H), 2.58 
(s, 3H), 1.80-1.76 (m, 2H), 1.63-1.61 (m, 2H); 13C NMR (CDCl3, 75 MHz): δ 197.1, 177.5, 
147.9, 131.8, 131.3, 129.0, 118.2, 107.3, 27.1, 26.9, 26.5, 19.8 ; FTIR (cm-1) (neat): 2920, 
2851, 1711, 1659, 1616, 1424, 1259, 826, 618, 535; HRMS (ESI, Pos) calcd for 
C13H13NNaO2 (M+Na)+: 238.0839 , found: 238.0834 m/z. 
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Ethyl 1'-methyl-2'-oxospiro[cyclopropane-1,3'-indoline]-5'-carboxylate (2f) 
The title compound 2f was prepared by the general procedure on a 0.432 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give an orange solid in 99% yield (105 mg, 0.426 
mmol. mp: 124-126°C; Rf: 0.38 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400MHz): δ 8.00 (d, J 
= 8.1 Hz, 1H), 7.50 (s, 1H), 6.91 (d, J = 8.1 Hz, 1H), 4.35 (q, J = 7.0 Hz, 2H), 3.32 (s, 3H), 
1.77 (d, J = 3.6 Hz, 2H), 1.61-1.60 (m, 2H), 1.38 (m, 3H); 13C NMR (CDCl3, 75 MHz):  δ 
177.4, 166.6, 147.6, 130.9, 129.5, 124.4, 119.6, 107.5, 61.0, 27.1, 26.9, 19.6, 14.5 ; FTIR (cm-
1) (neat): 2961, 1701, 1615, 1298, 1104, 1025, 772; HRMS (ESI, Pos) calcd for C14H15NNaO3 
(M+Na)+: 268.0944 , found: 268.0940 m/z. 
 
 
 
1'-methyl-2'-oxospiro[cyclopropane-1,3'-indoline]-5'-carbonitrile (2g) 
 
The title compound 2g was prepared by the general procedure on a 0.524 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give an orange solid in 78% yield (80.9 mg, 0.409 
mmol). mp: 124-127°C; Rf: 0.33 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400MHz): δ  7.58 (dd, 
J = 8.1, 1.5 Hz, 1H), 7.07 (d, J = 1.3 Hz, 1H), 6.95 (d, J = 8.1 Hz, 1H), 3.32 (s, 3H), 1.82 (m, 
2H), 1.60 (m, 2H); 13C NMR (CDCl3, 75 MHz):  δ 176.8, 147.4, 132.16, 132.12, 121.7, 119.5, 
108.4, 105.2, 27.0, 26.9, 20.2 ; FTIR (cm-1) (neat): 3053, 2919, 2220, 1711, 1618, 1591, 1253, 
829; HRMS (ESI, Pos) calcd for C12H10N2NaO (M+Na)+: 221.0685 , found: 221.0681 m/z. 
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1'-methyl-5'-(trifluoromethyl)spiro[cyclopropane-1,3'-indolin]-2'-one (2h) 
The title compound 2h was prepared by the general procedure on a 0.485 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give an orange solid in 85% yield (99.4 mg, 0.412 
mmol). mp: 132-134°C; Rf: 0.56 (1:1 EtOAc : Hex); 1H NMR (CDCl3, 400MHz): δ 7.53 (d, J 
= 8.2 Hz, 1H), 7.05 (dd, J = 1.2, 0.5 Hz, 1H), 6.96 (d, J = 8.2 Hz, 1H), 3.32 (s, 3H), 1.82-1.79 
(m, 2H), 1.59-1.61 (m, 2H). ; 13C NMR (CDCl3, 75 MHz): 177.1, 146.5, 131.6, 124.6 (q, J= 
271 Hz), 124.6 (q, J= 4.1 Hz), 124.5 (q, J= 32.7 Hz), 119.2, 115.5 (q, J= 3.6 Hz), 114.4, 27.2, 
26.9, 19.8; 19F NMR (282 MHz, CDCl3): -61.3; FTIR (cm-1) (neat): 2925, 1708, 1624, 1460, 
1163, 954, 520; HRMS (ESI, Pos) calcd for C12H10F3NNaO (M+Na)+: 264.0607, found: 
264.0603 m/z. 
 
 
 
5'-chloro-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (2i) 
 
The title compound 2i was prepared by the general procedure on a 0.491 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give an pink-colored solid in 89% yield (90.4 mg, 
0.437 mmol). mp: 130-132°C; Rf: 0.43 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400MHz): δ  
7.23 (d, J = 8.3 Hz, 1H), 6.83-6.81 (m, 2H), 3.29 (s, 3H), 1.78-1.77 (m, 2H), 1.54 (m, 2H); 13C 
NMR (CDCl3, 75 MHz): δ 176.6, 142.2, 132.8, 127.5, 126.7, 118.9, 108.9, 27.3, 26.8, 19.6; 
FTIR (cm-1) (neat): 3058, 2924, 1697, 1612, 1587, 1388, 1085, 802, 666, 545, 458;  HRMS 
(APPI, Pos) calcd for C11H11ClNO (M+H)+: 208.0525 , found: 208.0524 m/z. 
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(1S,2R)-1'-methyl-2-(o-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-one and (1R,2R)-1'-
methyl-2-(o-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-one  (2j) 
The title compound 2j was prepared by the general procedure on a 0.471 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give a yellow oil in 94% yield (90.4 mg, 0.437 mmol) 
as a mixture of major and minor diastereomers (14:1 dr). Diastereomeric ratios were 
determined via 1H NMR. Rf: 0.53 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): Major: δ 
7.40 (d, J = 7.4 Hz, 1H), 7.28-7.15 (m, 3H), 7.06-7.05 (m, 1H), 6.89 (d, J = 7.8 Hz, 1H), 6.69-
6.65 (m, 1H), 5.88 (d, J = 7.5 Hz, 1H), 3.37 (s, 3H), 2.27 (dd, J = 9.0, 4.5 Hz, 1H), 2.06 (dd, J 
= 8.0, 4.5 Hz, 1H), 1.78 (s, 3H); 13C NMR (CDCl3, 100 MHz): Major and Minor: δ 176.6, 
173.9, 143.7, 143.5, 139.3, 138.0, 133.7, 130.7, 130.1, 130.0, 129.7, 129.1, 128.7, 127.7, 
127.6, 127.5, 126.7, 125.9, 125.7, 122.0, 121.6, 119.9, 118.2, 107.9, 107.8, 36.8, 35.1, 33.3, 
33.1, 26.8, 26.6, 22.6, 22.5, 19.5, 19.2; FTIR (cm–1) (neat): 2938, 1701, 1646, 1493, 1380, 
1344, 1133, 748, 728; HRMS (ESI, Pos): calcd for C18H18NO [M+H]+: 264.1383 m/z, found 
264.1379 m/z.  
 
(1S,2R)-1'-methyl-2-(m-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-one and (1R,2R)-1'-
methyl-2-(m-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-one (2k) 
The title compound 2k was prepared by the general procedure on a 0.485 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
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gradient of 10% to 50% EtOAc : Hex to give a yellow oil in 98% yield (126 mg, 0.477 mmol) 
as a mixture of major and minor diastereomers (11:1 dr). Diastereomeric ratios were 
determined via 1H NMR. Rf: 0.53, 0.46 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): 
Major: δ 7.18-7.14 (m, 2H), 7.08-7.06 (m, 1H), 7.03 (br s, 1H), 6.98 (d, J = 7.6 Hz, 1H), 6.88 
(d, J = 7.8 Hz, 1H), 6.71 (td, J = 7.6, 1.0 Hz, 1H), 6.03 (dt, J = 7.5, 0.5 Hz, 1H), 3.34 (s, 3H), 
2.31 (s, 3H), 2.18 (dd, J = 9.1, 4.5 Hz, 1H), 2.00 (dd, J = 8.0, 4.5 Hz, 1H), 13C NMR (CDCl3, 
100 MHz): Major and Minor: δ 176.5, 143.9, 138.1, 137.4, 135.1, 134.3, 131.0, 130.7, 
130.2, 128.2 (2C), 128.1, 127.8, 127.7, 126.9, 126.8, 126.6, 126.3, 121.9, 121.5, 120.8, 118.1, 
107.8 (2C), 38.2, 35.9, 33.9, 33.4, 26.7, 26.5, 22.6, 21.5, 21.4; FTIR  (cm-1)(neat): 2922, 
1702, 1650, 1613, 1492, 1346, 1128, 730, 672; HRMS (ESI, Pos) calcd for C18H18NO 
[M+H]+: 264.1383 m/z, found 264.1380 m/z.  
 
(1S,2R)-1'-methyl-2-(p-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-one and (1R,2R)-1'-
methyl-2-(p-tolyl)spiro[cyclopropane-1,3'-indolin]-2'-one (2l) 
The title compound 2l was prepared by the general procedure on a 0.496 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc :Hex to give a yellow oil in 93% yield (121 mg, 0.459 mmol) 
as a mixture of major and minor diastereomers (8:1 dr). Diastereomeric ratios were determined 
via 1H NMR. Rf: 0.48, 0.38 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): Major: δ 7.34-
7.07 (m, 5H), 6.90-6.86 (m, 1H), 6.72 (t, 1H, J = 7.5 Hz), 6.03 (d, 1H, J = 7.5 Hz), 3.33 (s, 
3H), 3.32-3.36 (m, 1H), 2.34 (s, 3H), 2.18 (dd, 1H, J = 8.9, 4.5 Hz), 1.99 (dd, 1H, J = 7.8, 4.5 
Hz), Minor: δ 7.37-6.86 (m, 8H), 3.19 (s, 3H), 3.13-3.16 (m, 1H), 2.42-2.38 (m, 1H), 2.34 (s, 
3H), 2.06 (dd, 1H, J = 9.0, 4.7 Hz); 13C NMR (CDCl3, 100 MHz): Major: δ 176.6, 143.8, 
137.0, 132.1, 129.8, 129.1, 127.7, 126.5, 121.5, 120.8, 107.8, 35.7, 33.4, 26.7, 22.6, 21.2, 
Minor: δ 176.6, 149.3, 136.8, 131.3, 129.4, 126.8, 125.8, 121.9, 118.7, 118.1, 107.8, 36.1, 
33.9, 26.5, 22.6, 21.3; FTIR (cm–1)(neat): 3001, 2922, 1701, 1614, 1517, 1378, 1215, 1158, 
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748, 585; HRMS (ESI, Pos) calcd for C18H17NNaO [M+Na]+: 286.1202 m/z, found 286.1200 
m/z.  
 
 
(1S,2R)-2-(4-methoxyphenyl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one and 
(1R,2R)-2-(4-methoxyphenyl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (2m) 
The title compound 2m was prepared by the general procedure on a 0.496 mmol scale and 
then purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a 
solvent gradient of 10% to 50% EtOAc : Hex to give an off-white in 92% yield (127 mg, 
0.456 mmol) as a mixture of major and minor diastereomers (10:1 dr). Diastereomeric ratios 
were determined via 1H NMR. mp: 76-74°C; Rf: 0.43, 0.37 (1:1 Hex : EtOAc); 1H NMR 
(CDCl3, 400 MHz): Major: δ 7.16 (td, 1H, J = 7.8, 1.1 Hz), 7.10 (d, 2H, J = 8.3 Hz), 6.88-
6.81 (m, 3H), 6.71 (td, 1H, J = 7.7, 0.6 Hz), 6.00 (dd, 1H, J = 7.5, 0.6 Hz), 3.79 (s, 3H), 3.32 
(s, 3H), 3.29-3.32 (m, 1H), 2.17 (dd, 1H, J = 9.2, 4.5 Hz), 1.95 (dd, 1H, J = 7.9, 4.5 Hz), 
Minor: δ 7.37-6.80 (m, 8H), 3.78 (s, 3H), 3.18 (s, 3H), 3.12-3.15 (m, 1H), 2.37 (dd, J = 8.6, 
4.8 Hz), 2.05 (dd, 1H, J = 8.6, 4.8 Hz); 13C NMR (CDCl3, 100 MHz): Major: δ 176.5, 158.8, 
143.8, 131.0, 127.7, 127.2, 126.5, 121.5, 120.8, 113.8, 107.8, 55.3, 35.3, 33.4, 26.6, 22.8, 
Minor: δ 174.0, 158.7, 143.4, 130.3, 128.3, 127.0, 126.7, 122.6, 121.9, 118.0, 113.4, 55.2, 
37.8, 33.9, 26.5, 22.7; FTIR (cm–1)(neat): 2933, 1704, 1613, 1515, 1494, 1346, 1249, 974, 
696; HRMS (ESI, Pos) calcd for C18H17NNaO2 [M+Na]+: 302.1152 m/z, found 302.1147 m/z.  
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(1S,2R)-2-(4-fluorophenyl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one and 
(1R,2R)-2-(4-fluorophenyl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (2n) 
The title compound 2n was prepared by the general procedure on a 0.498 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give a white solid in 99% yield (132 mg, 0.494 
mmol) as a mixture of major and minor diastereomers (8:1 dr). Diastereomeric ratios were 
determined via 1H NMR. The two diastereomers were also separable via flash chromatography 
(5 to 20% EtOAc : Hex) both yielding white solids. Major: mp: 69-70 °C; Rf: 0.46 (1:1 Hex : 
EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.19-7.13 (m, 3H), 7.01-6.96 (m, 2H), 6.89-6.87 (m, 
1H), 6.72 (td, 1H, J = 7.6, 1.0 Hz), 5.94 (d, 1H, J = 7.8 Hz), 3.33 (s, 3H), 3.29-3.32 (m, 1H), 
2.19 (dd, 1H, J = 9.2, 4.6 Hz), 1.93 (dd, 1H, J = 7.9, 4.3 Hz); 13C NMR (CDCl3, 100 MHz): δ 
176.3, 162.0 9 (d, J = 245 Hz), 143.9, 131.5 (d, J = 8.0 Hz), 130.6 (d, J = 3.2 Hz), 127.3, 
126.8, 121.6, 120.7, 115.3 (d, J = 22 Hz), 107.9, 34.9, 33.2, 26.7, 22.7; 19F NMR (CDCl3, 300 
MHz): δ -114.6 (m); FTIR (cm–1)(neat): 2938, 2844, 1696, 1612, 1510, 1379, 1245, 1090, 
1015, 841, 750; HRMS (ESI, Pos) calcd for C17H15FNO [M+H]+: 268.1132 m/z, found 
268.1128 m/z. Minor: mp: 111-114 °C; Rf: 0.37 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 
MHz): δ 7.31-7.27 (m, 3H), 7.08 (td, 1H, J = 7.5, 0.9 Hz), 7.01-6.96 (m, 3H), 6.90 (d, 1H, J = 
7.8 Hz), 3.19 (s, 3H), 3.12-3.15 (m, 1H), 2.36 (dd, 1H, J = 8.6, 5.0 Hz), 2.07 (dd, 1H, J = 9.1, 
5.0 Hz); 13C NMR (CDCl3, 75 MHz): δ 173.9, 162.0 (d, J = 245 Hz), 143.6, 130.9 (d, J = 8.1 
Hz), 130.7, 130.1 (d, J = 3.1 Hz), 127.0, 122.1, 118.2, 114.9 (d, J = 21.5 Hz), 108.0, 37.3, 
33.9, 26.6, 22.8; 19F NMR (CDCl3, 300 MHz): δ -115.2 (m); FTIR (cm–1) (neat): 2922, 1704, 
1615, 1512, 1469, 1315, 1252, 1230, 1196, 1131, 1102, 908, 730. HRMS (ESI, Pos) calcd for 
C17H15FNO [M+H]+: 268.1132 m/z, found 268.1130 m/z.  
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(1S,2R)-2-(4-chlorophenyl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one and 
(1R,2R)-2-(4-chlorophenyl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (2o) 
The title compound 2o was prepared by the general procedure on a 0.348 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give an orange solid in 95% yield (93.8 mg, 0.331 
mmol) as a mixture of major and minor diastereomers (5:1 dr). Diastereomeric ratios were 
determined via 1H NMR. The two diastereomers were also separable via flash chromatography 
(5 to 20% EtOAc : Hex). Major: orange solid; mp: 126-128 °C; Rf: 0.58 (1:1 Hex : EtOAc); 
1H NMR (CDCl3, 400 MHz): δ 7.28-7.25 (m, 2H), 7.19 (td, 1H, J = 7.7, 1.1 Hz), 7.12 (d, 2H, 
J = 8.7 Hz), 6.89 (d, 1H, J = 8.0 Hz), 6.75 (td, 1H, J = 7.7, 0.9 Hz) 5.98 (d, 1H, J = 7.5 Hz), 
3.34 (s, 3H), 3.27-3.31 (m, 1H), 2.19 (dd, 1H, J = 9.0, 4.5 Hz), 1.94 (dd, 1H, J = 7.9, 4.5 Hz); 
13C NMR (CDCl3, 100 MHz): δ 176.2, 143.9, 133.8, 133.2, 131.3, 128.6, 127.1, 126.4, 121.7, 
120.7, 108.0, 35.0, 33.2, 26.7, 22.4. FTIR (cm–1) (neat): 2927, 1686, 1610, 1491, 1465, 1292, 
1085, 1016, 785, 548. HRMS (ESI, Pos) calcd for C17H15ClNO [M+H]+: 284.0837 m/z, found 
284.0834 m/z. Minor: off-white solid; mp: 110-111 °C; 1H NMR (CDCl3, 400 MHz): δ 7.56 
(td, 1H, J = 7.8, 1.2 Hz), 7.27-7.24 (m, 4H), 7.08 (td, 1H, J = 7.5, 0.9 Hz), 6.97 (dd, 1H, J = 
7.5, 0.9 Hz), 6.90 (d, 1H, J = 7.8, 0.9), 3.19 (s, 3H), 3.10-3.14 (m, 1H), 2.35(dd, 1H, J = 8.6, 
5.0 Hz), 2.07 (dd, 1H, J = 8.8, 4.9 Hz). 13C NMR (CDCl3, 75 MHz): δ 173.8, 143.6, 133.1, 
133.0, 130.7, 130.6, 128.2, 127.1, 122.1, 118.2, 108.0, 37.3, 34.0, 26.6, 22.6.  FTIR (cm–1) 
(neat): 2923, 1697, 1614, 1492, 1469, 1345, 1315, 1195, 1109, 975, 746, 530. HRMS (ESI, 
Pos) calcd for C17H15ClNO [M+H]+: 284.0837 m/z, found 284.0837 m/z.  
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(1S,2R)-1'-methyl-2-(4-(trifluoromethyl)phenyl)spiro[cyclopropane-1,3'-indolin]-2'-one 
and (1R,2R)-1'-methyl-2-(4-(trifluoromethyl)phenyl)spiro[cyclopropane-1,3'-indolin]-2'-
one (2p) 
The title compound 2p was prepared by the general procedure on a 0.30 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give an orange solid in 85% yield (80.7 mg, 0.254 
mmol) as a mixture of major and minor diastereomers (5:1 dr). Diastereomeric ratios were 
determined via 1H NMR. The two diastereomers were also separable via flash chromatography 
(5 to 20% EtOAc : Hex). Rf: 0.58 (1:1 hexanes: ethyl acetate); Major: orange solid; mp: 123-
125 °C; 1H NMR (CDCl3, 400 MHz): δ 7.55 (d, 2H, J = 8.2 Hz), 7.31 (d, 2H, J = 8.2 Hz), 
7.18 (td, 1H, J = 7.7, 0.9 Hz), 6.89 (d, 1H, J = 7.9 Hz), 6.72 (td, 1H, J = 7.6, 0.9 Hz) 5.95 (d, 
1H, J = 7.3 Hz), 3.34 (s, 3H), 3.35-3.31 (m, 1H), 2.13 (dd, 1H, J = 9.1, 4.7 Hz), 2.00 (dd, 1H, 
J = 8.0, 4.7 Hz); 13C NMR (CDCl3, 100 MHz): δ 176.0, 143.9 139.4, 130.3, 130.0 (q, J = 32 
Hz), 128.2-120.0 (q, J = 272 Hz), 127.0, 126.8, 125.3 (q, J = 3.9 Hz), 121.7, 120.5, 108.0, 
35.1, 32.3, 26.7, 22.2; 19F NMR (CDCl3, 300 MHz): δ -62.4 (s). FTIR (cm–1) (neat): 2934, 
1695, 1615, 1496, 1322, 1160, 1112, 1066, 977, 852, 751; HRMS (ESI, Pos) calcd for 
C18H15F3NO [M+H]+: 318.1100 m/z, found 318.1097 m/z. Minor: off-white solid; mp: 138-
139 °C; 1H NMR (CDCl3, 400 MHz): δ 7.56 (d, 2H, J = 8.2 Hz), 7.44 (d, 2H, J = 8.2 Hz), 
7.31 (td, 1H, J = 7.6, 1.2 Hz), 7.10 (td, 1H, J = 7.5, 0.9 Hz), 6.99 (dd, 1H, J = 7.5, 0.9), 6.91 
(d, 1H, J = 7.8 Hz), 3.19 (s, 3H), 3.16-3.20 (m, 1H), 2.41(dd, 1H, J = 8.5, 5.0 Hz), 2.12 (dd, 
1H, J = 9.0, 5.0 Hz); 13C NMR (CDCl3, 75 MHz): δ 173.7, 143.7, 138.5, 130.4, 129.7, 129.5 
(q, J = 32 Hz), 124.4 (q, J = 272 Hz), 127.5, 125.0 (q, J = 3.8 Hz), 122.2, 118.3, 108.2, 37.3, 
34.2, 26.6, 22.6; 19F NMR (CDCl3, 300 MHz): δ -62.4 (s). FTIR (cm–1) (neat): 2930, 1699, 
1615, 1493, 1379, 12544, 1193, 1121, 1069, 744; HRMS (ESI, Pos) calcd for C18H15F3NO 
[M+H]+: 318.1100 m/z, found 318.1097 m/z. 
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(1S,2S)-2-(furan-2-yl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one (1S,2S)-2-(furan-
2-yl)-1'-methylspiro[cyclopropane-1,3'-indolin]-2'-one and (1R,2S)-2-(furan-2-yl)-1'-
methylspiro[cyclopropane-1,3'-indolin]-2'-one (2q) 
The title compound 2q was prepared by the general procedure on a 0.494 mmol scale and then 
purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent 
gradient of 10% to 50% EtOAc : Hex to give a yellow oil in 79% yield (92.2 mg, 0.388 mmol) 
as a mixture of major and minor diastereomers (9:1 dr). Diastereomeric ratios were determined 
via 1H NMR. Rf: 0.53, 0.31 (1:1 Hex : EtOAc);  Major: 1H NMR (CDCl3, 400 MHz): δ 7.32-
7.31 (m, 1H), 7.20 (t, 1H, J = 7.7 Hz), 6.87 (d, 1H, J = 7.7 Hz), 6.83 (t, 1H, J = 7.6 Hz), 6.48 
(d, 1H, J = 7.4 Hz), 3.31 (s, 3H), 3.11-3.14 (m, 1H), 2.18 (dd, 1H, J = 9.2, 4.5 Hz), 2.12 (dd, 
1H, J = 7.5, 4.5 Hz); 13C NMR (CDCl3, 100 MHz): δ 175.7, 150.4, 144.0, 142.2, 127.3, 127.1, 
122.0, 120.2, 110.7, 109.4, 108.1, 33.9, 28.7, 26.7, 21.3; FTIR (cm–1 )(neat): 2937, 1699, 
1613, 1494, 1421, 1375, 1342, 1329, 1128, 1011, 735, 547; HRMS (ESI, Pos) calcd for 
C15H14NO2 [M+H]+: 240.1019 m/z, found 240.1016 m/z.  
 
(1S,2S)-1'-methyl-2-(thiophen-2-yl)spiro[cyclopropane-1,3'-indolin]-2'-one and (1R,2S)-
1'-methyl-2-(thiophen-2-yl)spiro[cyclopropane-1,3'-indolin]-2'-one (2r) 
The title compound 2m was prepared by the general procedure on a 0.496 mmol scale and 
then purified via column chromatography over silica gel (RediSep® Rf Gold 24g) using a 
solvent gradient of 10% to 50% EtOAc : Hex to give a yellow oil in 92% yield (127 mg, 0.456 
mmol) as a mixture of major and minor diastereomers (10:1 dr). Diastereomeric ratios were 
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determined via 1H NMR. Rf: 0.56 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): Major: δ 
7.22-7.18 (m, 2H), 6.97-6.96 (m, 1H), 6.91-6.87 (m, 2H), 6.78 t(d, 1H, J = 7.6, 0.8 Hz), 6.24 
(d, 1H, J = 7.5 Hz), 3.32 (s, 3H), 3.28-3.32 (m, 1H), 2.25 (dd, 1H, J = 9.0, 4.5 Hz), 2.02 (dd, 
1H, J = 7.6, 4.5 Hz); Minor: δ 7.41-6.85 (m, 7H), 3.21 (s, 3H), 3.20-3.18 (m, 1H), 2.35 (dd, 
1H, J = 8.5, 5.0 Hz), 2.14 (dd, 1H, J = 8.9, 4.6 Hz); 13C NMR (CDCl3, 100 MHz): Major: δ 
175.9, 143.9, 139.1, 127.5, 127.0, 126.8, 125.4, 121.8, 120.4, 108.0, 34.2, 30.1, 28.6, 26.7, 
23.8, Minor: δ 176.1, 143.5, 137.9, 127.1, 126.9, 126.7, 125.9, 124.7, 122.0, 118.2, 34.3, 
32.7, 26.5, 24.0; FTIR (cm–1 )(neat): 2937, 1699, 1649, 1613, 1493, 1423, 1380, 1028, 749, 
696; HRMS (ESI, Pos): calcd for C15H14NOS [M+H]+: 256.0791 m/z, found 256.0787 m/z.  
 
 
(1S,2R)-1'-methyl-2-phenylspiro[cyclopropane-1,3'-indolin]-2'-one and (1R,2R)-1'-
methyl-2-phenylspiro[cyclopropane-1,3'-indolin]-2'-one (2sa and 2sb) 
The title compounds 2s and 2sb were prepared by the general procedure from trans-racemic 
1sa on a 0.5 mmol scale and then purified via column chromatography over silica gel 
(RediSep® Rf Gold 24g) using a solvent gradient of 10% to 50% EtOAc : Hex to give a 
yellow oil in 90% yield (112 mg, 0.449 mmol) as a mixture of major and minor diastereomers 
(6:1 dr). From cis-racemic 1sb on 0.4 mmol scale: 93% yield, (93 mg, 0.37 mmol) in 1:5 dr. 
Diastereomeric ratios were determined via 1H NMR. Rf: 0.51, 0.44 (1:1 Hex : EtOAc); 1H 
NMR (CDCl3, 400 MHz): Major: δ 7.33-7.26 (m, 4H), 7.21-7.14 (m, 3H), 6.99 (d, 1H, J = 
7.9 Hz), 6.70 (t, 1H, J = 7.5 Hz), 5.98 (d, 1H, J = 7.6 Hz), 3.34 (s, 3H), 3.38-3.34 (m, 1H), 
2.20 (dd, 1H, J = 9.1, 4.5 Hz), 2.0 (dd, 1H, J = 8.0, 4.4 Hz), Minor: δ 7.35-6.87 (m, 9H), 3.16 
(s, 3H), 3.18-3.15 (m, 1H), 2.41 (dd, J = 8.6, 4.9 Hz), 2.07 (dd, 1H, J = 8.9, 4.6 Hz); 13C NMR 
(CDCl3, 100 MHz): δ 176.5 (2), 143.9, 135.2, 134.4, 130.9, 130.0, 129.3, 128.7, 128.0, 127.6, 
127.4, 127.3, 126.9, 126.6, 125.8, 121.9, 121.5, 120.7, 118.1, 107.9, 107.8, 38.2, 35.9, 33.9, 
33.4, 26.7, 26.5, 22.6, 22.5; FTIR (cm–1)(neat): 3056, 3028, 1699, 1614, 1468, 1345, 1128, 
747, 696; HRMS (ESI, Pos): calcd for C17H16NO [M+H]+: 250.1226 m/z, found 250.1224 
m/z. 
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Mechanistic Studies 
 
Synthesis of d-labeled trans-rac-N-(2-bromophenyl)-N-methyl-2-
phenylcyclopropanecarboxamide  
 
 
 
Deuterated ethyl diazoacetate was synthesized according to the literature procedure15 and then 
used in the Rh-catalyzed cyclopropanation of styrene as described in the synthesis of 1sb 
 The trans product (410 mg, 2.15 mmol) was dissolved in 6 mL of THF and transferred to a 
25-mL round-bottom flask. To this was added NaOD (2.0 M, 3.2 mL, 6.45 mmol, 3.0 equiv) 
and the reaction was heated to 55ºC for 3 days. It was then acidifed with 10 mL of 2.0 M HCl 
and extracted with EtOAc (3x’s, 10 mL). The combined organics were dried over anhydrous 
Na2SO4, filtered and conc in vacuo to give a yellow solid in quantitative yield which was used 
crude in the amide synthesis by Route B. The deuterated trans-racemic product was obtained 
as a white solid in 70% yield (500 mg, 1.51 mmol) and confirmed by 1H NMR. 
 
 
 
                                                
15 Baldwin, J. E.; Carter, C. G. J. Am. Chem. Soc. 1982, 104, 1362. 
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Kinetic Isotope Effect Studies 
 
Two parallel reactions using trans-rac-N-(2-bromophenyl)-N-methyl-2-
phenylcyclopropanecarboxamide and d-labeled trans-rac-N-(2-bromophenyl)-N-methyl-2-
phenylcyclopropanecarboxamide were performed on a 0.5 mmol scale in accordance with the 
general procedure (Ref. S21).  A known amount of internal standard (1,3,6-
trimethoxybenzene) was added to each reaction and the formation of the major product was 
monitored over time using 1H NMR.  The product concentration for the major product was 
then plotted vs. time to determine the rate of reaction (kH and kD) for both reactions.  
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Entry [P] Deuterated [P] Non-deuterated 
Time 
(min) 
1 0.028 0.056 30 
2 0.033 0.0714 45 
3 0.039 0.11 60 
4 0.053 0.1792 90 
5 0.07 0.21 120 
 
 
Linear equation for d-labeled substrate: y = 4.6897E-04x + 1.2241E-02 
 
Linear equation for normal substrate (1sa): y = 1.8363E-03x - 1.3862E-03 
 
kH/kD = 3.9 
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Epimerization Studies 
 
Preparation of enantioenriched 1sa 
 
 
Preparation of enantioenriched 1sb 
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Enantioenriched samples of both trans- and cis- N-(2-bromophenyl)-N-methyl-2-
phenylcyclopropanecarboxamide were synthesized as shown above, starting from either trans- 
or cis- cinnamyl alcohol via an asymmetric Simmons-Smith cyclopropanation according to the 
literature procedure.16 The enantioenriched trans- or cis- cyclopropanes were then oxidized to 
the corresponding carboxylic acid17 and then converted to their amide analogues via route B.  
The enantiomeric excess for both substrates were determined by SFC analysis on a chiral 
stationary phase. Enantioenriched 1sb could not be separated by SFC; % ee was determined 
using the cis-carboxylic acid. For 1sa: (Ad-H 25 cm, 5% MeOH, 5mL/min, 35ºC, 150 bar, 254 
nm, tr (major) 4.3 min, tr (minor) 6.6 min). SFC trace:  
 
 
 
 
                                                
16  Charette, A.B.; Lebel, H. Org. Synth. 1999, 76, 86. 
17 Charette, A. B.; Cote, B. J. Am. Chem. Soc. 1995, 117, 1272.	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For 1sb: (Ad-H 25 cm, 5% MeOH, 5mL/min, 35ºC, 150 bar, 254 nm, tr (major) 5.49 min, tr 
(minor) 3.98 min). SFC trace: 
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Two sets of reactions were set up and carried out in parallel using general procedure C on a 
0.4 mmol scale. Samples were taken out of the reactions after 3 hours and analyzed by 1H 
NMR and SFC. The results are tabulated below. 
 
 
 
Diastereomeric ratio was determined by 1HNMR analysis of the crude mixture. Enantiomeric 
excess was determined by SFC analysis on chiral stationary phase. 
 For 2sa:(Ad-H 25 cm, 5% MeOH, 5mL/min, 35ºC, 150 bar, 254 nm, tr (major) 14.6, 11.3 
min, tr (minor) 7.32, 8.22, 9.23 min), SFC traces: 
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For 2sb:(Ad-H 25 cm, 5% MeOH, 5mL/min, 35ºC, 150 bar, 254 nm, tr (major) 11.2, 15.2 min, 
tr (minor) 7.36, 8.24 min), SFC traces: 
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Racemic SFC trace for 2sa+2sb: 
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X-ray Data for Compounds 
 
For 2o major: 
 
      Table 1.  Crystal data and structure refinement for C17 H14 Cl N O.  
    
      Identification code               cha217  
   
      Empirical formula                 C17 H14 Cl N O  
   
      Formula weight                    283.74  
   
      Temperature                       150K  
   
      Wavelength                        1.54178 Å  
   
      Crystal system                    Orthorhombic  
   
      Space group                       Pna21  
   
      Unit cell dimensions              a = 12.5875(8) Å    α = 90°  
                                        b = 17.8684(12) Å    β = 90°  
                                        c = 6.0173(4) Å    γ = 90°  
   
      Volume                            1353.40(15)Å3  
   
      Z                                 4  
   
      Density (calculated)              1.393  g/cm3  
   
      Absorption coefficient            2.440 mm-1  
   
      F(000)                            592  
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      Crystal size                      0.25 x 0.15 x 0.15 mm  
   
      Theta range for data collection   4.30 to 69.70°  
   
      Index ranges                      -15 ≤ h ≤ 15, -21 ≤ k ≤ 21, -5 ≤ ℓ ≤ 7  
   
      Reflections collected             39869  
   
      Independent reflections           1968 [Rint = 0.039]  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.6935 and 0.5640  
   
      Refinement method                 Full-matrix least-squares on F2  
   
      Data / restraints / parameters    1968 / 1 / 183  
   
      Goodness-of-fit on F2             1.080  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0299, wR2 = 0.0791  
   
      R indices (all data)              R1 = 0.0299, wR2 = 0.0791  
   
      Absolute structure parameter      0.127(18)  
   
      Largest diff. peak and hole       0.254 and -0.251 e/Å3  
 
For 2p minor: 
 
  Table 1.  Crystal data and structure refinement for C18 H14 F3 N O.  
   
   
      Identification code               cha227  
   
      Empirical formula                 C18 H14 F3 N O  
   
      Formula weight                    317.30  
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      Temperature                       100K  
   
      Wavelength                        1.54178 Å  
   
      Crystal system                    Monoclinic  
   
      Space group                       P21/n  
   
      Unit cell dimensions              a = 15.2477(7) Å    α = 90°  
                                        b = 5.8321(3) Å    β = 90.669(3)°  
                                        c = 16.7963(9) Å    γ = 90°  
   
      Volume                            1493.53(13)Å3  
   
      Z                                 4  
   
      Density (calculated)              1.411  g/cm3  
   
      Absorption coefficient            0.964 mm-1  
   
      F(000)                            656  
   
      Crystal size                      0.22 x 0.04 x 0.02 mm  
   
      Theta range for data collection   3.89 to 70.51°  
   
      Index ranges                      -18 ≤ h ≤ 18, -6 ≤ k ≤ 7, -20 ≤ ℓ ≤ 20  
   
      Reflections collected             18994  
   
      Independent reflections           2813 [Rint = 0.042]  
   
      Absorption correction             Semi-empirical from equivalents  
   
      Max. and min. transmission        0.9809 and 0.7716  
   
      Refinement method                 Full-matrix least-squares on F2  
   
      Data / restraints / parameters    2813 / 84 / 219  
   
      Goodness-of-fit on F2             1.112  
   
      Final R indices [I>2sigma(I)]     R1 = 0.0453, wR2 = 0.1269  
   
      R indices (all data)              R1 = 0.0515, wR2 = 0.1323  
   
      Largest diff. peak and hole       0.358 and -0.253 e/Å3  
   
 
 
 
XLV 
 
Experimental Section for Chapter 3 
Synthesis of Starting Materials 
Starting materials not listed below were obtained commercially and the reagents were used 
without further purification.  
Synthesis of 2-bromobenzoic acids 
2-Bromo-3,4,5-trimethoxybenzoic acid 18 (used in the synthesis of 1i) and 2-bromo-3,5-
dimethylbenzoic acid19 (used in the synthesis of 1d) were synthesized according to literature 
procedures. 
 
General Synthesis of 2-halobenzamides (1a-1k) (example for 1a shown below) 
 
 
 
To a 100-mL round-bottom flask, flame-dried and cooled under argon containing 40 
mL THF was added 2-bromobenzoic acid (1.98 g, 8.25 mmol), followed by 2-3 drops of 
DMF.  Oxalyl chloride (1.02 mL, 11.8 mmol) was then slowly added over 15 minutes, causing 
bubbling and the formation of a bright yellow solution.  The reaction was stirred for 30 min. 
To this was added cyclopropylamine (0.8 mL, 11.8 mmol). After 10 min, triethylamine (3.40 
mL, 24.6 mmol) was added slowly, forming a faint yellow precipitate. The reaction was stirred 
overnight (16 hours) at ambient temperature. It was then quenched with 10% HCl (50 mL), 
dissolving the white precipitate, and then transferred to a 250-mL separatory funnel. The 
                                                
18 Meyers, A.;  Flisak, J. ;Aitken, R.  J. Am. Chem. Soc. 1987, 109, 5446-5452.  
19 Moorthy, J.; Samanta, S. J. Org. Chem. 2007,72, 9786-9789.	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layers were separated, and the aqueous layer was extracted with dichloromethane (3x's, 50 mL 
each). The combined organics were then washed with brine (50 mL), dried over anhydrous 
sodium sulfate, filtered and concentrated in vacuo to give the desired product as an off-white 
solid. It was used crude in the subsequent methylation step. 
This intermediate was dissolved in 50 mL THF, cooled to 0°C, and sodium hydride 
was added (0.495 g, 12.4 mmol) forming a grey solution. After 15 minutes, iodomethane was 
added dropwise (3.60 mL, 58.0 mmol). The reaction was then warmed to ambient temperature 
and stirred overnight (16 hours). It was then quenched with water (50 mL), ethyl acetate was 
added (50 mL), and transferred to a 250-mL separatory funnel. The layers were separated, and 
the aqueous layer was extracted with ethyl acetate (3x’s, 50 mL). The combined organics were 
washed with brine (50 mL), dried over anhydrous sodium sulfate, filtered and concentrated in 
vacuo to give the desired product as a brown oil. The crude was then purified via column 
chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent gradient of 10% to 
50% EtOAc : Hex. The desired product was isolated as a yellow oil (2.09 g, 8.25 mmol, 100% 
yield). 
 
 
 
2-Bromo-N-cyclopropyl-N-methylbenzamide (1a) 
 
 Rf: 0.31 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.49-7.44 (m, 1H), 7.29-7.23 (m, 
1H), 7.18-7.11 (m, 2H), 3.05 (s, 2.38H), 2.85-2.73 (m, 0.24H), 2.69 (s, 0.63H), 2.67-2.59 (m, 
0.80H), 0.84-0.74 (m, 0.86H), 0.41-0.39 (m, 2.93H); 13C NMR (CDCl3, 75MHz): δ 171.1, 
170.6, 139.9, 138.9, 132.63, 132.50, 130.1, 129.8, 127.85, 127.71, 127.61, 127.2, 118.98, 
118.92, 36.3, 34.0, 31.9, 29.9, 9.3 (br), 7.68 (br), 6.7 (br); FTIR (cm-1) (neat): 3012, 1637, 
1455, 1362, 1076, 766; HRMS (APPI, Pos): calc. for C11H13BrNO (M+H)+ : 254.0182, found: 
254.0175  m/z 
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2-Iodo-N-cyclopropyl-N-methylbenzamide (1a’) 
 
The title compound 1a’ was prepared by the general synthesis on a 12.4 mmol scale and then 
purified via column chromatography (20:1 Hex : EtOAc) to give a light brown oil in 85% 
yield (3.17 g, 10.5 mmol) over two steps: Rf: 0.53 (1:1 EtOAc : Hex); 1H NMR (CDCl3, 400 
MHz): δ 7.80-7.76 (m, 1H), 7.37-7.32 (m, 1H), 7.19-7.16 (m, 1H), 7.06-7.00 (m, 1H), 3.10 (s, 
2.32H), 2.87-2.84 (m, 0.26H), 2.74 (s, 0.76H), 2.69-2.66 (m, 0.79H), 0.87-0.84 (br m, 1.02H), 
0.53-0.45 (br m, 3.12H); 13C NMR (CDCl3, 75MHz): δ 171.6, 171.2, 143.2, 142.2, 138.24, 
138.12, 129.5, 129.1, 127.8, 127.2, 126.75, 126.58, 126.3, 92.0, 91.7, 77.6, 77.2, 76.7, 36.0, 
33.5, 31.6, 29.3, 8.2 (br), 6.0 (br); FTIR (cm-1) (neat): 3050, 1634, 1381, 1210, 930 ; HRMS 
(APPI, Pos): calc. for C11H13INO (M+H)+ : 302.0042 , found: 302.0036  m/z. 
 
 
 
2-Bromo-N-cyclopropyl-N,4-dimethylbenzamide (1b) 
 
The title compound 1b was prepared by the general synthesis on a 2.3 mmol scale and then 
purified via column chromatography (20:1 Hex : EtOAc) to give a canary yellow solid in 79% 
yield (0.49 g, 1.82 mmol) over two steps: mp: 53°C; Rf: 0.35 (1:1 Hex : EtOAc); 1H NMR 
(CDCl3, 400 MHz): δ 7.40 (dd, J = 8.0, 5.1 Hz, 1H), 7.05-7.00 (m, 2H), 3.10 (s, 2.17H), 2.90-
2.86 (m, 0.29H), 2.77 (s, 0.75H), 2.74-2.69 (m, 0.72H), 2.28 (s,3H), 0.91-0.80 (br m, 1.03H), 
0.49-0.47 (m, 2.9H); 13C NMR (CDCl3, 75 MHz ) δ 171.3, 170.8, 139.7, 138.7, 137.8, 137.2, 
132.3, 131.0, 128.2, 115.58, 115.48, 36.3, 32.0, 29.8, 20.8, 9.5 (br), 7.5 (br), 6.8 (br); FTIR 
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(cm-1) (neat): 3002, 1635, 1508, 1020, 815, 630, 591; HRMS (APPI, Pos): calc. for 
C12H15BrNO  (M+H)+ : 268.0334 , found: 268.0332 m/z.  
 
 
 
2-Bromo-N-cyclopropyl-N,5-dimethylbenzamide (1c) 
 
The title compound (1c) was prepared by the general synthesis on a 10.0 mmol scale and then 
purified via column chromatography (20:1 Hex : EtOAc) to give a light brown oil in 21% 
yield (0.55 g, 2.05 mmol) over two steps: Rf: 0.34 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 
MHz): δ 7.38 (m, 1H), 7.13 (m, 2H), 3.10 (s, 2.33H), 2.89-2.87 (m, 0.29H), 2.77 (s, 0.68H), 
2.72-2.69 (m, 0.79H), 2.34 (s, 3H), 0.90-0.81 (br m, 1 H), 0.50-0.47 (br m, 2.96 H); 13C NMR 
(CDCl3, 75 MHz )  δ 170.9, 170.5, 140.1, 139.7, 136.7, 135.7, 132.60, 132.49, 128.2, 127.6, 
127.3, 127.1, 118.43, 118.36,  36.0, 33.7, 31.6, 29.6, 20.6, 8.2 (br), 6.3 (br), 5.90(br); FTIR 
(cm-1) (neat): 2922, 1640, 1380, 1287, 1028, 821,576; HRMS (APPI, Pos): calc. for 
C12H15BrNO (M+H)+: 268.0340 , found: 268.0332 m/z. 
 
 
 
2-Bromo-N-cyclopropyl-N, 3,5-trimethylbenzamide (1d) 
 
The title compound 1d was prepared by the general synthesis on a 8.1 mmol scale and then 
purified via column chromatography (20:1 Hex : EtOAc) to give a yellow oil in 83% yield 
(1.89 g, 6.69 mmol) over two steps: Rf: 0.21  (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 
MHz): 7.07-6.85 (m, 2H), 3.08 (s, 1.14H), 3.04 (s, 0.70H), 2.91-2.83 (m, 0.26H), 2.74 (s, 
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0.53H), 2.73-2.64 (m, 0.46H), 2.37-2.26 (m, 6H), 0.88-0.81 (m, 1.26H), 0.65-0.55 (br m, 
1.31H), 0.54-0.39 (br m, 2.21H).13C NMR (CDCl3, 75 MHz) δ 172.1, 171.5, 140.4, 139.4, 
138.6, 138.3, 137.1, 131.8, 131.6, 131.2, 126.0, 125.6, 125.1, 118.1, 36.4, 34.1, 32.1, 30.0, 
23.2, 23.2, 21.4, 20.9, 9.7 (br), 7.4 (br), 6.7(br); FTIR (cm-1) (neat): 3275, 2921, 1672, 1602, 
1417, 1113, 963, 835, 637; HRMS (APPI, Pos): calc. for C13H17 BrNO (M+H)+ : 282.0481 , 
found: 282.0488 m/z.  
 
 
2-Bromo-N-cyclopropyl-4-fluoro-N-methylbenzamide (1e) 
 
The title compound 1e was prepared by the general synthesis on a 10.0 mmol scale and then 
purified via column chromatography (20:1 Hex : EtOAc) to give a cream-colored solid in 87% 
yield (2.36 g, 8. 66 mmol ) over two steps: mp: 54°C; Rf: 0.31 (1:1 Hex : EtOAc); 1H NMR 
(CDCl3, 400 MHz): δ  7.32-7.28 (m, 1H), 7.26-7.20 (m, 1H), 7.05 (td, J = 8.0, 3.0 Hz, 1H), 
3.09 (s, 2.44H), 2.85 (dt, J=12.0, 6.0 Hz, 0.21 H), 2.76 (s, 0.64H), 2.68 (dt, J = 11.5, 5.5 Hz, 
0.82H), 0.90-0.79 (br m, 0.88H), 0.51-0.48 (br m, 3.12H); 13C NMR (CDCl3, 75MHz): δ 
170.1, 169.6, 161.9 (d, J=252.0 Hz), 161.7 (d, J=252.0 Hz), 136.1 (d, J= 4.0 Hz) 135.1 (d, 
J=4.0 Hz), 129.0 (d, J=9.0 Hz), 128.8, 119.8(d, J=25.0 Hz), 119.6 (d, J=25.0 Hz), 119.3 (d, 
J=9.0 Hz), 119.3 (d, J=9.0 Hz), 115.0 (d, J=22.0 Hz), 114.4 (d, J=22.0 Hz), 36.1, 33.9, 31.7, 
29.7, 8.5(br), 6.5(br);  19F NMR (CDCl3, 282 MHz): δ -109.9 (m), -110.4 (m); TIR (cm-1) 
(neat): 3016, 1637, 1418, 931, 826 ; HRMS (APPI, Pos): calc. for C11H12BrFNO (M+H)+ : 
272.0087 , found: 272.0081  m/z.  
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2-Bromo-N-cyclopropyl-5-fluoro-N-methylbenzamide (1f) 
 
The title compound 1f was prepared by the general synthesis on a 2.0 mmol scale and then 
purified via column chromatography (20:1 Hex : EtOAc) to give a light pink solid in 32% 
yield (0.17 g, 0.63 mmol) over two steps: mp: 52°C; Rf: 0. 35  (1:1 Hex : EtOAc); 1H NMR 
(CDCl3, 400 MHz): δ 7.51-7.48 (m, 1H), 6.98-6.93 (m, 2H), 3.10 (m, 2.35 H), 2.87-2.85 (m, 
0.24H), 2.77 (s, 0.59H), 2.72-2.67 (m, 0.79H), 0.90-0.80 (br m, 0.90H), 0.64-0.45 (br m, 
3.21H); 13C NMR (CDCl3, 75 MHz): 170.0, 162.1 (d, J=249.0 Hz), 161.8 (d, J=249.0 Hz), 
141.7 (d, J=7.0 Hz), 140.6 (d, J= 7.0 Hz), 134.5 (d, J=8.0 Hz), 134.3 (d, J= 8.0 Hz), 117.6 (d, 
J= 23.0 Hz), 117.4 (d, J=23.0 Hz), 115.4 (d, J= 24.0 Hz), 115.3 (d, J= 24.0 Hz), 113.6, 36.4, 
34.3, 32.0, 30.14, 30.14, 6.94 (br); 19F NMR (CDCl3, 282 MHz): δ -113.4 (ddd, J=8.0, 5.0, 
5.0Hz),-114.2 (ddd, J=8.0, 5.0, 5.0 Hz) ; FTIR (cm-1) (neat): 2923, 1638, 1433, 1361, 1026, 
893, 815, 588; HRMS (APPI, Pos): calc. for C11H12BrFNO (M+H)+ : 272.0087, found: 
272.0081  m/z.  
 
 
 
2-Bromo-N-cyclopropyl-4,5-difluoro-N-methylbenzamide (1g) 
 
The title compound 1g was prepared by the general synthesis on a 7.8 mmol scale and then 
purified via column chromatography (20:1 Hex : EtOAc) to give a light orange solid in 68% 
yield (1.55 g, 5.34 mmol) over two steps.: mp: 61°C ;Rf:  0.37 (1:1 Hex : EtOAc); 1H NMR 
(CDCl3, 400 MHz): δ  7.43-7.38 (m, 1H), 7.13-7.07 (m, 1H), 3.08 (s, 2.42 H), 2.86-2.85 (m, 
0.29H), 2.79 (s, 0.66H), 2.72-2.68 (m, 0.82H), 0.93-0.77 (br m, 0.90H), 0.55-0.50 (m, 2.91H);  
N
O
Br
F
N
O
BrF
F
LI 
 
13C NMR (CDCl3, 75 MHz ) δ 150.2 (dd, J=255.0 Hz, 14.0 Hz), 149.7 (dd, J= 252.0 Hz, 13.0 
Hz), 136.8 (t, J=5.0Hz),122.1 (dd, J= 20.0 Hz), 117.0 (dd, J=20.0 Hz),  113.3 (dd, J=4.0, 7.0 
Hz) , 36.5, 34.4, 32.0, 30.2, 9.0 (br); 19F NMR (282 MHz, CDCl3): -133.5 (m), -134.0 (m), -
136.8 (m), -137.6 (m); FTIR (cm-1) (neat): 2924, 1638, 1430, 1293, 887, 797,594; HRMS 
(APPI, Pos): calc. for C11H11BrF2NO  (M+H)+ : 289.9990 , found: 289.9987 m/z.  
 
 
2-Bromo-N-cyclopropyl-4-methoxy-N-methylbenzamide (1h) 
 
The title compound 1h was prepared by the general synthesis on a 12.5 mmol scale and then 
purified via column chromatography (20:1 Hex : EtOAc) to give a golden oil in 90% yield 
(3.20 g, 11.3 mmol) over two steps:  Rf: 0.36 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 
MHz): δ 7.45-7.40 (m, 1H), 6.79-6.76 (m, 2H), 3.80 (s, 3.83H), 3.11 (s, 3H), 2.91-2.86 (m, 
0.51H), 2.80 (s, 1.22H), 2.76-2.73 (m, 1.11H), 0.96-0.81 (m, 3.58H), 0.53-0.50 (m, 2.88H); 
13C NMR (CDCl3, 75 MHz) 170.6, 170.2, 158.9, 158.5, 140.4, 139.4, 133.25, 133.08, 116.2, 
115.7, 113.1, 112.6, 109.1, 108.9, 55.4, 36.0, 33.8, 31.7, 29.7, 9.1(br), 7.6(br), 6.5 (br); FTIR 
(cm-1) (neat): 3009, 1638, 1462, 1304, 12355, 1014, 815, 597; HRMS (APPI, Pos): calc. for 
C12H15BrNO2  (M+H)+ : 284.0287 , found: 284.0281  m/z.  
 
 
 
 
2-Bromo-N-cyclopropyl-3,4,5-trimethoxy-N-methylbenzamide (1i) 
 
N
O
BrMeO
N
O
Br
MeO
MeO
OMe
LII 
 
The title compound 1i was prepared by the general synthesis on a 10.0 mmol scale and then 
purified via column chromatography (20:1 Hex : EtOAc) to give a light pink solid in 50% 
yield (1.70 g, 4.95 mmol) over two steps: mp: 52°C; Rf: 0.28 (1:1 Hex : EtOAc); 1H NMR 
(CDCl3, 400 MHz): δ 6.58 (s, 1H), 3.86-3.82 (m, 6 H), 3.82-3.81 (m, 3H), 3.07 (s, 2.17H), 
2.89-2.82 (m, 3.29H), 2.76 (s, 0.82H), 2.73-2.68 (m, 0.72H), 0.90-0.75 (m, 1.24H), 0.63-0.56 
(m, 0.72H), 0.56-0.48 (m, 2.31H); 13C NMR (CDCl3, 75 MHz ) δ 171.0, 170.5, 153.6, 153.2, 
151.17, 151.06, 143.48, 143.34, 135.5, 134.5, 106.9, 106.4, 105.9,  61.3, 61.3, 56.4, 56.4 36.4, 
34.2, 32.0, 30.1,  7.2 (br), 6.5 (br); FTIR (cm-1) (neat): 3263, 3006, 1643, 1421, 1193, 1053, 
752, 532 ; HRMS (APPI, Pos): calc. for C14H19BrNO4   (M+H)+ : 344.0503 ,found: 344.0492  
m/z.  
 
 
 
N-Benzyl-2-bromo-N-cyclopropylbenzamide (1j) 
Following the general procedure, the intermediate 2-bromo-N-cyclopropylbenzamide was 
benyzlated as follows: 
To a 50-mL round-bottom flask was added the intermediate (0.50 g, 2.08 mmol) dissolved in 
DMF (10 mL). Cs2CO3 (1.35 g, 4.16 mmol, 2.0 equiv) was then added, followed by 
tetrabutylammonium iodide (TBAI) (77.0 mg, 0.02 mmol, 0.1 equiv). After stirring for 10 
min, benzyl bromide (0.27 mL, 2.29 mmol, 2.0 equiv) was added to the cloudy cream-colored 
solution. The reaction was stirred for 16 hours at ambient temperature. 
 The reaction was then quenched with 25 mL water and transferred to a 125-mL 
separatory funnel. The aqueous layer was then extracted with ethyl acetate (3x's, 25mL each). 
The combined organics were then washed with 5% LiCl solution to remove any trace DMF 
(25mL) and with brine (25mL). The organics were then dried over anhydrous sodium sulfate, 
filtered and concentrated in vacuo to give a brown oil. The crude product was then purified via 
column chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent gradient of 
5% to 50% EtOAc : Hex. The desired product 1j was isolated as a yellow oil (0.44 g, 1.49 
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mmol, 72% yield): Rf: 0.82 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz); δ  7.47-7.06 (m, 
9H), 4.73-4.61 (br m, 1.16 H), 4.63(s, 0.97 H), 4.21 (d, J = 9.5 Hz, 0.30 H), 3.18 (br m, 0.43 
H) 2.62-2.54 (m, 0.14 H), 2.48-2.40 (m, 0.0.62 H ), 0.90-0.30 (m, 3.22 H); 13C NMR (CDCl3, 
75 MHz ) δ 171.36, 171.17, 141.1, 139.8, 138.4, 137.6, 136.9, 132.87, 132.84, 132.80, 130.5, 
130.0, 128.75, 128.65, 128.62, 128.58, 128.00, 127.80, 127.67, 127.62, 127.48, 127.35, 
127.25, 127.06, 119.5, 119.2, 65.4, 53.2, 50.2, 30.7, 28.6, 9.8 (br), 8.7 (br), 7.0 (br) ;FTIR 
(cm-1) (neat): 3435, 2923, 1639, 1454, 1046, 768, 697, 505 ; HRMS (APPI, Pos): calc. for 
C17H17BrNO (M+H)+ : 330.0493 , found: 330.0488  m/z 
 
 
2-Chloro-N-cyclopropyl-N-methylbenzamide (1k)  
 
The title compound 1k was prepared by the general synthesis on a 12 mmol scale and then 
purified via column chromatography (20:1 Hex : EtOAc) to give a yellow oil in 91% yield 
(2.06 g, 9.82 mmol) over two steps: Rf: 0.58 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz):  
δ 7.35-7.22 (m, 4H), 3.07 (s, 2.35 H), 2.8-2.83 (m, 0.20 H), 2.73 (s, 0.58 H), 2.70-2.63 (m, 
0.79H), 0.81-0.75 (br m, 0.85H), 0.44-0.42 (br m, 3.17H); 13C NMR (CDCl3, 75MHz):δ 
169.3, 168.9, 137.1, 136.1, 129.3, 129.09, 128.98, 128.63, 128.50, 127.04, 126.86, 126.5, 
126.0, 35.2, 33.1, 30.9, 29.0, 7.6 (br), 5.9 (br) ; FTIR (cm-1) (neat): 3060, 1637, 1482, 1433, 
1319, 859 ; HRMS (APPI, Pos): calc. for C11H13ClNO (M+H)+ : 210.0688, found: 210.0680 
m/z.  
 
 
General Procedure for the Synthesis of Benzo[c]azepin-1-ones (2a-3j) 
N
O
Cl
N
O
Br
Pd(OAc)2 (5 mol %)
PtBu3•BF4 (5 mol %)
Ag3PO4 (0.33 equiv)
K2CO3 (1.1 equiv)
toluene, 125°C, 16 h
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To a 5.0-mL microwave vial in a glovebox was added in the following order: Pd(OAc)2 (5.6 
mg, 0.025 mmol), PtBu3•HBF4 (7.2 mg, 0.025 mmol), K2CO3 (76.0 mg, 0.55 mmol) and 
Ag3PO4 (0.16 mmol, 69.1 mg). The vial was crimped shut. The benzamide (1a-1j) (0.50 
mmol) was weighed into a vial, dissolved in 0.5 mL of toluene and added to the reaction vial. 
The vial containing benzamide was rinsed with 4x’s 0.5 mL of toluene for a total volume of 
2.5 mL. This yellowish-orange solution was then heated to 125°C in an oil bath for 16 h. The 
reaction turned black within five minutes. The reaction was cooled to ambient temperature, 
filtered over a cotton-Celite® plug, and rinsed with 25 mL of ethyl acetate. It was then 
concentrated in vacuo to give the crude product. The crude was then purified via column 
chromatography over silica gel (RediSep® Rf Gold 24g) using a solvent gradient of 10% to 
50% EtOAc : Hex to give isomers 2a-2j and 3a-3j. 
 
 
 
2-Methyl-2,5-dihydro-1H-benzo[c]azepin-1-one (2a) and  
2-Methyl-2,3-dihydro-1H-benzo[c]azepin-1-one (3a) 
 
The title compounds 2a and 3a were prepared by the general procedure to give an orange oil 
in 66% yield (58 mg, 0.34 mmol) and an orange oil in 26% yield (23 mg, 0.13 mmol): 2a: Rf: 
0.55 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.87-7.84 (m, 1H), 7.37 (td, J = 7.4, 
1.4 Hz, 1H), 7.30-7.25 (m, 2H), 7.06 (d, J = 7.6 Hz, 1H), 5.96 (d, J = 7.5 Hz, 1H), 5.62 (q, J = 
7.3 Hz, 1H), 3.28 (s, 3H), 3.21 (d, J = 7.2 Hz, 2H); 13C NMR (CDCl3, 75MHz): δ 169.5, 
143.4, 134.0, 131.6, 131.3, 130.7, 126.6, 126.2, 117.8, 36.4, 31.4; FTIR (cm-1) (neat): 2924, 
1656, 1364, 1285, 735, 609; HRMS (APPI, Pos): calc. for C11H12 NO  (M+H)+ :  174.0914 , 
found:  174.0913  m/z. 3a: 1H NMR (CDCl3, 400 MHz): δ 8.03-8.01 (m, 1H), 7.46-7.36 (m, 
2H), 7.22-7.20 (m, 1H), 6.81 (d, J = 9.9 Hz, 1H), 6.41-6.35 (m, 1H), 3.62 (d, J = 6.8 Hz, 2H), 
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3.22 (s, 3H); 13C NMR (CDCl3, 75MHz): δ 168.8, 135.6, 134.7, 131.2, 130.3, 129.8, 128.5, 
127.8, 106.2, 46.3, 36.5; FTIR (cm-1) (neat): 2923, 1688, 1428, 756, 708, 595; HRMS (APPI, 
Pos): calc. for C11H12 NO (M+H)+: 174.0913, found: 174.0913   m/z. 
 
 
 
2-Methyl-1a,2-dihydro-1H-cyclopropa[c]isoquinolin-3(7bH)-one (4a) 
 
The title compound 4a was prepared by the general procedure using PCy3 instead of 
PtBu3•HBF4 as a ligand at 135oC to give an orange oil in 39% yield (34 mg, 0.20 mmol): Rf: 
0.42 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz):  δ  8.15 (d, J = 7.6 Hz, 1H), 7.44-7.36 
(m, 2H), 7.31-7.27 (m, 1H), 3.25 (s, 3H), 3.14 (ddd, J = 8.2, 6.5, 3.9 Hz, 1H), 2.30 (ddd, J = 
9.6, 8.3, 5.8 Hz, 1H), 1.34 (ddd, J = 9.8, 6.4, 5.2 Hz, 1H), 0.28-0.24 (m, 1H); 13C NMR 
(CDCl3, 75MHz): δ 161.5, 139.2, 131.8, 129.0, 128.2, 126.6, 125.5, 36.3, 34.9, 15.0, 13.7; 
FTIR (cm-1) (neat): 2928, 1621, 1333, 903, 724, 649; HRMS (APPI, Pos): calc. for  C11H12 
NO  (M+H)+ :  174.0914 , found: 174.0913   m/z.  
 
 
 
2'-Methylspiro[cyclopropane-1,1'-isoindolin]-3'-one (5a) 
 
The title compound 5a was prepared by the general procedure using PCy3 instead of 
PtBu3•HBF4 as a ligand at 135oC to give an orange oil in 15% yield (13 mg, 0.075 mmol): Rf: 
0.11 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz):  δ 7.88 (d, J = 7.6 Hz, 1H), 7.52-7.48 
(m, 1H), 7.42 (td, J = 7.4, 0.7 Hz, 1H), 7.05 (d, J = 7.6 Hz, 1H), 2.87 (s, 3H), 1.59-1.56 (m, 
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2H), 1.36-1.33 (m, 2H); 13C NMR (CDCl3, 75MHz): δ 168.1, 147.2, 131.8, 131.4, 127.4, 
123.6, 117.7, 45.1, 24.0, 10.3; FTIR (cm-1) (neat): 3502, 2926, 1722, 1591, 1472, 765, 690; 
HRMS (APPI, Pos): calc. for C11H12 NO (M+H)+ : 174.0914  , found:  174.0913  m/z.  
 
 
 
2,7-Dimethyl-2,5-dihydro-1H-benzo[c]azepin-1-one (2b) and 2,7-Dimethyl-2,3-dihydro-
1H-benzo[c]azepin-1-one (3b) 
 
The title compounds 2b and 3b were prepared by the general procedure to give a yellow oil in 
71% yield (65 mg, 0.35 mmol) and a yellow oil in 27% yield (25 mg, 0.13 mmol): Rf: 0.55  
(1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.68 (s, 1H), 7.17 (d, J = 8.0 Hz, 1H), 6.95 
(dd, J = 7.7, 2.7 Hz, 1H), 5.94 (dd, J = 8.0, 3.0 Hz, 1H), 5.62 (qd, J = 7.0, 3.0 Hz, 1H), 3.27 (s, 
3H), 3.17 (dd, J = 7.0, 3.0 Hz, 2H), 2.33 (s, 3H); 13C NMR (CDCl3, 75 MHz):  δ 169.7, 140.6, 
136.3, 133.7, 132.4, 131.6, 130.5, 126.1, 118.1, 36.5, 30.9, 21.0; FTIR (cm-1) (neat): 3325, 
2952, 1626, 1602, 1405, 1098, 752, 681; HRMS (APPI, Pos): calc. for C12H14NO (M+H)+: 
188.1079, found: 188.1070 m/z. 3b: Rf: 0.26 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 
MHz): δ 7.82 (s, 1H), 7.23 (s, 1H), 7.11-7.09 (m, 1H), 6.78 (d, J = 9.8 Hz, 1H), 6.34-6.28 (m, 
1H), 3.60 (d, J = 6.8 Hz, 2H), 3.21 (s, 3H), 2.40 (s, 3H); 13C NMR (CDCl3, 75 MHz) δ  168.8, 
137.7, 135.2, 134.5, 132.0, 131.28, 131.21, 128.6, 128.4, 46.3,36.3, 21.2; FTIR (cm-1) (neat): 
3339, 2921, 1626, 1603, 1391, 835, 713; HRMS (APPI, Pos): calc. for C12H14NO (M+H)+ : 
188.1077 , found: 188.1070 m/z.  
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2,8-Dimethyl-2,5-dihydro-1H-benzo[c]azepin-1-one (2c) and 2,8-Dimethyl-2,3-dihydro-
1H-benzo[c]azepin-1-one (3c) 
The title compounds 2c and 3c were prepared by the general procedure to give an orange oil in 
62% yield (57 mg, 0.31 mmol) and an orange oil in 30% yield (28 mg, 0.15 mmol): 2c: Rf: 
0.52  (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ  7.76 (d, J = 7.9 Hz, 1H), 7.09 (d, J = 
7.9 Hz, 1H), 6.87 (s, 1H), 5.95 (d, J = 7.6 Hz, 1H), 5.63-5.57 (m, 1H), 3.27 (s, 3H), 3.17 (d, J 
= 7.2 Hz, 2H), 2.34 (s, 3H); 13C NMR (CDCl3, 75 MHz): δ 169.4, 143.2, 142.0, 131.29, 
131.11, 130.7, 127.4, 126.8, 117.5,  36.4, 31.3, 21.3 ; FTIR (cm-1) (neat): 3332.42, 2921, 
1608, 1389, 1282, 1151, 764; HRMS (APPI, Pos): calc. for C12H14NO (M+H)+ : 188.1078 , 
found: 188.1070 m/z. 3c: Rf: 0.15  (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ  7.91 
(d, J = 8.0 Hz, 1H), 7.19 (d, J = 8.0, 1H), 7.01 (s, 1H), 6.76 (d, J = 10 Hz, 1H), 6.37-6.31 (m, 
1H), 3.61 (d, J = 7.0 Hz, 2H), 3.19 (s, 3H), 2.36 (s, 3H); 13C NMR (CDCl3, 75 MHz):  δ 
169.0, 140.6, 134.78, 134.71, 132.8, 131.2, 129.5, 128.91, 128.81, 46.4, 36.4, 21.4 ; FTIR 
(cm-1) (neat): 3305, 2922, 1621, 1605, 1394, 1064, 832, 755; HRMS (APPI, Pos): calc. for 
C12H14NO (M+H)+ : 188.1079 , found: 188.1070  m/z.  
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2,6,8-Trimethyl-2,5-dihydro-1H-benzo[c]azepin-1-one (2d) and 2,6,8-Trimethyl-2,3-
dihydro-1H-benzo[c]azepin-1-one (3d) 
The title compounds 2d and 3d were prepared by the general procedure to give an orange oil 
in 81% yield (72 mg, 0.36 mmol) and an orange oil in 13% yield (12 mg, 0.59 mmol): 2d: Rf: 
0.75  (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.48 (d, J = 1.0 Hz, 1H), 7.07 (d, J = 
1.0 Hz, 1H), 5.98 (d, J = 7.0 Hz, 1H), 5.62 (dt, J = 15.0, 7.0Hz, 1H), 3.28 (s, 3H), 3.17 (d, J = 
8.0 Hz, 2H), 2.33 (s, 3H), 2.29 (s, 3H); 13C NMR (CDCl3, 75 MHz): δ 170.4, 139.2, 135.6, 
134.5, 134.1, 132.3, 130.9, 129.3, 117.6, 36.3, 26.0, 20.9, 19.9; FTIR (cm-1) (neat): 3350, 
2920, 1625, 1600, 1385, 1119, 1042, 774, 722; HRMS (APPI, Pos): calc. for C13H16NO 
(M+H)+: 202.1236, found: 202.1236 m/z. 3d:  Rf: 0.15  (1:1 Hex : EtOAc); 1H NMR (CDCl3, 
400 MHz): δ  7.60 (td, J = 0.7, 0.4 Hz, 1H), 7.08 (ddd, J = 1.1, 0.8, 0.5 Hz, 1H), 6.83-6.80 (m, 
1H), 6.37-6.31 (m, 1H), 3.56 (d, J = 7.0 Hz, 2H), 3.18 (s, 3H), 2.33 (s, 3H), 2.29 (s, 3H);13C 
NMR (CDCl3, 75 MHz):δ 169.2, 141.9, 137.6, 136.9, 133.0, 131.7, 128.9, 128.4, 123.0, 
46.32, 46.30, 29.8, 21.2, 20.3; FTIR (cm-1) (neat): 3276, 2920, 1629, 1601, 1094, 1035,814; 
HRMS (APPI, Pos): calc. for C13H16NO (M+H)+ : 202.1236  , found: 202.1226 m/z.  
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7-Fluoro-2-methyl-2,5-dihydro-1H-benzo[c]azepin-1-one (2e) and 7-Fluoro-2-methyl-2,3-
dihydro-1H-benzo[c]azepin-1-one (3e) 
 
The title compounds 2e and 3e were prepared by the general procedure to give a light yellow 
oil in 54% yield (51 mg, 0.27 mmol) and a light yellow oil in 31% yield (29 mg, 0.15 mmol): 
2e: Rf: 0.44  (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.86 (dd, J = 9.0, 6.0 Hz, 
1H), 6.96-6.96 (m, 1H), 6.78-6.75 (m, 1H), 5.98 (dt, J = 8.0, 1.0 Hz, 1H), 5.61-5.59 (m, 1H), 
3.27 (s, 3H), 3.19 (d, J = 7.0Hz); 13C NMR (CDCl3, 75 MHz):  δ 168.3, 164.5 (d, J = 252.1 
Hz), 145.7 (d, J = 8.0 Hz), 133.7 (d, J = 9.3 Hz),  131.0, 130.1 (d, J = 3.0 Hz) 116.9, 113.6 (d, 
J = 21.3 Hz),  113.0 (d, J = 21.8 Hz) 36.3, 31.2; 19F NMR (CDCl3, 282 MHz): δ -109.0 (ddd, 
J = 23.0, 8.0, 6.0 Hz); FTIR (cm-1) (neat): 2922, 1621, 1604, 1276, 1060, 900, 742 ; HRMS 
(APPI, Pos): calc. for C11H11FNO  (M+H)+ : 192.0828 , found: 192.0819 m/z. 3e: Rf: 0.21  
(1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 8.03 (ddd, J = 9.0, 6.0, 0.3 Hz, 1.0H), 7.07 
(td, J = 8.4, 3.0 Hz, 1H), 6.88 (dd, J = 9.0, 3.0 Hz, 1H), 6.75 (d, J = 10.0 Hz, 1H), 6.44-6.40 
(m, 1H), 3.63 (d, J = 7.0 Hz, 2H), 3.20 (s, J = 2.4 Hz, 3H); 13C NMR (CDCl3, 75 MHz): δ 
168.0, 163.5 (d, J = 251.0 Hz), 137.1 (d, J = 8.4 Hz), 133.4, 133.9 (d, J = 2.0 Hz), 133.8, 
131.9 (d, J = 2.8 Hz), 130.9, 115.3 (d, J = 21.7 Hz), 114.5 (d, J = 21.6 Hz), 46.2, 36.5; 19F 
NMR (CDCl3, 282 MHz): δ -110.3 (dd, J = 14.6, 8.2 Hz); FTIR (cm-1) (neat): 2925, 1619, 
1600, 1478, 1432, 1237, 936, 799, 760, 572, 432; HRMS (APPI, Pos): calc. for C11H11FNO 
(M+H)+ : 192.0817 , found: 192.0819 m/z.  
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8-Fluoro-2-methyl-2,5-dihydro-1H-benzo[c]azepin-1-one (2f) and 8-Fluoro-2-methyl-2,3-
dihydro-1H-benzo[c]azepin-1-one (3f) 
 
The title compounds 2f and 3f were prepared by the general procedure to give a light yellow 
oil in 64% yield (59 mg, 0.31 mmol) and a light yellow oil in 24% yield (22 mg, 0.12 mmol): 
2f: Rf: 0.55  (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz):  δ  7.58 (dd, J = 10.0, 3.0 Hz, 
1H), 7.10-7.04 (m, 2H), 5.97 (d, J = 7.6 Hz, 1H), 5.69-5.63 (m, 1H), 3.30 (s, 3H), 3.20 (d, J = 
7.0 Hz, 2H); δ 13C NMR (CDCl3, 75 MHz): δ 168.2, 161.4 (d, J = 244.0 Hz), 139.3 (d, J = 4.0 
Hz), 135.6 (d, J = 7.0 Hz), 130.5, 127.8 (d, J = 8.0 Hz), 118.5 (d, J = 22.0 Hz), 118.0 117.9 (d, 
J = 24.0 Hz), 36.5, 30.5; 19F NMR (CDCl3, 282 MHz): δ -116.5 (m); FTIR (cm-1) (neat): 
3345, 2926, 1625, 1582, 1489, 1321, 719, 545; HRMS (APPI, Pos): calc. for C11H11FNO 
(M+H)+ : 192.08277 , found: 192.08192 m/z. 3f: Rf: 0.26  (1:1 Hex : EtOAc); 1H NMR 
(CDCl3, 400 MHz):  δ 7.72-7.70 (m, 1H), 7.22-7.11 (m, 2H), 6.77 (d, J = 10.0 Hz, 1H), 6.36-
6.33 (m, 1H), 3.62 (d, J = 7.0 Hz, 2H), 3.20 (s, 3H); 13C NMR (CDCl3, 75 MHz):  δ 167.5, 
161.9 (d, J = 249.0 Hz), 137.7 (d, J = 7.0 Hz), 133.8, 131.10 (d, J = 3.0 Hz), 130.7 (d, J = 8.0 
Hz), 129.2, 118.0 (d, J = 22.0 Hz), 117.7 (d, J = 23.0 Hz), 46.3, 36.5; 19F NMR (CDCl3, 282 
MHz): δ -113.0 (m) ;FTIR (cm-1) (neat): 3271, 2923, 1627, 1606, 1484, 1393, 1026, 756, 557; 
HRMS (APPI, Pos): calc. for C11H11FNO (M+H)+ : 192.0828 , found: 192.0819 m/z. 
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7,8-Difluoro-2-methyl-2,5-dihydro-1H-benzo[c]azepin-1-one (2g) and 7,8-Difluoro-2-
methyl-2,3-dihydro-1H-benzo[c]azepin-1-one (3g) 
 
The title compounds 2g and 3g were prepared by the general procedure to give an orange oil 
in 69% yield (69 mg, 0.33 mmol) and an orange oil in 15% yield (15 mg, 0.73 mmol): 2g: Rf: 
0.54 (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.70 (dd, J = 11.1, 8.2 Hz, 1H), 6.88 
(dd, J = 10.2, 7.4 Hz, 1H), 5.98 (dt, J = 7.6, 0.9 Hz, 1H), 5.65-5.59 (m, 1H), 3.27 (s, 3H), 3.17 
(d, J = 7.2 Hz, 2H); 13C NMR (CDCl3, 75MHz):  167.3, 152.2 (dd, J =227.0, 13.0 Hz), 148.9 
(dd, J = 220.0, 13.0 Hz), 140.3 (dd, J = 6.0, 4.0 Hz), 131.0, 130.6 (dd, J =5.0, 3.5 Hz), 122.0 
(d, J = 20.0 Hz),  120.5 (dd, J = 19.0, 1.5 Hz), 117.2, 117.0 (d, J = 20.0 Hz), 115.0 (d, J = 18.0 
Hz), 36.6, 30.6; 19F NMR (CDCl3, 282 MHz): δ -133.3 (m), -140.8 (m) ; FTIR (cm-1) (neat): 
3280, 2920, 1658, 1615, 1508, 1439, 1387, 1157, 957, 758, 548; HRMS (APPI, Pos): calc. for  
C11H10F2NO (M+H)+ : 210.0724  , found:  210.0725  m/z. 3g: Rf: 0.20  (1:1 Hex : EtOAc); 1H 
NMR (CDCl3, 400 MHz): δ 7.85 (dd, J = 11.2, 8.2 Hz, 1H), 7.00 (dd, J = 10.7, 7.6 Hz, 1H), 
6.70 (d, J = 9.9 Hz, 1H), 6.42-6.36 (m, 1H), 3.63 (d, J = 6.9 Hz, 1H), 3.19 (s, 3H).  ; δ 13C 
NMR (CDCl3, 75 MHz):  δ 166.7, 151.3 (dd, J = 254.0, 13.0 Hz), 149.6 (dd, J = 252.0, 13.0 
Hz), 132.9 (d, J = 1.0 Hz), 132.6 (dd, J = 5.0, 3.0 Hz), 132.1 (dd, J = 7.0, 4.0 Hz), 130.3 (d, J 
=2.0 Hz), 120.3 (dd, J =19.0, 2.0 Hz), 116.7 (d, J = 17.0 Hz), 46.1, 36.5; 19F NMR (CDCl3, 
282 MHz): δ -134.1 (m), -137.2 (m); FTIR (cm-1) (neat): 3047, 2923, 1626, 1613, 1479, 1278, 
886, 818, 754, 606; HRMS (APPI, Pos): calc. for C11H10F2NO (M+H)+ : 210.0733 , found: 
210.0725 m/z.  
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7-Methoxy-2-methyl-2,5-dihydro-1H-benzo[c]azepin-1-one (2h) and 7-Methoxy-2-
methyl-2,3-dihydro-1H-benzo[c]azepin-1-one (3h) 
The title compounds 2h and 3h were prepared by the general procedure to give an orange oil 
in 51% yield (51 mg, 0.25 mmol) and an orange oil in 43% yield (43 mg, 0.21 mmol): 2h: Rf: 
0.61  (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ  7.41 (d, J = 2.0 Hz, 1H), 6.98-6.91 
(m, 2H), 5.93 (d, J = 8.0 Hz, 1H), 5.67-5.61 (dt, J =15.0, 7.0 Hz, 1H), 3.81 (s, 3H), 3.28 (s, 
3H), 3.15 (d, J = 7.2 Hz, 2H); 13C NMR (CDCl3, 75 MHz): δ 169.4, 158.3, 136.0, 134.7, 
130.34, 130.29, 127.4, 118.60, 118.44, 115.0, 55.6, 36.6, 30.4; FTIR (cm-1) (neat): 3328, 
1626, 1601, 1282, 1032, 750; HRMS (APPI, Pos): calc. for C12H14NO2 (M+H)+ : 204.10271 , 
found: 204.10191 m/z. 3h: Rf: 0.20  (1:1 Hex: EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.51 
(t, J = 2.5 Hz, 1H), 7.12 (dd, J = 8.7, 2.4 Hz, 1H), 7.01-6.98 (m, 1H), 6.76-6.73 (m, 1H), 6.27-
6.21 (m, 1H), 3.86, 3.60 (d, J = 6.8 Hz, 2H), 3.20 (s, 3H). ; 13C NMR (CDCl3, 75 MHz): δ 
168.5, 158.9, 136.7, 134.3, 130.2, 128.0, 127.4, 118.2, 114.2, 55.6, 46.5, 36.4; FTIR (cm-1) 
(neat): 3356, 2928, 1626, 1601, 1481, 1233, 1030, 789; HRMS (APPI, Pos): calc. for 
C12H14NO2  (M+H)+ : 204.1028 , found: 204.1019 m/z. 
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6,7,8-Trimethoxy-2-methyl-2,5-dihydro-1H-benzo[c]azepin-1-one (2i) and 6,7,8-
Trimethoxy-2-methyl-2,3-dihydro-1H-benzo[c]azepin-1-one (3i) 
The title compounds 2i and 3i were prepared by the general procedure to give an orange oil in 
17% yield (22 mg, 0.08 mmol) and an orange oil in 10% yield (12.8 mg, 0.05 mmol): 2i: Rf: 
0.58  (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.23 (s, 1H), 5.97 (d, J = 8.0 Hz, 
1H), 5.61 (dt, J = 15, 8 Hz, 1H), 3.90, (s, 3H), 3.87 (s, 3H), 3.82 (s, 3H), 3.28 (s, 3H), 3.23 (d, 
J = 7.3 Hz, 2H); 13C NMR (CDCl3, 75 MHz): δ 169.1, 151.6, 148.2, 145.2, 131.1, 130.4, 
129.5, 118.1, 109.9, 61.0, 56.1, 36.6, 22.2; FTIR (cm-1) (neat): 2937, 1656, 1485, 1209, 1166, 
1009, 907, 760, 708; HRMS (APPI, Pos): calc. for C14H18NO4 (M+H)+ : 264.1238 , found: 
264.1230 m/z. 3i: Rf: 0.20  (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz):  δ  7.38 (s, 1H), 
7.02-6.99 (m, 1H), 6.36-6.30 (m, 1H), 3.96-3.94 (m, 6H), 3.88 (s, 3H), 3.65-3.63 (m, 2H), 
3.23 (s, 3H); 13C NMR (CDCl3, 75 MHz): 169.2, 147.2, 143.0, 136.5, 136.4, 128.5, 128.4, 
127.1, 108.9, 60.8, 60.5, 55.6, 46.0, 38.4; FTIR (cm-1) (neat): 2933, 1626, 1195, 1019, 972, 
701; HRMS (APPI, Pos): calc. for C14H18NO4 (M+H)+ : 264.1239 , found: 264.1230 m/z. 
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2-Benzyl-2,5-dihydro-1H-benzo[c]azepin-1-one (2j) and 2-Benzyl-2,3-dihydro-1H-
benzo[c]azepin-1-one (3j) 
 
The title compounds 2j and 3j were prepared by the general procedure to give an orange oil in 
59% yield (71.9 mg, 0.29 mmol) and an orange oil in 37% yield (45.5 g, 0.18 mmol): 2j: Rf: 
0.78  (1:1 Hex : EtOAc); 1H NMR (CDCl3, 400 MHz): δ 7.92 (dd, J = 7.7, 1.1 Hz, 1H), 7.41-
7.26 (m, 7H), 7.07 (d, J = 7.4 Hz, 1H), 5.99 (d, J = 7.6 Hz, 1H), 5.67 (q, J = 7.4 Hz, 1H), 4.95 
(s, 2H), 3.20 (d, J = 7.2 Hz, 2H); 13C NMR (CDCl3, 75 MHz): δ 169.3, 143.5, 137.6, 133.9, 
131.7, 131.4, 129.6, 128.8, 128.0, 127.6, 126.7, 126.2, 119.0, 51.8, 31.6; FTIR (cm-1) (neat): 
3060, 3030, 2922, 1619, 1569, 1446, 1311, 724, 698, 463; HRMS (APPI, Pos): calc. for 
C17H16NO  (M+H)+: 250.1231, found: 250.1226 m/z. 3j: Rf: 0.56  (1:1 Hex : EtOAc); 1H 
NMR (CDCl3, 400 MHz): δ 8.13-8.11 (m, 1H), 7.50-7.30 (m, 7H), 7.24 (d, J = 7.5 Hz, 1H), 
6.78 (d, J = 9.9 Hz, 1H), 6.16-6.12 (m, 1H), 4.85 (s, 2H), 3.60 (d, J = 6.8 Hz, 2H); 13C NMR 
(CDCl3, 75 MHz): δ 171.7, 138.0, 134.3, 131.5, 130.5, 129.1, 128.8, 128.7, 128.6, 128.3, 
127.9, 127.7, 106.9, 51.9, 43.8 ; FTIR (cm-1) (neat): 3064, 3033, 2957, 1629, 1495, 1421, 
1277, 797, 700, 474; HRMS (APPI, Pos): calc. for C17H16NO(M+H)+ : 250.1232 , found: 
250.1226 
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